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ABSTRACT 
Castration-resistant prostate cancer (CRPC) is a deadly disease. The mechanism 
by which CRPC develops is only partially understood. The best understood 
alteration in CRPC is the overexpression of the androgen receptor (AR). Prostate 
cells rely on AR for growth and differentiation as much as prostate cancer (PC) cells 
rely on it for disease progression. Thus, AR is one of the major contributors to the 
development of CRPC.  
This study aimed to investigate the molecular changes occurring in AR-
overexpressing PC cells, particularly at the transcriptional level. Furthermore, this 
study also aimed to identify AR target genes that are important for PC progression 
that could be used as potential drug targets or biomarkers. 
The data demonstrated that the overexpression of AR enhances the binding of the 
receptor to chromatin in the presence of relatively low concentrations of androgens. 
Furthermore, under the same conditions, AR overexpression also altered the 
dynamics of chromatin binding of the receptor and the binding of basic components 
of the transcriptional machinery, such as RNA Pol II. The recruitment occurred 
earlier and more powerfully in AR-overexpressing cells. These changes seemed to 
translate into an increased acetylation of positioned histones. Furthermore, the data 
suggested that the chromatin is more open in AR-overexpressing cells that are 
already in hormone-deprived conditions. Thus, AR overexpression favors chromatin 
accessibility, which results in enhanced gene transcription. Interestingly, the AR and 
RNA Pol II binding pattern, and the transcriptional enhancement of the target genes 
differ from gene to gene. 
In addition, several new AR target genes were identified and characterized. 
SKP2, ZWINT and FEN1 were found to be overexpressed in CRPC specimens, 
whereas SNAI2 expression was reduced. Functional studies showed that ZWINT, 
SNAI2 and FEN1 may be important in PC cell growth. FEN1 overexpression was 
also associated with a shorter time to progression. Thus, FEN1 may be important in 
the progression of PC to CRPC and may represent a potential drug target. 
Altogether, these results offer a mechanism for how overexpression of AR leads 
to resistance to androgen ablation. 
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SINTESI 
Iper-espressione del recettore degli androgeni nel 
cancro alla prostata 
L’incidenza del cancro alla prostata in Europa é del 20 %. L’inizio della malattia 
é subdolo ma fortunatamente, anche grazie al test del “prostate specific antigen” 
(PSA), meno del 5 % di questi casi presenta metastasi al momento della diagnosi. 
Nonostante ció, il cancro alla prostata é tra le prime cause di morte legate a tumori 
maschili nei paesi occidentali: in Europa la mortalitá è stimata tra 8 e 12 uomini 
ogni 100.000. Nella maggior parte dei casi  la malattia é curabile, ma circa un quarto 
dei pazienti presenta recidiva dopo circa 2-3 anni dalla prostatectomia iniziale. 
Infatti, le terapie in uso selezionano forme resistenti. 
Il carcinoma prostatico metastatico refrattario alla castrazione (CRPC) é una 
malattia mortale per la quale attualmente non ci sono cure efficaci. I meccanismi 
attraverso i quali queste forme refrattarie di CRPC si sviluppano sono noti solo in 
parte. Tra le diverse alterazioni studiate, la piú frequente (il 95 % dei casi) é l’iper-
espressione del recettore degli androgeni (AR). AR é un fattore di trascrizione in 
grado di controllare l’espressione di circa il 2 % del genoma. Infatti, in condizioni 
fisiologiche le cellule prostatiche ne hanno bisogno per la crescita e per il 
differenziamento. Tuttavia, anche le cellule di tumore prostatitco ne traggono 
vantaggio in tutti gli stadi della malattia, dal tumore primario al CRPC, per questo 
motivo, il recettore é molto importante nello sviluppo della malattia. Le terapie piú 
usate intendono impedire l’attivazione di AR nelle cellule cancerogene di prostata, 
sopprimendo, per esempio, i livelli di testosterone e altri androgeni, tra i quali il 
diidrotestosterone, che sono in grado di attivare il recettore. Tuttavia, numerosi studi 
hanno evidenziato come l’iper-espressione di AR è in grado di eludere gli effetti 
delle terapie.  
Questo studio si propone di chiarire i meccanismi molecolari legati all’iper-
espressione di AR nelle cellule di tumore prostatico, in particolare a livello 
trascrizionale, e di identificare i geni bersaglio del recettore implicati nella 
progressione del tumore. Tali geni rappresentano potenziali target terapeutici e 
prognostici.  
I dati ottenuti dimostrano che l’iper-espressione di AR incrementa il legame dello 
stesso recettore alla cromatina, in presenza di concentrazioni relativamente basse di 
androgeni. Nelle stesse condizioni, l’iper-espressione di AR altera la dinamica del 
suddetto legame e del legame di fattori base di trascrizione, quali l’RNA Polimerasi 
II, nelle regioni regolatorie dei geni bersaglio, enhancers e promotori. Il 
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recrutamento di tali fattori é potenziato ed é piú veloce in cellule che iper-esprimono 
il recettore. Inoltre, si osserva un incremento di acetilazione degli istoni. Questi 
cambiamenti si riflettono anche sulla struttura della cromatina, in particolar modo 
sul posizionamento dei nucleosomi. La cromatina é infatti piú aperta giá in assenza 
di androgeni. Quindi si evince che l’iper-espressione del recettore favorisce 
l’accesso alla cromatina, che risulta in un aumento dei livelli di trascrizione. É anche 
interessante notare come la dinamica dei legami con la cromatina e l’incremento dei 
livelli trascrizionali, sia potenzialmente diverso di gene in gene. I dati ottenuti hanno 
anche portato all’identificazione di nuovi geni bersaglio di AR, che sono stati 
caratterizzati. SKP2, ZWINT e FEN1 sono risultati iper-espressi in campioni di 
CRPC mentre SNAI2 é risultato ipoespresso. Studi sulla funzione di questi geni 
hanno rivelato che ZWINT, SNAI2 e FEN1 potrebbero essere coinvolti nella 
crescita delle cellule tumorali di prostata. In particolare, l’espressione di FEN1 é 
anche risultata essere associata con il tempo di progressione e recidiva della 
malattia. Dunque, FEN1 potrebbe essere importante nello sviluppo del CRPC e 
perció un potenziale target terapeutico. 
In conclusione, questi risulati offrono una spiegazione meccanistica dei processi 
che portano alla resistenza delle terapie ormonali nel contesto dell’iper-espressione 
del recettore per gli androgeni. 
 
10 
INTRODUCTION 
The best-recognized risk factor for prostate cancer (PC) is age. Several studies 
have reported that ethnicity and family history also contribute to the risk (Grönberg 
et al., 2003; Patel and Klein, 2009). Genome-wide association studies continue to 
report genetic factors that may be involved in the onset of the disease. However, 
although many low penetrance risk loci have been identified, most have not yet been 
conclusively functionally validated (Freedman et al., 2011). Migration studies have 
shown that immigrants acquire the risk of their new location, indicating that 
environmental factors contribute to the risk of PC (Patel and Klein, 2009). However, 
none of the environmental risk factors have conclusively been associated with the 
onset of PC (Giovannucci and Platz, 2006; Patel and Klein, 2009).  
Due to the increasing quality of life in Western countries, the overall population 
ages and faces an increasing number of PC cases every year (Scardino and Kelman, 
2005). In Europe, the incidence rate is 1 case per 5 men (Heidenreich et al., 2011). 
Fortunately, the increasing incidence of PC no longer leads to increased mortality. 
The mortality rates grew until 1995 but have now been decreasing (Bosetti et al., 
2011). Currently, fewer than 5 % of men with newly diagnosed PC have distant 
metastases at diagnosis compared to 25 % more than 20 years ago (Ryan and Small, 
2005). However, PC is still among the top causes of cancer-related deaths in men in 
Western countries (Ferlay et al., 2010; Jemal et al., 2010). Estimated age-adjusted 
PC mortality rates in 2011 vary between 8.1 and 12.6 for every 100,000 men in 
Europe (Malvezzi et al., 2011). 
PC is asymptomatic in the early phase of the disease and is often diagnosed by 
screening based on the measurement of serum levels of prostate specific antigen 
(PSA) (see also Figure 2A) accompanied by a digital rectal examination and needle 
biopsy (Heidenreich et al., 2011). PSA screening increases the diagnostic sensitivity 
and decreases mortality by 20-30 % (Schröder et al., 2009) but leads to problems 
such as high cost and overdiagnosis (Borofsky and Makarov, 2011) and subsequent 
overtreatment (Klotz and Thompson, 2011; Froehner and Wirth, 2011; Shigeta et 
al., 2011). 
Although most patients are initially diagnosed with a curable disease, 
approximately 20 % of the cases progress within 5 years after the initial 
prostatectomy (Bianco et al., 2005). For the past 70 years, the standard care for 
advanced PC has been chemical or surgical castration (Huggins and Hodges, 1941). 
However, the treatment is only palliative and, although most of the patients respond 
to treatment, the disease eventually progresses (Gittes, 1991) (see also Figure 2A). 
Such recurrent cases are called castration-resistant prostate cancers (CRPCs). Only 
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recently have new treatment options for CRPC been approved by the Food and Drug 
Administration (FDA), but these options show only a few months benefit in the 
median survival (Vasani et al., 2011). 
AR is overexpressed in 95 % of the CRPC cases (Linja et al., 2001; Chen et al., 
2004). Thus, understanding how the overexpression of AR is advantageous for this 
type of cancer and the mechanisms it drives is critical and serves as the basis for 
identifying new drug targets and biomarkers for this disease. 
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1.1 Prostate cancer 
1.1.1 Natural history of prostate cancer 
The prostate is a walnut-sized exocrine gland that surrounds the prostatic urethra, 
the ejaculatory ducts and the neck of the urinary bladder. The prostate is an 
accessory reproductive organ formed by small glands (acini) that open into 
excretory ducts (Figure 1A). The prostate produces approximately 30 % of the total 
volume of the ejaculate (Pahuja et al., 2006). The function of prostatic fluid is to 
support the spermatozoa, and this fluid is comprised of many components, including 
acid phosphatases, albumin, zinc, magnesium and calcium. The ductal epithelium is 
responsible for the production and the excretion of PSA in the seminal plasma. PSA 
is a protease that normally functions in the liquefaction of the seminal coagulum 
(Lilja, 2003). The basement membrane in the prostate forms a barrier that prevents 
the escape of secreted PSA into the blood circulation. In PC or other pathological 
conditions of the prostate, this barrier is disrupted and the PSA can enter the 
circulation (Ward et al., 2001). For this reason, PSA is generally used as a 
diagnostic biomarker for prostate disorders (Stamey et al., 1987), including PC 
(Partin et al., 2001; Graff et al., 2007). 
Anatomically, the prostate can be divided according to two classifications: by 
zone or by lobes. However, because the prostate does not have a clear lobular 
structure, the "zone" classification is used more frequently (McNeal, 1981; Myers et 
al., 2010). According to this classification, the prostate gland is divided into four 
glandular zones, two of which arise from different segments of the prostatic urethra: 
- The peripheral zone (PZ), which surrounds the distal urethra and represents 
up to 70 % of the volume in young men. Approximately 70-80 % of PCs 
originate from this portion of the gland (McNeal et al., 1988).  
- The central zone (CZ), which surrounds the ejaculatory ducts, represents 
approximately 25 % of the total volume. Roughly 2.5 % of PCs arises from the 
CZ. These cancers tend to be more aggressive and more likely to invade the 
seminal vesicles (Cohen et al., 2008).  
- The transition zone (TZ), which represents 5 % of the prostate volume at 
puberty, surrounds the proximal urethra and is responsible for benign prostatic 
hyperplasia (BPH) (McNeal, 1978). Approximately 10-20 % of PCs originate 
from this zone (McNeal et al., 1988). 
- Anterior fibro-muscular zone (or stroma) accounts for approximately 5 % of 
the volume (McNeal, 1981).  
 
Three cells types form the epithelial compartment of the prostate. These cell 
types are the basal cells, neuroendocrine and luminal cells. Basal and 
neuroendocrine cells are AR negative, whereas luminal and stromal cells are AR 
positive (Klocker, 2006). PC is thought to arise from the epithelial cellular 
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compartment and is thus classified as adenocarcinoma. However, from which type 
of epithelial cells cancer arises is not known (Maitland and Collins 2008, Wang and 
Shen 2011). 
 
 
Figure 1. Anatomy of the prostate and prostate cancer. (A) Anatomy of the prostate 
gland in relation to the urinary bladder, rectum, seminal vesicles and urethra. (B) Staging of 
prostate cancer according to the American Joint Committee on Cancer TNM System (N and 
M staging are omitted) (Adapted from http://www.cancer.gov/). 
Prostatic intraepithelial neoplasia (PIN) is considered to be a premalignant stage 
but is not a prerequisite for PC development. Another possible premalignant lesion 
of the prostate is proliferative inflammatory atrophy (PIA) (DeMarzo et al., 2003). 
PIA is often located in the PZ of the prostate. The proliferative nature of PIA has led 
to the hypothesis that PIA could also be a precursor of PC (Woenckhaus and Fenic, 
2008), but the evidence is still not strong. Once the tumor escapes out of the prostate 
capsule, it invades surrounding tissues and eventually metastasizes, primarily to the 
local lymph nodes and bone (Porkka and Visakorpi, 2006) (Figure 1B).  
1.1.2 Androgen dependency and treatment options for prostate 
cancer 
Androgens, primarily testosterone and dihydrotestosterone (DHT), drive the 
growth and development of the prostate. The production of testosterone is regulated 
by luteinizing hormone (LH) and luteinizing hormone releasing hormone (LHRH). 
The hypothalamus secretes the LHRH in a pulsatile manner, which in turn 
stimulates the secretion of the LH by the anterior pituitary gland. LH induces the 
production of the testosterone by Leydig cells in the testicles. A negative feedback 
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loop prevents LHRH release (Burger, 2002). In the blood stream, only 1 to 2 % of 
testosterone is free. The majority is bound to albumin and sex hormone binding 
globulin (SHBG). Testosterone can enter the cell by diffusion or, when bound to 
SHBG, can be actively transported via a special receptor. 
The effect of androgens is mediated by AR (Klocker, 2006). In the cytoplasm, 
testosterone binds to AR as such or after conversion into DHT by the enzyme 5α-
reductase. DHT is considered the most active form of androgens because DHT can 
bind to AR with high affinity (So et al., 2003).  
In 1941, Huggins and Hodges (1941) first reported the dependency of metastatic 
PC on androgens. Today, an increasing amount of evidence has shown that PC is 
dependent on the androgen/AR signaling pathway in all stages of the disease 
(Isaacs, 1994; Linja and Visakorpi, 2004; Chen et al., 2004). Consequently, the 
therapies for PC mostly rely on blocking this signaling axis by either preventing 
androgen production from the testes and/or blocking the function of AR with 
antiandrogens. Androgen-deprivation therapy (ADT) (hormonal therapy), through 
bilateral orchiectomy (castration) or treatment with LHRH agonists or antagonists, 
is the standard first-line therapy for advanced PC (Heidenreich et al., 2011). ADT is 
often also used for other indications, such as neoadjuvant or adjuvant therapy to 
surgery or radiotherapy, biochemical relapse after surgery or radiation and even 
primary therapy for localized disease in elderly men (Kram et al., 2011). 
LHRH agonists, such as goserelin and leupropelin, downregulate the receptor for 
LHRH, desensitizing the pituitary gland. This downregulation results in inhibition 
of LH release. In contrast, LHRH antagonists, such as abarelix and degarelix, 
directly suppress the production of LH by acting on the anterior pituitary gland 
(Tammela, 2004). Surgical or chemical castration can be combined with 
antiandrogens to achieve a maximum androgen blockade (Mottet et al., 2011). 
Commonly used antiandrogens include flutamide, bicalutamide and nilutamide, 
which are non-steroidal compounds that bind the receptor and inhibit its activity. 
Thus, these compounds directly block the actions of testosterone and DHT within 
the cells. However, the clinical benefit of maximal androgen blockade is still 
marginal compared to castration alone (Tammela, 2004). On the other hand, in men 
with non-metastatic locally advanced PC, the survival has been shown to be similar 
in patients treated with bicalutamide monotherapy compared to castration (Iversen 
et al., 1998; Boccardo et al., 1999). Furthermore, an increasing body of evidence 
supports the use of bicalutamide in favor of LHRH agonist to preserve bone mineral 
density (Smith et al., 2004; Wadhwa et al., 2011). For these reasons, the use of 
bicalutamide monotherapy is widely approved in PC patients with locally advanced 
disease (Wadhwa et al., 2011).  
1.1.3 Castration-resistant prostate cancer and treatment options 
Most patients initially respond to hormonal therapies, but the disease eventually 
relapses and the tumor becomes castration-resistant (Sadar, 2011). Treatments for 
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CRPC include second-line hormonal therapy (Mottet et al., 2011) or chemotherapy 
with docetaxel (Petrylak et al., 2004; Tannock et al., 2004). In 2010, the FDA also 
approved the use of the sipuleucel-T for the treatment of patients with asymptomatic 
or minimally symptomatic CRPC (Longo, 2010; Kantoff et al., 2010). Sipuleucel-T 
is a form of immunotherapy in which the patient’s immune system is ex vivo 
stimulated to a host antitumor response (Longo, 2010). More recently, the FDA 
approved abiraterone acetate for use in combination with prednisone for the 
treatment of patients with metastatic CRPC who have received chemotherapy 
containing docetaxel (de Bono et al., 2011a; Attard and de Bono, 2011). Abiraterone 
is an inhibitor of one of the enzymes, cytochrome P450 (CYP)17 (steroid 17α-
hydroxylase/C17,20 lyase) (CYP17A), involved in the steroidogenesis. 
Other agents, including the novel antiandrogen MDV3100, are in phase III 
clinical trials (Scher et al., 2010). None of the therapies for CRPC are curative 
(Antonarakis and Armstrong, 2011a). Thus, CRPC is still associated with poor 
prognosis, and the median survival is 18 to 24 months (Hussain and Dawson, 2000; 
Small et al., 2004) (Figure 2A). Therefore, new drug targets are clearly needed.  
 
 
Figure 2. Prostate cancer: an overview. (A) Disease progression and interventions. 
Serum PSA levels are used for diagnosis and to monitor progression of the disease (B) 
Molecular mechanisms of PC involving AR and not involving AR. Dashed lines indicate 
interplay between the pathways. 
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1.1.4 Molecular pathology of prostate cancer 
1.1.4.1 PC susceptibility 
PC is a heterogeneous disease, and several molecular mechanisms can contribute 
to its development (Figure 2B). According to a Scandinavian twin study 
(Lichtenstein et al., 2000), up to 40 % of the PC risk can be inherited. Still, no 
common high-risk, PC susceptibility genes seem to exist (Foulkes, 2008). One 
candidate is BRCA2 since mutations in BRCA2 are associated with aggressive PC 
(Tryggvadóttir et al., 2007; Agalliu et al., 2007). However, BRCA2 mutations are 
rare in men with PC (Agalliu et al., 2007). Furthermore, despite considerable 
collaborative efforts, no recurrent risk loci have yet been conclusively identified by 
linkage analysis (Schleutker, 2011). Genome-wide association studies have 
identified several low risk candidate genes and loci (Easton and Eeles, 2008; Kote-
Jarai et al., 2011; Freedman et al., 2011). Nevertheless, we are currently able to 
explain only approximately 25 % of the inherited risk (Kote-Jarai et al., 2011; 
Schleutker, 2011). 
1.1.4.2 GSTP1 
The glutathione S-transferase class π (GSTP1) protein is a member of the GST 
family of multifunctional enzymes and is involved in cell detoxification by 
catalyzing the conjugation of many hydrophobic and electrophilic compounds with 
reduced glutathione (Li et al., 2011a). To date, the most common somatic alteration 
in PC is the silencing of the tumor suppressor GSTP1 expression by 
hypermethylation of the promoter region of the gene. Hypermethylation has been 
detected in 90–95 % of PC, suggesting that it is an early event in prostate 
tumorigenesis (Lee et al., 1994; Porkka and Visakorpi, 2004). The mechanism of 
hypermethylation is not well understood, but a recent study has suggested that the 
process is dependent on the histone deacetylase 1 (HDAC1). The silencing of 
GSTP1 leads to oxidative stress–induced DNA damage and the expression of 
hypoxia-induced factor 1α (HIF-1α) (Li et al., 2011a). 
1.1.4.3 NKX3.1  
NKX3.1 encodes a homeodomain transcription factor that is regulated by 
androgens and is expressed specifically in luminal epithelial cells of the prostate. 
One of the most frequent genetic alteration in PC is the somatic loss of 
heterozygosity (LOH) in chromosome 8p (Taylor et al., 2010), which harbors the 
NK3 homeobox 1 (NKX3.1) gene. NXK3.1 is associated with initiation and 
19 
progression of PC and is a well-known prostate tumor suppressor gene (Hughes et 
al., 2005; Gelmann, 2003). NKX3.1 expression is decreased or absent in 
approximately 50 % of PIN lesions and primary prostate tumors and in as many as 
80 % of metastatic tumors (Taylor et al., 2010). The role of NKX3.1 loss in PC 
initiation is not well understood, but a recent study found that NKX3.1 activates the 
cellular response to DNA damage and has a protective effect against DNA-
damaging agents, although it does not directly influence apoptosis (Bowen and 
Gelmann, 2010). However, the role of NKX3.1 is becoming more controversial, due 
to the discovery of rare castration-resistant NKX3.1-expressing cells (CARN) in a 
murine model. These cells can self-renew in vivo and can reconstitute prostate ducts 
in renal grafts using single-cell transplantation assays. Moreover, the concomitant 
deletion of the phosphatase and tensin homolog (PTEN) tumor suppressor gene in 
CARNs results in rapid formation of carcinoma following androgen-mediated 
regeneration (Wang et al., 2009a). These characteristics would make CARNs the 
putative PC stem cells (Wang and Shen 2011). 
1.1.4.4 ETS rearrangement 
A recent study by Taylor and colleagues (2010), which screened for genetic 
alterations in a large cohort of primary PC and metastatic PC, confirmed that 
although mutations in known tumor suppressors and oncogenes exist, they are rare 
(Taylor et al., 2010). However, in approximately 50 % of PC cases analyzed by 
Taylor and colleagues (2010), the genomic region 21q22.2-3 between v-ets 
erythroblastosis virus E26 oncogene homolog (avian) (ERG) and transmembrane 
protease, serine 2 (TMPRSS2) was lost. This area is of particular importance in PC 
because Tomlins and colleagues (2005) have shown that, due to the deletion, ERG is 
fused with the androgen-regulated gene TMPRSS2. The TMPRSS2:ERG fusion 
gene is thus androgen-regulated (Tomlins et al., 2005). ERG is a member of the E26 
transformation-specific (ETS) family of transcription factors. These transcription 
factors are involved in embryonic development, cell proliferation, differentiation, 
angiogenesis, inflammation, and apoptosis (Seth and Watson, 2005). The 
identification of TMPRSS2:ERG broke the paradigm that fusion transcripts are rare 
in solid tumors (Helgeson et al., 2008; Rickman et al., 2009). Additionally, less 
common non-ETS fusion genes have recently been found (Palanisamy et al., 2010; 
Pflueger et al., 2010). Interestingly, all non-ETS fusion genes occur in the context of 
the TMPRSS2:ERG rearrangement, suggesting that particular fusions may 
predispose cancer to rearranging events (Pflueger et al., 2010). 
Haffner et al. (2010) have suggested that the TMPRSS2:ERG gene fusion event 
is AR dependent. According to these authors, AR induces the proximity of the ERG 
and TMPRSS2 genes and triggers topoisomerase-2b (TOP2B)-mediated gene fusion 
formation (Haffner et al., 2010). 
The formation of the TMPRSS2:ERG fusion seems to be an early event in the 
development of PC because this fusion is found in approximately 20 % of PIN 
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lesions (Lawson & Witte, 2007). However, in a transgenic mouse model, ERG is not 
able to drive PC alone, and a possible cooperation with PTEN loss and PI3K 
pathway activation has been suggested (Zong et al., 2009; Carver et al., 2009; King 
et al., 2009).  
TMPRSS2:ERG is found with the same frequency in PC and CRPC (Saramaki et 
al., 2008). The data regarding the prognostic value of the fusions are still 
controversial, and investigations to understand the mechanisms that these fused 
transcription factors regulate are ongoing (Saramaki et al., 2008; Barwick et al., 
2010; Leinonen et al., 2010; Rubio-Briones et al., 2010; Minner et al., 2011; 
Tomlins et al., 2011). 
Recently, a tumor suppressor, ring finger and WD repeat domain 2 (RFWD2 
alias COP1) was shown to cause degradation of some ETS family members. The 
expression of COP1 is low in PC specimens showing concomitant overexpression of 
ETS transcription factors but not in specimens with ETS rearrangement (Vitari et 
al., 2011; McCarthy, 2011). Another study by Brenner et al. (2011) has found that 
the fusion product of the TMPRSS2:ERG gene physically interacts with and is 
dependent upon for its oncologic activity, the enzyme poly (ADP-ribose) 
polymerase 1 (PARP1) and the catalytic subunit of DNA protein kinase (DNA-
PKcs). PARP1 is also upregulated in response to DNA damage (Brenner et al., 
2011). The authors showed that inhibition of PARP1 has an antitumor activity 
(Brenner et al., 2011), and clinical evaluation in combination with chemotherapy is 
already ongoing in advanced sporadic PC (de Bono et al., 2011b; Sandhu et al., 
2011). 
1.1.4.5 PTEN  
PTEN targets primarily phosphatidylinositol 3,4,5-triphosphate (PIP3), 
downregulating the PI3K/AKT signaling pathway, which is crucial for cell survival 
and apoptosis (Li et al., 1997). 
Taylor and colleagues have also confirmed deletions targeting PTEN on 
10q23.31 (Taylor et al., 2010). The PI3K/AKT signaling pathway has been shown 
to be altered in 42 % and up to 100 % of primary and metastatic PC, respectively 
(Taylor et al., 2010).  
Deletions and mutations of the PTEN gene are more frequent in metastatic than 
in primary PC. Because the loss of one allele (i.e., LOH) at the PTEN locus occurs 
in approximately 40 % of cases, haploinsufficiency has been suggested to be enough 
to trigger PC initiation/progression (Vlietstra et al., 1998; Davies et al., 2002; 
Fernandez and Eng, 2002). 
As consequence of PTEN expression downregulation, PI3K/AKT pathway 
activation is very common in late stage tumors (Li et al., 1997; Taylor et al., 2010). 
Furthermore, PTEN expression inversely correlates with AR expression, and direct 
downregulation of PTEN by AR has been proposed (Wang et al., 2011a). A recent 
report has suggested that PC can progress to the CRPC stage independently of the 
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AR axis via the PI3K/AKT signaling pathway; these data suggest that there is 
crosstalk between AR and the PI3K/AKT pathway (Mulhoand et al., 2011). 
Subsequently, Carver and colleagues (2011) have confirmed that this crosstalk 
between AR and PI3K/AKT signaling exists, suggesting that the concomitant 
inhibition of AR and PI3K/AKT signaling could be beneficial (Mulhoand et al., 
2011; Carver et al., 2011). The crosstalk is dependent on the AR target gene 
androgen-regulated FK506 binding protein 5 (FKBP5), which encodes for the 
chaperon protein of the AKT phosphatase PHLPP (PH domain and leucine rich 
repeat protein phosphatase 1) (Pei et al., 2009). The data suggest that AR negatively 
regulates AKT activity and that therapeutic inhibition of AR may destabilize 
PHLPP1 because FKBP5 would no longer be produced. The destabilization of 
PHLPP1 leaves the activation of the AKT pathway intact, especially in the context 
of PTEN loss, leading to castration-resistant growth (Mulhoand et al., 2011; Carver 
et al., 2011). Subsequently, Chen and colleagues (2011a) have identified PHLPP1 
as tumor suppressor that is significantly co-deleted with PTEN in metastatic PC. 
Another regulator of the PI3/AKT signaling pathway is the membrane associated 
guanylate kinase, WW and PDZ domain containing 2 (MAGI2) (Wu et al., 2000; 
Vazquezet al., 2001). Berger and colleagues (2011) have sequenced seven primary 
PC (three harboring ETS rearrangements) and their matched normal controls. The 
authors found several rearrangements occurring within genes, especially in the 
context of the TMPRSS2:ERG fusion. Specifically, they confirmed that PTEN 
signaling may be disrupted by these microrearrangements. They further 
characterized rearrangements impeding the function of MAGI2. Loss of function of 
MAGI2 may also deregulate the PI3/AKT signaling pathway (Berger et al., 2011), 
suggesting that the PI3/AKT pathway is subjected to diverse activating forces. In the 
context of PTEN loss, SMAD family member 4 (SMAD4) was recently shown to be 
downregulated in advanced compared to localized PC and to exert metastatic 
potential in a mouse model (Ding et al., 2011). This finding links cytokine 
pathways, such as the transforming growth factor–β (TGFβ) signaling pathway, to 
PC progression (Ding et al., 2011). 
1.1.4.6 TP53  
The tumor suppressor gene TP53 is a key regulator of the cell cycle that controls 
the transition from the G1 phase to the S phase. Although TP53 is the most 
commonly mutated gene in human cancers, mutations are rare in early PC but are 
found in approximately 20-40 % of advanced PCs cases (Porkka and Visakorpi, 
2004), suggesting a role in tumor recurrence and metastasis. Interestingly, p53 
inhibition has been proposed to upregulate AR transcription in cellular models 
(Alimirah et al., 2007). Chen and colleagues (2011a) have also found that 
concomitant loss of PTEN and PHLPP is associated with the loss of TP53 in 
advanced PC (Chen et al., 2011a). Taken together, these data suggest that p53 is not 
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involved in PC initiation but rather in progression (Chen et al., 2011a; Shiota et al., 
2011). 
1.1.4.7 RAS/RAF signaling 
The activated RAS/RAF pathway mediates expression of genes involved in cell 
proliferation and prevention of apoptosis via the activation of several transcription 
factors, such as ETS and MYC, and the modulation of mitochondrial localized 
proteins (McCubrey et al., 2007). 
The frequency of RAS mutations varies with ethnicity; in the Western 
population, mutations are found in 5 % of the tumors, whereas in the Japanese 
population, mutated RAS can be found in 26 % of the tumors (Konishi et al., 2005). 
However, Taylor and colleagues (2010) have reported that 43 % and 90 % of 
primary and advanced PCs, respectively, harbor activating alterations in genes 
involved in the RAS/RAF signaling pathway (Taylor et al., 2010). 
1.1.4.8 RB1 
RB1 is a well-known tumor suppressor gene that encodes for a protein that 
controls the cell cycle at the level of the G1/S phase by repressing the transcriptional 
activity of the activator class of E2F transcription factors (E2F1–E2F3) (Burkhart 
and Sage, 2008). E2F1 has been shown to upregulate AR transcriptional activity as a 
consequence of RB1 depletion. This finding was confirmed in the clinical setting by 
data showing that tumors that do not express an RB1 gene expression signature also 
show upregulation of AR (Sharma et al., 2010). The RB1 gene is lost in up to 20 % 
of early stage PCs, and mutated forms of pRB are found in up to 50 % of advanced 
PCs (Konishi et al., 2005, Taylor et al., 2010). Furthermore, alterations in the RB 
signaling pathway or loss or mutation of RB1 occur in 34 % and 74 % of primary 
and advanced PCs, respectively (Taylor et al., 2010). 
1.1.4.9 Non-coding RNAs 
Non-coding RNAs (ncRNAs) have been implicated in cancer initiation and 
progression (Di Leva and Croce, 2010). MicroRNAs (miRs) are small ncRNAs that 
regulate protein translation by targeting specific messenger RNAs (Bartel, 2004). A 
general down-regulation of miRs has been shown in CRPC compared to PC (Porkka 
et al., 2007); these data have been confirmed just recently (Martens-Uzunova et al., 
2011). Several miRs, such as miR-15 and miR-16-1, miR-193b and miR-34a, have 
also been suggested to be tumor suppressor genes (Cimmino et al., 2005; Bonci et 
al., 2008; Rauhala et al., 2010; Liu et al., 2011). These miRs modulate various 
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cellular processes, such as cell cycle regulation and apoptosis, invasion and 
migration, androgen-independent growth and epigenetic changes (Coppola et al., 
2010). More recently, miR expression signatures have also suggested to be both 
diagnostic and prognostic for PC (Martens-Uzunova et al., 2011). Waltering et al. 
(2011) have also demonstrated that a small number of miRs are also androgen-
regulated. 
In addition, a recent report has shown that long intergenic ncRNAs can also be 
involved in PC progression. Prostate cancer-associated ncRNA transcript 1 
(PCAT1) has been implicated in disease progression (Prensner et al., 2011). The 
expression of PCAT1 is mutually exclusive with the expression of enhancer of zeste 
homolog 2 (Drosophila) (EZH2) (Prensner et al., 2011). Overexpression of EZH2 is 
a marker of advanced and metastatic disease in many solid tumors, including 
prostate and breast cancer (Chase and Cross, 2011). Furthermore, EZH2 is an 
enzymatic component of the polycomb repressive complex 2 (PRC2), which has 
recently been found to regulate the expression of a substantial number of miRs 
involved in PC progression together with the PRC1 (Cao et al., 2011). 
1.1.4.10 Amplification and overexpression of MYC 
MYC is a transcription factor that plays a key role in regulating a number of 
cellular processes, including cell-cycle progression, metabolism, ribosome 
biogenesis, protein synthesis, mitochondrial function, and stem cell self-renewal 
(Dang et al., 2006). 
One of the most common amplified loci in PC includes v-myc myelocytomatosis 
viral oncogene homolog (avian) (MYC) at 8q24.21 (Taylor et al., 2010). MYC is a 
well-known oncogene and is overexpressed in many cancers (Nesbit et al., 1999). 
The amplification of the 8q24 locus and MYC in PC has been known for a long time 
(Visakorpi et al., 1995; Jenkins et al., 1997; Nupponen et al., 1998). The 
overexpression of MYC protein has been difficult to evaluate for technical reasons 
(Koh et al., 2010). Nupponen et al. (1998) have found that gains of copy number in 
the same loci are even more common than the amplification and occur in up to 70 % 
of advanced tumors. However, MYC is not overexpressed according to these studies 
(Nupponen et al., 1999; Savinainen et al., 2004). 
A murine model harboring prostate-specific overexpression of MYC (Hi-MYC 
model) has shown that MYC is sufficient to induce PC (Ellwood-Yen et al., 2003). 
Moreover, the most recent data suggest that nuclear MYC protein overexpression is 
an early alteration in PC that also persists to late stage disease (Gurel et al., 2008). 
MYC was also recently found to cooperate with the AKT pathway and altering the 
sensitivity to mTOR inhibitors (Balakumaran, et al., 2009; Clegg et al., 2011), 
probably through the MYC target eukaryotic translation initiation factor 4E binding 
protein 1 (4EBP1) (Balakumaran, et al., 2009). Other MYC-associated mechanisms 
have also been implicated in PC initiation and progression. Among these are 
NKX3.1 downregulation, upregulation of EZH2 (Koh et al., 2010), and interplay of 
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regulation with TMPRSS2:ERG fusion (see chapter 1.1.4.4) (Sun et al., 2008; Koh 
et al., 2010). Furthermore, MYC has been proposed to upregulate AR levels in PC 
cells through the MYC target endothelin 1 (ET-1) (Lee et al., 2009). 
 
1.2 Androgen receptor-mediated mechanisms 
1.2.1 Androgen receptor: structure and function 
The nuclear receptor AR is a member of the steroid hormone receptors (SHRs) 
superfamily. SHRs are sensors of the intra- and extracellular physiology and control 
several processes, such as development, differentiation, metabolic homeostasis and 
reproduction (Perissi and Rosenfeld, 2005). The SHRs consists of at least the 
following three distinct domains: a ligand binding domain (LBD), which is at the C-
terminal side of the protein, a DNA binding domain (DBD), and an N-terminal 
domain (NTD) (see also Figure 5 A&B).  
The LBD and DBD share a high degree of homology among the members of the 
family. The activation of the SHRs involves conformational changes in the LBD as 
a consequence of ligand binding. The LBD differs only to account for the properties 
of the various ligands. Thus, the volume of the ligand pocket can vary dramatically. 
Furthermore, the LBD contains amino acid motifs that can be recognized by other 
proteins, which are able to modulate the transactivation of the receptors; these 
proteins are named coregulatory proteins or coregulators and can be coactivators or 
corepressors. In addition, the LBD also contains residues that form a surface 
involved in dimerization and a region called activation function 2 (AF2) that is 
essential for specific ligand binding, dimerization, and transactivation. Some nuclear 
receptors, such as the retinoid X receptor, can form heterodimers, while others, such 
as AR, can form homodimers. The LBD is linked to the DBD by a hinge region. The 
DBD is needed for the SHRs to perform their functions (Reviewed by McEwan, 
2009). The activated SHRs bind to DNA response elements (REs) in relative 
proximity to target genes (see chapter 1.2.4.1.1). The DBD also acts as an allosteric 
modulator by regulating the dimerization and the structure of the NTD and its 
protein interactions (Lefstin and Yamamoto, 1998). The NTD is the domain that 
varies the most among the family members. The NTD can vary in length and amino 
acid sequence and does not show great homology among the members of the family. 
Additionally, the structure of the NTD of SHRs is modulated by the binding to DNA 
and coregulatory proteins. The NTD contains a region named activation function 1 
(AF1), which is required for transactivation (Reviewed by McEwan, 2009). 
Inactive AR is found in the cytoplasm bound to chaperone proteins from the 
family of the heat-shock proteins (HSPs) (Reviewed by McEwan, 2009). The LBD 
has been shown to exert inhibitory properties on the receptor to prevent its 
25 
inappropriate activation (Jenster et al., 1991). When the ligand, testosterone or 
DHT, binds in the pocket of the LBD, a conformational change is induced that 
causes the release of AR from the HSPs. AR is then able to interact with other 
receptor molecules or with itself intramolecularly (Reviewed by McEwan, 2009). 
The activated receptor translocates into the nucleus via a particular portion of its 
amino acid sequence that is functionally similar to a nucleoplasmin nuclear 
localization signal (Jenster et al., 1993). In the nucleus, AR dimerizes (Gelmann et 
al., 2002; McEwan, 2004) and interacts with other transcription factors and proteins, 
which may drive the recognition of specific target regions in the chromatin (Massie 
et al., 2007; Lupien et al., 2008; McEwan, 2009; Wang et al., 2009b; Lupien and 
Brown, 2009; Wang et al., 2011b; Robinson et al., 2011).  
Once bound to the promoter and/or enhancer elements of target genes, the SHRs 
activate transcription via AF1 and/or AF2 by recruiting protein complexes with 
enzymatic activities with the final scope of opening the chromatin structure and 
components of the general transcription machinery, resulting in the formation of the 
transcription initiation complex (see chapter 1.2.4.2) (Reviewed by Perissi and 
Rosenfeld, 2005; McEwan, 2009; He et al., 2010). 
Much evidence has led to the conviction that the assembly and disassembly of the 
protein complexes on a target gene regulatory region in response to a hormone 
signal follows a cyclical pattern. The mechanism may be shared among the SHRs 
(Hager et al., 2004; Perissi and Rosenfeld, 2005; Stavreva et al., 2009; Carlberg et 
al., 2010;) and is dependent on the proteasome (Kang et al., 2002; Jia et al., 2006) 
and HSP activity (Conway-Campbell et al., 2011). The former dependency may 
explain why AR constantly shuttles from the nucleus to the cytoplasm in response to 
androgen stimulation (Black et al., 2001; Gioeli et al., 2006; Kesler et al., 2007). 
1.2.2 Androgen receptor and castration-resistant prostate 
cancer 
Given the dependency of the prostate on androgens/AR signaling in 
physiological and pathological conditions, AR has been extensively studied. The 
importance of AR signaling in the progression of this disease is increasingly 
evident, and AR is currently recognized to be an important driver and a validated 
drug target in advanced PC (Ryan and Tindall, 2011).  
Lowering tissue levels of DHT with 5α-reductase (steroid-5α-reductase (SRD5A) 
inhibitors, such as finasteride or dutasteride, decreases the risk of PC (Thompson et 
al., 2003; Andriole et al., 2010). Furthermore, several recent clinical studies on 
CRPC have reported successful results in targeting the AR axis by either preventing 
steroidogenesis with the CYP17 inhibitor abiraterone (deBono et al., 2011a) or 
inhibiting AR activity with the novel super antiandrogen MDV3100 (Tran et al., 
2009; Scher et al., 2010). 
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During progression to CRPC, AR signaling is maintained through several 
mechanisms (Attar et al., 2009; Antonarakis and Armstrong, 2011b) (Figure 2B). 
These mechanisms include: 
- AR overexpression; 
- steroidogenesis; 
- AR mutations; 
- alterations in AR interacting proteins; 
- ligand-independent activation of AR signaling and AR variants. 
1.2.2.1 Androgen receptor overexpression 
AR overexpression has been suggested to be associated with poor prognosis 
(Henshall et al., 2001; Donovan et al., 2010). In 1995, Visakorpi and colleagues 
found recurrent amplification of the AR gene locus resulting in AR overexpression 
in one third of CRPCs (Visakorpi et al., 1995; Linja et al., 2001). Amplification of 
AR (Xq12) occurs in approximately 30 % of patients, but it is found only in CRPCs 
(Visakorpi et al., 1995; Koivisto et al., 1997; Taylor et al., 2010), suggesting that the 
ADT selects for this genetic alteration (Porkka and Visakorpi, 2004). Furthermore, 
patients with AR gene amplification respond better to a second line of androgen 
blockade than patients without the amplification (Palmberg et al., 2000), suggesting 
that the relapse is driven by the amplification. However, other mechanisms leading 
to AR overexpression must exist because AR is overexpressed in approximately 80-
90 % of advanced PCs (Edwards et al., 2003; Linja et al., 2004; Chen et al., 2004; 
Tamura et al., 2007; Liu et al., 2009). The finding of AR gene overexpression has 
led to the hypothesis that CRPCs might be androgen-hypersensitive (Nupponen and 
Visakorpi, 1999). Indeed, in a tumor xenograft model, modest AR overexpression 
was demonstrated to be sufficient to drive androgen independence and convert 
androgen antagonists, such as bicalutamide and flutamide, into agonists (Chen et al., 
2004). 
All of the mechanisms leading to the AR overexpression in CRPCs are still not 
known. In addition to AR gene amplification, loss of the tumor suppressor RB1 or 
regulation through other transcription factors may partially explain the AR 
overexpression (see chapter 1.1.4.8). Another mechanism involving the loss of 
purine-rich element binding protein A (PURA), part of a transcriptional repressor 
complex, has been proposed (Wang et al., 2008). This repressor complex was shown 
to bind immediately after the AR gene’s transcription start site (TSS) and repress 
AR mRNA transcription. Moreover, in CRPC specimens, diminished expression of 
PURA has been observed, which correlates with AR overexpression (Wang et al., 
2008). 
Thus, understanding the molecular advantage that AR overexpression provides to 
the therapy-resistant disease is important. 
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1.2.2.2 Steroidogenesis 
Castration does not affect androgen synthesis in the adrenal glands. This lack of 
effect is important because the increased level of AR suggests that the tumor may 
become hypersensitive to residual androgens, which are not abolished by castration 
(Nupponen and Visakorpi, 1999). Several studies support the idea that CRPCs can 
be maintained by low levels of androgens produced by the tumor cells or by the 
adrenal gland through the conversion of a steroid precursor (Yamaoka et al., 2010; 
Cai and Balk, 2011). Specifically, the adrenal gland produces approximately 10–30 
% of serum androgens, which may play a significant role in activating AR signaling 
(Bruno et al., 2007). 
 
Figure 3. Enzymes involved in both classical (left/middle) and backdoor (far right, 
bold font) steroidogenesis pathways. Many of the steroidogenic enzymes catalyze more 
than one step in the pathway. Standards available for underlined steroids. Adapted from 
Lubik and colleagues (2011), the image now also shows the alternative de novo pathway 
(dashed arrows) as described in Chang et al. (2011). The enzymes involved in the de novo 
pathway are written in Italic. Finasteride inhibits SRD5A1/2, while abiraterone inhibits 
CYP17A1 (Adapted from Lubik et al. Insulin increases de novo steroidogenesis in prostate 
cancer cells. Cancer Res. 2011;71:5754-64 with permission by American Association for 
Cancer Research and from Auchus RJ. The backdoor pathway to dihydrotestosterone. 
Trends Endocrinol Metab. 2004 Nov;15(9):432-8 with permission from Elsevier.). 
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LHRH agonists fail to prevent synthesis of androgens by the adrenal glands, and 
patients developing resistance to antiandrogen therapy have been shown to maintain 
sufficient intratumoral levels of testosterone and DHT to activate AR (Chen et al., 
2004). Furthermore, adipose tissue has also been shown to be able to produce 
androgens (Puche et al., 2002). Dehydroepiandrosterone (DHEA) and other steroid 
precursors secreted by the adrenal glands, which represents 5-10 % of the total 
androgens in the bloodstream, can be converted into potent androgens (Labrie et al., 
1987). In addition, CRPCs may be able to synthesize testicular androgens through 
intracrine production from adrenal androgens and cholesterol (Titus et al., 2005) 
(Figure 3). Therefore, the adrenal androgens DHEA and androstenedione (AD) can 
be transported to CRPC tissue and converted to testosterone and DHT. DHEA and 
AD can also be synthesized intratumorally in CRPC from cholesterol tissues and 
converted to testosterone and DHT via the de novo route 
(DHEAADTestosteroneDHT). In fact, compared to primary PC and normal 
prostate (e.g., BPH), CRPC has been shown to overexpress enzymes needed during 
the conversion of adrenal androgens to DHT and enzymes needed for the de novo 
synthesis of DHT (Stanbrough et al., 2006; Mostaghel et al., 2007; Locke et al., 
2008; Locke et al., 2010). Pathways that enable CRPCs to synthesize androgens 
offer the tumor an escape route from ADT (Montgomery et al., 2008) (Figure 3). 
Intratumoral enzymes involved in androgen biosynthesis, such as CYP17A1 and 
CYP19A1 (which also produce DHEA), are upregulated in CRPCs (Montgomery et 
al., 2008), and their expression seems to correlate with high stage, high Gleason 
score and short recurrence-free time (Stigliano et al., 2007). Therefore, these 
enzymes are now considered promising drug targets (Antonarakis and Armstrong, 
2011). 
The importance of steroidogenesis in PC progression and as a mechanism of 
resistance has today been confirmed by successful trials with a CYP17 inhibitor, 
abiraterone, which has shown improved survival in CRPC (deBono et al., 2011a). 
However, resistance to abiraterone has already been reported (Attard et al., 2008), 
suggesting that androgen steroidogenesis is a labile process that can rely on several 
mechanisms to escape these therapeutic approaches. For instance, treatment with 
abiraterone has recently been demonstrated to select for tumor cells overexpressing 
CYP17A1, providing a mechanism for the development of resistance to CYP17A1 
inhibitors (Cai et al., 2011). Furthermore, CRPC cells have also been shown to be 
able to use a novel synthetic pathway through which DHT is produced in tumor 
cells from the adrenal precursor AD via upregulation of steroid 5α-reductase 
isoenzyme-1 (SRD5A1), bypassing testosterone production (Chang et al., 2011) 
(Figure 3). This observation suggests alternative mechanisms of recurrence upon 
treatment with other drugs, such as dutasteride and other primary therapies. 
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1.2.2.3 Androgen receptor mutations 
In 1995, the first study reported AR somatic mutations in the androgen-receptor 
gene in CRPCs that were not present in the primary tumors of the same patients 
(Taplin et al., 1995). However, in general, AR mutations are rare (Wallén et al., 
1999; Culig et al., 2001; Taylor et al., 2010). Mutations are found in approximately 
20-30 % of patients treated with antiandrogens and play a role in the resistance to 
such drugs (Taplin et al., 1995; Haapala et al., 2001). These mutations are most 
commonly found in the LBD and are known to affect the specificity of AR toward 
its ligand (Veldscholte et al., 1992; Sack et al., 2001). These mutations allow other 
nuclear hormones (estrogen and progestin), corticosteroids (cortisol and cortisone) 
and, paradoxically, antiandrogens such as cyproterone, hydroxyflutamide and 
bicalutamide to activate AR (Newmark et al., 1992; Suzuki et al., 1993; Culig et al., 
1993; Taplin et al., 1995; Culig et al., 1999; Thin et al., 2002; Hara et al., 2005).  
Mutations affecting the NTD of AR have also been reported (Tilley et al., 1996). 
Although mutations in the NTD may affect the ability of AR to bind its coregulators 
(Bergerat & Céraline, 2009), no clear effect on AR activity could be predicted due 
to lack of an NTD crystal structure (McEwan, 2009). The tumors used in these 
studies were rare forms of already metastasized late stage PC (Tilley et al. 1996), 
and such mutations have not been found in other studies (Wallen et al., 1999). 
Mutations in the DBD may also interfere with the nuclear localization signal and 
thus affect transactivation and transrepression abilities or favor binding to unspecific 
promoters, affecting the set of target genes regulated by AR (Bergerat & Céraline, 
2009). 
1.2.2.4 Androgen receptor interacting proteins 
More than 300 proteins have now been reported to interact with AR. 
Approximately 75 % interact directly with the receptor. Approximately half of the 
proteins are coactivators, and approximately 30 % are corepressors. The rest are of 
unknown function or do not seem to elicit a clear activity on the receptor. For the 
majority of these proteins, it is not clear with which domain of the receptor they 
interact. An updated list of coregulators is available on-line 
(http://androgendb.mcgill.ca/). In general, the definition of AR coregulators is 
proteins that either enhance (coactivator) or decrease (corepressor) the 
transactivation of AR, meaning that they do not modify the AR basal transcriptional 
activity (Heemers and Tindall, 2007). However, this vision is arguable, given the 
number of proteins with unknown function that interact with AR. 
According to the most recent classification by Heemers and Tindall (2007), the 
AR interacting proteins can be divided into the following 3 distinct classes: 
- components of the general transcription machinery; 
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- functionally diverse proteins with AR coactivating or corepressing properties 
(coregulators modifying chromatin status and coregulators with other 
functions);  
- specific transcription factors (see chapter 1.2.4.2). 
1.2.2.4.1 Components of the general transcription machinery 
It is increasingly evident that AR can modulate the transcription of target genes 
by regulating both transcription initiation and transcription elongation (Heemers and 
Tindall, 2007). For instance, AR is able to interact with two proteins of the basal 
transcription machinery, general transcription factor IIF, polypeptide 1 (GTF2F1) 
and general transcription factor IIF, polypeptide 2 (alias GTF2F2), which are 
subunits of the TFIIF (transcription factor IIF) complex and with TFIIH 
(transcription factor IIH). These complexes are recruited to the RNA polymerase to 
facilitate strand preparation. The interaction of AR with TFIIF is thought to induce 
more open chromatin via the further recruitment of other transcriptional activators, 
while the interaction with TFIIH has been demonstrated to result in the 
phosphorylation of the RNA polymerase, which is essential in transcription 
initiation (Lee and Chang, 2003). Transcription elongation is, on the other hand, 
activated by polymerase (RNA) II (DNA directed) polypeptide B (POLR2B), which 
activates the RNA polymerase. Again, AR also interacts with this protein, resulting 
in transcription elongation (Lee et al., 2003). 
1.2.2.4.2 Coregulators modifying chromatin status 
The AR coregulators have been recently classified according to their function 
(Heemers and Tindall, 2007). Because transcription occurs on the chromatin, it is 
not surprising that a vast number of AR coregulators function as components of the 
chromatin remodeling complex or are histone modifiers.  
The local chromatin structure is influenced, in part, by the presence or absence of 
the nucleosomes, but principally by the covalent modifications on the histone tails 
and DNA methylation (Li et al., 2007). To date, the most commonly identified 
histone modifications are acetylation, methylation, phosphorylation, ubiquitination, 
biotinylation, SUMOylation or poly-ADP-ribosylation (Heemers and Tindall, 2007). 
These modifications affect the physical properties of the histones and, thus, of the 
nucleosomes, which in turn affect the chromatin and the accessibly of the genome 
(Felsenfeld and Groudine, 2003; Cosgrove and Wolfberger, 2005). The great variety 
of histone modifications has led to the hypothesis of the “histone code” (Santos-
Rosa and Caldas, 2005). 
Acetylation is the most studied histone modification. The general consensus is 
that hyperacetylation favors gene expression, whereas hypoacetylation is associated 
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with genes that are not actively transcribed. For example, the tail of H3 contains 13 
positively charged lysine (K) residues and only one to four of these residues become 
acetylated, which decreases the positive charge by only 10-30 %. These 
modifications offer a platform for other non-histone proteins that either activate or 
repress transcription (Munshi et al., 2009). For example, acetylation of H4K8, 
H3K9 and H3K14 have an important role in the recruitment of the 11 subunit 
SWI/SNF chromatin remodeling complex and TFIID during transcription initiation 
(Fukuda et al., 2006). The SWI/SNF complex has been shown to be capable of 
disrupting, repositioning or displacing histones in vitro and in vivo (Côté et al., 
1994; Owen-Hughes et al., 1996; Whitehouse et al., 1999; Becker and Horz, 2002) 
(Figure 4). 
AR has been found to interact deeply with the components of the chromatin 
remodeling complex such as SWI/SNF. Coactivators, such as AR interacting protein 
4 (ARIP4), BRG1 (alias SMARCA4: SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, member 4) and BAF57 (alias 
SMARCE1: SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1), all bridge AR activation and are all SWI/SNF 
dependent (Heemers and Tindall, 2007). 
The first SHR coactivator was identified in 1995 by Oñate and colleagues (1995) 
and was revealed to be a member of the family of the p160 SRC (steroid receptor 
coactivator) gene family named SRC1 (the official name was then changed to 
nuclear receptor coactivator 1 (NCOA1)) (Oñate et al., 1995). Subsequently, other 
members of the p160 SRC family have been identified: SRC2 (alias nuclear receptor 
coactivator 2 (NCOA2) or glucocorticoid receptor-interacting protein-1 (GRIP1) or 
transcriptional intermediary factor 2 (TIF2)) and SRC3 (alias p300/CBP interacting 
protein (p/CIP) or receptor-associated coactivator-3 (RAC3) or amplified in breast 
cancer 1 (AIB1)). Moreover, SRCs have been shown to recruit more activators, such 
as E1A binding protein p300 (EP300) and CREB binding protein (CREEBP alias 
CBP). All of these coactivators have histone acetyltransferase (HAT) activity and 
others, such as K (lysine) acetyltransferase 5 (KAT5 or Tat interactive protein 60 
kDa (TIP60)) and KAT7, have been identified to belong in this group (Heemers and 
Tindall, 2007). The activity of HAT proteins is counterbalanced by histone 
deacetylases (HDACs). Among them, Sirtuin1 (SIRT1) (Fu et al., 2006) and 
HDAC7 (Karvonen et al., 2006) have been shown to directly interact with AR and 
repress AR activity. However, only SIRT1 (but not HDAC7) has been shown to 
directly deacetylate AR (Fu et al., 2006; Karvonen et al., 2006). Other HDACs have 
been shown to indirectly repress AR activity through the association with other 
subunits of the nuclear receptor corepressor complex (NCoR) (Perissi et al., 2010). 
Although the NCOR1 and NCOR2 complexes have been shown to comprehend only 
proteins with HDAC activity, other complexes have been identified, such as the 
nucleosome remodeling and histone deacetylation (NURD) complex, which 
combines HDAC activity and histone demethylase activity. These complexes 
include the AR coregulator lysine specific histone demethylase 1 (LSD1) (Perissi et 
al., 2010) (Figure 4). 
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Figure 4. Coactivator and corepressor complexes required for nuclear-receptor-
mediated transcriptional regulation. The regulation of target genes by nuclear receptors 
requires a vast number of coregulatory complexes with various functions and enzymatic 
activities. Coactivator complexes (top side of the chromatin filament) include factors that 
contain ATP-dependent chromatin remodeling activity, histone arginine methyltransferases 
histone acetyltransferases and factors that are involved in RNA processing and components 
of the so-called Mediator complex that mediate the interaction with the RNA Pol II 
machinery. Conversely, corepressors (bottom side of the chromatin filament) include ATP-
dependent chromatin remodeling complexes basal corepressors, such as NCoR and 
SMRT, which function as platforms for the recruitment of several subcomplexes that often 
contain histone deacetylase activity, and specific corepressors, such as LCoR and RIP140, 
which are able to recruit general corepressors. The recruitment of these complexes is not 
simultaneous, and this schematic representation does not illustrate the dynamics of their 
recruitment. IIA, IIB, IIE, IIF, IIH, IIJ, general transcription factors A, B, E, F, H, J; HDAC, 
histone deacetylase; LCoR, ligand-dependent nuclear-receptor corepressor; NCoR, 
nuclear-receptor corepressor; RIP140, receptor-interacting protein-140; SMRT, silencing 
mediator of retinoic acid and thyroid hormone receptors; TAF, TBP-associated factor; TBP, 
TATA-binding protein. (Reprinted by permission from Macmillan Publishers Ltd: [Nature 
Reviews Molecular Cell Biology] (Perissi and Rosenfeld, 2005), copyright (2005)). 
The methylation of the histones tails is the least understood histone modification. 
H3 and H4 lysines residues can be mono-, di-, or trimethylated, which increases the 
variety of possible modification patterns. Unlike acetylation and phosphorylation, 
methylation is thought to be a stable histone modification. Methylation can be a sign 
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of both transcriptional activity and inactivity according to the specific modified 
residue (Munshi et al., 2009).  
Demethylation at distinct lysine residues in histone H3 by LSD1 causes either 
gene repression (Shi et al., 2004) or activation (Metzger et al., 2005). Furthermore, 
LSD1 may selectively act as a component of co-repressor complexes, removing 
mono- and dimethyl marks from H3K4 or, during AR mediated gene transcription, 
removing mono- and dimethyl marks from H3K9. In AR-dependent gene activation, 
LSD1 cooperates with a trimethyl demethylase, the Jumonji C (JMJC) 5 domain-
containing protein JMJD2C (also known as KDM4C), in removing repressive 
histone marks from H3K9 (Wissmann et al., 2007). Recently, Metzger and 
colleagues (2010) found that during AR-dependent gene transcription, LSD1 
activity is subject to the proof-reading activity of another enzyme, which catalyzes 
the phosphorylation of H3T6: protein kinase C beta I (PKCβI, also known as 
PRKCβ) (Metzger et al., 2010). Other demethylases have also been shown to be 
involved in AR transcription. One is the lysine (K)-specific demethylase 3A 
(KDM3A alias JHMD2A or JMJD1A), which has been shown to be an AR 
coactivator (Yamane et al., 2006). As it is easy to imagine, AR transcription 
depends not only on demethylases but also on methylases acting in a concerted 
manner to tightly regulate AR-mediated transcription (Heemers and Tindall, 2007). 
For instance, coactivator-associated arginine methyltransferase 1 (CARM1, alias 
protein arginine methyltransferase 5 (PRMT5)), which methylates H3R17, and 
PRMT1, which methylates H4R3, have been shown to be recruited in an androgen-
dependent manner to activated transcription complexes of AR target genes. 
However, their activity was also shown to be dependent on SRC proteins (Figure 4) 
(Chen et al., 1999; Wang et al., 2001). 
1.2.2.4.3 Coregulators with other functions 
As previously mentioned, the AR-mediated transcription of target genes is 
dependent on proteasome activity (Lin et al., 2002, Kang et al., 2002; Jia et al., 
2006). The proteasome is a large protein complex, in which polyubiquitinated 
proteins are degraded (Groll et al., 2011). Several AR interacting proteins have been 
shown to have E3 ligase activity, ligating ubiquitin groups to target proteins. Thus, 
AR and AR coregulators are also targets for ubiquitination (Heemers and Tindall, 
2007). The ring finger protein 14 (RNF14 alias ARA54) is one of the E3 ligases 
(Kang et al., 1999). 
Proteins involved in DNA repair are also recruited to the AR-mediated 
transcription, which suggests that AR-mediated transcription may also involve DNA 
disrupting events as demonstrated in cancer cells (Mani et al., 2009). BRCA1, with 
E3 ubiquitin ligase activity, and BRCA2, a component of the homologous 
recombination machinery, are both AR coactivators (Park et al., 2000; Yeh et al., 
2000; Shin et al., 2003).  
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In absence of ligand, AR is kept stably in the cytoplasm by HSPs. Specifically, a 
variant of BCL2-associated athanogene (BAG1), BAG1L (which is an HSP 
associated protein), has been demonstrated to physically interact with AR, to be 
recruited to AR target genes and to function as coactivator (Knee et al., 2001). AR 
trafficking into the nucleus is regulated not only by HSPs, but also by cytoskeletal 
proteins, such as supervillin and gelsolin. These proteins interact with AR and 
enhance androgen-dependent AR activity (Nishimura et al., 2003; Ting et al., 2004).  
Furthermore, AR shows a quite extensive interplay with several signal integrators 
and transducers, scaffolds and adaptor proteins. For instance, AR has been shown to 
interact with tyrosine kinase, non-receptor, 2 (TNK2, Alias: activated Cdc42-
associated tyrosine kinase (ACK1)), which is able to enhance AR-mediated gene 
transcription in the nucleus in an androgen-independent manner. Another 
Cdc42/Rac interactive protein p21 protein (Cdc42/Rac)-activated kinase 6 (PAK6) 
is activated by AR and translocates into the nucleus where it represses AR-mediated 
transcription. RanBPM (Ran (member RAS oncogene family)-binding protein in the 
microtubule-organizing center) and RAN (alias ARA24), another AR coactivator, 
have also been shown to be involved in AR nuclear translocation. 
Finally, AR is in the middle of interplay with several adaptors for multiple signal 
transduction events, such as the STAT (signal transducer and activator of 
transcription) signaling pathway via STAT3 and PIAS3 interaction, inhibition of 
TGFβ (transforming growth factor, beta 1) signaling via repression of SMAD family 
member 3 (SMAD3), ErbB (v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 3 (avian)), and the Notch and Wnt signaling pathways (reviewed by 
Heemers and Tindall, 2007). The most critical component of the Wnt signaling 
pathway is β-catenin (CTNNB1 catenin (cadherin-associated protein), beta 1, 88 
kDa), which has been shown to bind AR in a ligand-dependent manner and scaffold 
to the nucleus with AR enhancing its target genes transcription (Yardy and 
Brewster, 2005). 
AR activity is also enhanced by several cell cycle regulators, such as RB1 and 
various cyclins (reviewed by Heemers and Tindall, 2007). Interestingly, Cyclin D1 
(CCND1), independently of its function in cell cycle progression, has been shown to 
repress AR activity in a ligand-dependent manner (Knudsen et al., 1999). However, 
a genome-wide approach has more recently shown that cyclin D1 represses AR-
mediated transcription on selected AR target genes (Comstock et al., 2011). 
AR activation may also occur by post-translational modifications, such as 
phosphorylation. AR has been shown to be phosphorylated at several sites in 
response to the binding of the ligand and nuclear localization (Gioeli and Paschal, 
2011). Furthermore, several kinases have also been shown to enhance AR-mediated 
transcription (Heemers and Tindall, 2007). For instance, male germ cell-associated 
kinase (MAK) physically interacts with AR and is recruited to the chromatin, 
enhancing AR activity (Ma et al., 2006). Some phosphatases, such as protein 
phosphatase 2A activator, regulatory subunit 4 (PPP2R4 alias PP2A), can directly 
dephosphorylate sites in the NTD of the activated AR and repress its activity (Yang 
et al., 2006). 
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Several other not as well studied AR coregulators have been identified, such as 
NCOA6 (alias AIB3) (coactivator) (Goo et al., 2004), amino-terminal enhancer of 
split (AES) (corepressor) (Yu et al., 2001), RAD54-like 2 (S. cerevisiae) (RAD54L2 
alias ARIP4) (coactivator) (Rouleau et al., 2002), NCOR1 (Zamir et al., 1997) and 
the cell cycle regulator, BTG family, member 2 (BTG2) (corepressor) (Hu et al., 
2011). One of these coregulators, the melanoma antigen gene protein (MAGEA11 
alias MAGE11), has been shown to be an AR coactivator. MAGE11 can specifically 
bind the AR NTD, resulting in stabilization of the ligand-free AR. It was also shown 
that MAGE11 may favor interdomain interaction in presence of AR agonists (Bai et 
al., 2005). 
1.2.2.5 Androgen receptor coregulators and prostate cancer 
Studies in knock-out mice of several coregulators have revealed only mild 
phenotypes (Reyes et al., 1998; Xu et al., 1998; Gehin et al., 2002; Cheung-Flynn et 
al., 2005; Yong et al., 2007), suggesting that coregulators can supplement the 
function of the absent proteins. This suggestion leads to the hypothesis that the 
stoichiometry of the coregulators may be most important for the AR physiological 
functions, and the deregulation of such stoichiometry may lead to pathological 
conditions such as PC. However, it has been shown that deregulation of specific 
coregulators may derive from tissue-specific splice variants (Tao et al., 2006) or by 
variants with gained functions (Burd et al., 2006; Desai et al., 2006). Mutations in 
coactivators that provide a means for antiandrogens to activate AR could represent 
another mechanism for how coregulators may deregulate AR activity. For example, 
some AR mutations, together with the interaction with coactivators such as NCOA4 
(alias ARA70) and ARA54, can alter the receptor response to antiandrogens, such 
hydroxyflutamide, or render the receptor promiscuous to 17β-estradiol (Rahman et 
al., 2004). In contrast, some evidence has suggested that AR mutations may enhance 
the binding of AR coactivators, such as AIB1 (Zhou et al., 2010). 
In light of such a stoichiometric mechanism of the activity of the coregulators, 
many groups have investigated the abundance of the coregulators in PC. The most 
systematic and comprehensive studies investigating the expression profile of the AR 
coregulators in PC were those by Linja et al. (2004) and, to some extent, the more 
recent by Taylor et al. (2010). Linja et al. (2004) have found that the levels of AR 
coregulators do not change dramatically in PC, excluding their involvement in 
disease progression. The study by Taylor and colleagues (2010) also seems to 
support this observation because of the coregulators, only NCOA2 is upregulated in 
a proportion of PCs. However, other studies have found coactivators that are 
overexpressed in PC compared with matched normal tissues (Li et al., 2002; 
Mestayer et al., 2003; Culig et al., 2004). Experiments in PC cell lines and studies of 
human clinical tumors have suggested that the overexpression of SRCs (NCOAs) 
may be involved in PC progression (Desai et al., 2006; Shi et al., 2008; Xu et al., 
2009). However, studies on NCOA1 have reported discordant results. Linja et al. 
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(2004) found that NCOA1 mRNA levels are upregulated in primary PC but not in 
CRPC specimens. Subsequently Mäki et al. (2006) showed that the protein levels of 
NCOA1 are only mildly elevated in CRPC. Thus, NCOA1 is not likely to play an 
important role in PC progression. 
Altered levels of coactivators, including NCOA2, 3 and 4, MAGE11 and NFκB 
p100 subunit, have been found in PC specimens (Gregory et al., 2001; Comuzzi et 
al., 2003; Léotoing et al., 2008; Karpf et al., 2009; Nadiminty et al., 2010). As 
mentioned above, the NCOA2 expression level correlates with early biochemical 
recurrence in PC patients (Agoulnik et al., 2006), and NCOA2 has recently been 
reported to function as an oncogene in a subset of PCs. The chromosomal region 
8q13.3, which harbors the NCOA2 gene, is the most commonly amplified locus in 
PC (Taylor et al., 2010). NCOA3 overexpression has been found to correlate with 
the grade of PC (Zhou et al., 2005). NCOA4 protein levels are elevated in high 
grade PCs and in CWR22 xenograft tumors that have become castration-resistant 
(Hu et al., 2004). 
ARA24/Ran was found to be upregulated in cancer tissue compared with 
adjacent benign tissue isolated from PC patients (Li et al., 2002). Tip60 was also 
found to be overexpressed upon androgen ablation in both xenograft and cell line 
models (Halkidou et al., 2003). BAG1L has been shown to be amplified and 
overexpressed in a subset of CRPC specimens (Mäki et al., 2007). The levels of 
p300 correlate with larger tumor volumes, extra-prostatic growth and tumor 
progression (Debes et al., 2003). The levels of CBP have been shown to be high in 
advanced PC and, specifically, in tissues from patients that failed endocrine therapy 
(Comuzzi et al., 2004), although these results are discordant with the study by Linja 
et al. (2004). Additionally, the levels of histone demethylases, such as KDM1A 
(alias LSD1), KDM3A and KDM4C have been investigated in PC. KDM3A and 
KDM4C levels have been shown to be increased in primary PC, and KDM4C is also 
overexpressed in CRPC (Suikki et al., 2010). 
Finally, the downregulation of AR corepressors may also be involved in the 
development of CRPC. For example, the corepressor PIAS1 was found to be under-
repressed in CRPC specimens by Linja et al. (2004). Additionally, the recently 
identified AR corepressor BTG2 (Hu et al., 2011) is frequently downregulated in PC 
and is associated with PC aggressiveness (Ficazzola et al., 2001, Hu et al., 2011), 
while the abundance of the corepressor arrestin, beta 2 (ARRB2) inversely 
correlates with the AR activity in prostate tissues (Lakshmikanthan et al., 2009). 
1.2.3 Ligand independent activation of the androgen receptor 
AR signaling may also be activated in the absence of the ligand via other 
pathways. Several signaling cascades influence AR activation by phosphorylating 
AR or AR coregulators. Growth factors that may stimulate AR signaling include 
IGF-I, TGF-β, EGF and IL6 (Heinlein & Chang, 2004). IL-6 regulates 
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hematopoiesis, immune responses, inflammation, and bone metabolism and has the 
ability to stimulate the proliferation of PC cells. IL-6 levels are elevated in patients 
with CRPC. It has been demonstrated that IL-6 activates the Jak/STAT pathway and 
MAPK pathway, both mediating a cross-talk that leads to AR activation (Culig and 
Puhr, 2011). 
1.2.3.1 Androgen receptor variants 
The AR gene spans almost 180 kb of DNA and is composed of 8 exons that 
encode a 4314 bp mature mRNA (Figure 5A). The exons of the AR gene encode for 
functionally distinct regions of the gene that are similar to other SHR genes. The 
long exon 1 encodes for the AR NTD, which is approximately 60 % of the AR 
protein but is variable in length because it contains polymorphic (CAG)n and 
(GGN)n repeat units (Ding et al., 2004; 2005; Ferro et al., 2002; 
www.ncbi.nlm.nih.gov/gene). The lengths of such repeats have been associated with 
an increased risk of PC in the African black population (Gu et al., 2011). An 
alternative exon 1 has been identified, and the resulting naturally occurring splice 
variant (Figure 5B) was characterized to be expressed in several tissues (Ahrens-
Fath et al., 2005). However, the significance of this splice variant and the abundance 
relative to the main variant remain to be defined (Dehm and Tindall, 2011). Exon 2 
and exon 3 of AR encode the two zinc-fingers in the DBD, which are also 
responsible for dimerization in the presence of two adjacent androgen responsive 
elements (AREs) half-site (Shaffer et al. 2004) or other DNA binding site motifs of 
other transcription factors (Massie et al., 2007) (see chapter 1.2.4). Exons 4-8 
encode the hinge region and the LBD (Sack et al., 2001). Because the LBD has 
inhibitory effects on AR activation (Jenster et al., 1991), the absence of this 
particular domain may lead to aberrant AR activation. Several truncated AR 
isoforms that lack the LBD have now been reported, and some of these isoforms are 
constitutively active (Figure 5C). Furthermore, the truncated isoforms are found 
primarily in advanced CRPC tumors and PC cell lines that represent late stage 
disease, offering a further explanation for the resistance of PC cells to endocrine 
therapies (Dehm and Tindall, 2011; Mostaghel et al., 2011). 
Tepper et al. (2002) first described a novel AR protein product present in the 
CWR22Rv1 cell line that contains intact transactivation and DBDs but lacks the 
LBD. More recently, several independent reports have characterized the alternative 
splicing that results in up to seven different AR splice variants in the same 
CWR22Rv1 cell line (Dehm et al., 2008, Hu et al., 2009, Guo et al., 2009), some of 
which were also found in VCaP cells (Dehm et al., 2008, Hu et al., 2009) and in 
some of the LuCaP xenografts (Dehm et al., 2008, Sun et al., 2010). These AR 
splice variants share the feature of being constitutively active because all of these 
variants lack the LBD (Dehm et al., 2008, Hu et al., 2009, Guo et al., 2009, Sun et 
al., 2010). The transcripts contain exon 1, exon 2 and one of the several cryptic exon 
3 discovered in the intronic region between the normally occurring exon 3 and exon 
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4 (Figure 5A). Some variants have been described to include a duplication of exon 3 
and others to be the result of exon 5, 6 and 7 skipping (Dehm and Tindall, 2011). 
More recently, another splice variant lacking the DBD has been described as being 
associated with the plasma membrane (Yang et al., 2011). Finally, Watson et al., 
(2010) have sequenced AR mRNAs. They confirmed the previous data and 
identified several additional AR variants (Watson et al., 2010). The molecular 
mechanisms that lead to differential AR splicing are not known, although they could 
be attributed to a misregulation of the cellular “splicing code” (Rajan et al., 2009). 
However, the AR variants in the CWR22Rv1 cell line were found to be produced as 
consequence of an approximately 35 kb intragenic tandem duplication in the AR 
locus that was induced by androgen ablation (Li et al., 2011b). These data suggest 
that mechanisms other than the splicing machinery may also influence the 
appearance of AR variants in PC. 
 
 
Figure 5. Androgen receptor and prostate cancer. (A) Androgen receptor gene genomic 
structure. (B) mRNA structure of normally occurring androgen receptor variants and 
corresponding (indicated by dashed lines) protein domain structure. In prostate cancer, the 
most frequently found point mutation in the androgen receptor ligand binding domain is the 
T877A originally characterized in the LNCaP cell line (Veldscholte et al., 1990). (C) Known 
constitutively active androgen receptor mRNA variants in advanced prostate cancer. Exon 1 
is 2731 bp, while exon 8 is longer than represented (the 3’UTR is approximately 7 kb long). 
Darker shades indicate translated portion of the mRNAs. Numbers inside the squares 
represent exon numbers, AR = androgen receptor, CE = cryptic exon, UTR = untranslated 
region, NTD = N-terminal Domain, DBD = DNA-binding Domain, NLS = Nuclear Localization 
Signal, LBD = Ligand-binding Domain, AF1 & 2 = Activation Function 1 & 2. The numbering 
of the cryptic exons was adapted for this illustration, and the names of the splice variants 
are as in the original publications in the absence of a systematic classification. 
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The clinical relevance of these AR variants has yet to be fully established. These 
variants have also been found in androgen independent LuCaPs (Dehm et al., 2008), 
PC metastasis (Sun et al., 2010) and CRPC specimens (Hu et al., 2009), where they 
correlate with worse clinical outcome (Hu et al., 2009). Guo et al. (2009) have 
reported three truncated AR isoforms lacking the LBD (designated as AR3, AR4, 
and AR5) and have performed an immunohistochemical analysis of 429 PC tissues; 
their data indicate that AR3 is significantly up-regulated during CRPC progression. 
AR3 expression levels correlate with the risk of tumor recurrence after radical 
prostatectomy (Guo et al., 2009). Castration in mice has also been shown to induce 
the expression of AR variants in xenografted tumors (Watson et al., 2010). 
Recently, abiraterone treatment in mice was shown to upregulate several AR 
splice variants in xenografted tumors (Mostaghel et al., 2011). These findings 
suggest that androgen deprivation therapy may select for expression of these 
variants in the tumor, possibly contributing to the emergence of castration 
resistance. 
Gene expression profile studies have shown that particular AR splice variants 
may activate different gene transcription programs (Hu et al., 2009; Guo et al., 
2009). For example, unlike the full length AR, AR3 was shown to directly increase 
AKT1 expression (Guo et al., 2009). An alternatively spliced AR form selectively 
posttranscriptionally controlled EGFR and ERBB2 expression in 22Rv1 cells 
(Pignon et al., 2009). Taken together, these data suggest that these alternatively 
spliced AR forms may play an overlapping but distinct role in prostate cells by 
regulating different target genes. As previously mentioned, the abundance of AR 
splice variants relative to the full length AR form remains to be assessed in a large 
cohort of clinical samples. However, a recent study by Hörnberg et al. (2011) has 
assessed the protein expression of three of the most abundant AR variants in 10 
primary tumors and 40 CRPC bone metastasis specimens. Interestingly, the authors 
found that together with the full length AR, some of the variants were detectable in 
primary tumors. However, the variants displayed substantially higher expression in 
the CRPC samples. Furthermore, in a subgroup of the patients, the levels of the 
variants were comparable with the full length AR. The expression of these variants 
was associated with a high nuclear AR immunostaining score, disturbed cell cycle 
regulation and short patient survival (Hörnberg et al., 2011). It has also been shown 
that not all the splice variants are active, and even the active variants may require 
the full length AR to be functional (Watson et al., 2010). These data suggest that the 
potent super antiandrogen MDV3100 (Tran et al., 2009), which is now in a phase III 
clinical trial (Payton, 2010; Scher et al., 2010), may still be effective in 
counteracting the activity of these splice variants, even though the drug targets the 
LBD (Watson et al., 2010). 
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1.2.4 Androgen receptor-mediated transcription 
1.2.4.1 Formation of the transcription initiation complex 
AR mediated transcription initiation has been extensively studied for the 
androgen-regulated PSA gene using chromatin immunoprecipitation (ChIP), 
quantitative real-time PCR (qPCR), chromosome conformation capture (3C) assays, 
and fluorescence recovery after photobleaching (FRAP) (Carlberg and Seuter, 
2010). 
Ligand-bound and activated AR is recruited to both enhancer and promoter 
regulatory regions (Shang et al., 2002). AR binding leads to the recruitment of RNA 
polymerase II (Pol II) and AR coregulators. The recruitment of AR and its 
coactivators is stronger at the enhancer than at the promoter (Wang et al., 2005). 
From a temporal point of view, there are two recruitment patterns. The short-term 
recruitment pattern of AR is cyclical. AR is recruited to the PSA regulatory regions 
and disposed in approximately 90 minute cycles (Figure 6).  
The same cyclic behavior can also be observed in the promoter of kallikrein-
related peptidase 2 (KLK2), another androgen-regulated gene, indicating that the 
cyclical recruitment is not unique to PSA. Proteasome activity has been shown to be 
needed for maintaining this cyclical behavior. In fact, when the activity of the 
proteasome is inhibited pharmacologically, AR cannot be released from the 
promoter after the first cycle (Kang et al., 2002). More recently, HSPs have also 
been shown to be essential in such dynamic binding (Conway-Campbell et al., 
2011). The cyclicity of this short recruitment pattern has also been shown for other 
SHRs and their coregulatory proteins (Carlberg and Seuter, 2010; Perissi et al., 
2010). Upon androgen stimulation, the long-term AR recruitment to the PSA 
enhancer and promoter increases for 16 hours and declines after 96 hours (Wang et 
al., 2005) (Figure 7). The spatial arrangement of the AR-mediated transcription 
complex is yet to be defined. When AR binds an antagonist (e.g., bicalutamide), AR 
is recruited to the promoter along with corepressor proteins, including NCoR and 
SMRT, but not to the enhancer. In this case, RNA Pol II is not recruited (Kang et 
al., 2002; Shang et al., 2002), supporting the hypothesis that chromatin looping is 
needed for gene transcription activation. 
This looping/sliding model suggests that AR, which is recruited to both the 
promoter and enhancer, favors the interaction between these two elements via a 
common coactivator complex. This complex slides onto DNA, bringing RNA Pol II 
from the enhancer to the promoter. This model is supported by the finding that the 
enhancer and promoter recruit coactivators and RNA Pol II in the same way (Wang 
et al., 2005). Wang et al. (2005) also showed, using ChIP-3C, that upon androgen 
stimulation, the enhancer and the promoter are in direct contact (Wang et al., 2005). 
The transcription regulation by chromosomal looping is not unique to PSA and has 
been shown to occur in various genes (reviewed by Kadauke and Blobel, 2009). 
Today, there is increasing evidence of the importance of chromosomal looping in 
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gene transcription regulation (Naumova and Dekker, 2010). Other AR target genes, 
such as FKBP5, have also been shown to be transcribed via a similar looping 
mechanism, which involves several AR binding sites across the gene locus 
(Makkonen et al., 2009). FKBP5 has also been shown to be transcribed, most likely 
by a similar mechanism, by the glucocorticoid receptor (GR) (Paakinaho et al., 
2011). 
 
 
 
Figure 6. Transient loading of holo-AR and recruitment of RNA Pol II and coactivators 
to the PSA promoter in response to testosterone treatment of LNCaP cells. (A) LNCaP 
cells were incubated with 100 nM testosterone for the indicated times before harvesting for 
the ChIP assay. Chromatin samples were immunoprecipitated with the indicated antibodies 
prior to PCR with PSA promoter-specific primers followed by agarose gel electrophoresis 
and ethidium bromide staining. Input (DNA prior to immunoprecipitation). (B) AR and RNA 
Pol II occupancy of the PSA promoter after androgen treatment of LNCaP cells (This 
research was originally published in the Journal of Biological Chemestry. Kang Z, Pirskanen 
A, Jänne OA, Palvimo JJ. Involvement of proteasome in the dynamic assembly of the 
androgen receptor transcription complex. J Biol Chem. 2002;277(50):48366-71 © the 
American Society for Biochemistry and Molecular Biology.).  
AR-driven chromatin looping is believed to be responsible for bringing 
TMPRSS2 and ERG in spatial proximity (Mani et al., 2009). This androgen-induced 
process leads to the formation of the fusion gene (Rubin et al., 2011). Furthermore, 
the newly established ChIP technique coupled with massive high-throughput 
sequencing (ChIP-seq) has allowed mapping of AR binding across the entire 
genome. The majority of AR binding occurs in non-promoter regions, which 
suggests that such looping must be common (Wu et al., 2011). A recent work by 
Chen et al. (2011b) has suggested that this process is mediated by a selective 
PI3K/AKT-induced phosphorylation of the coactivator Mediator 1(MED1) (Chen et 
al., 2011b). 
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Figure 7. Models of AR coactivator complex assembly on PSA regulatory regions. (A) 
From a temporal view, the level of PSA regulatory regions bound to AR complexes 
gradually increases after androgen treatment, peaks at 16 hours, and then gradually 
declines following longer treatment. (B) From a spatial view, the AR coactivator complex is 
predominantly recruited to the PSA enhancer, which communicates with the AR 
transcription complex weakly associated with the PSA promoter through the 4 kb 
intervening DNA through which RNA Pol II tracks. (Reprinted from Wang et al. Spatial and 
temporal recruitment of AR and its coactivators involves chromosomal looping and 
polymerase tracking. Mol Cell 2005;19:631-42 with permission from Elsevier, copyright 
2005). 
1.2.4.1.1 Androgen responsive elements 
Like other members of the SHRs family, AR binds to the chromatin at specific 
consensus sequences known as AREs (Luke and Coffey, 1994). In general, the DNA 
REs are formed by half-sites arranged as monomeric direct or inverted repeats. The 
consensus sequences for the SHRs’ DNA REs are 5’AGAACA3’ or 
5’AGGTCA3’(Reviewed by McEwan, 2009). AREs can be non-canonical, with no 
specific sequence, and they are thought to be present when AR binds indirectly to 
the DNA through interaction with other transcription factors. However, canonical 
AREs are present when AR binds in the form of a homodimer to DNA. AREs are 
composed of 2 hexanucleotide repeats with a 3 nucleotide spacer in between. The 
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AREs in different promoter areas vary in sequence, but the consensus sequence 
motif for a canonical ARE is GGTACAnnnTGTTCT (Beato, 1989). Although these 
consensus motifs are quite conserved, the specific interaction between the receptor 
and the DNA can also be achieved through protein-protein interactions with other 
monomers or with coregulators. Additionally, specific interactions with other 
transcription factors, such as AP-1, ETS proteins, and forkhead transcription factors, 
may lead to deviations from the canonical 15 bp ARE (Massie et al., 2007; Lupien 
et al., 2008; McEwan, 2009; Wang et al., 2009b; Lupien and Brown, 2009; Wang et 
al., 2011b; Robinson et al., 2011). In vitro assays of single AREs show a low AR 
affinity for the canonical sequence. However, in vivo, the presence of multiple 
AREs in tandem causes promoter binding and stabilizes AR, leading to AR-
mediated gene transcription activation. 
This indicates that some of the specificity of the hormone response derives from 
other regions of the promoter and interacting proteins (Gelmann, 2002). However, 
recent studies have shown that only a small proportion of AREs are canonical. On 
the other hand, 80 % of the AR binding sites contains a six bp ARE “half-site” or a 
binding site with a non-canonical sequence (Massie et al., 2007; Yu et al., 2010). 
1.2.4.2 Modulation of androgen receptor transcriptional activity by other 
transcription factors 
Interestingly, the canonical responsive elements for AR, GR and other SHRs are 
similar to each other. Because the physiological functions of these hormones are 
different, the binding of the different SHRs to different target genes must be 
regulated by other factors (Gao et al., 2011). The mechanism for this discrimination 
remained unknown until recently when several studies showed that the deregulation 
of these mechanisms might contribute to cancer initiation and progression (Wang et 
al., 2007; Lupien et al., 2008; Wang et al., 2009b; Hurtado et al., 2011; Wang et al., 
2011b). One of such mechanisms is linked to the activity of the transcription factor 
forkhead box A1 (FOXA1) overexpression. FOXA1 was originally hypothesized to 
be a potential drug target in breast cancer because it was found to be overexpressed 
in most luminal cells (Nakshatri and Badve, 2007). More recently, FOXA1 has also 
been suggested to play a role in prostate development (Gao et al., 2011). High 
expression of FOXA1 has been found in metastatic PC (Jain et al., 2011), although 
low expression has been associated with poor prognosis (Wang et al., 2011b; Jain et 
al., 2011). Most importantly, FOXA1 has been demonstrated to be a major pioneer 
factor in AR and ER transcriptional program regulation (Lupien et al., 2008; Wang 
et al., 2009b). The most striking and intriguing evidence is that suppressing FOXA1 
expression in breast cancer cells leads to a decrease in the number of ER binding 
sites (Hurtado et al., 2011). In contrast, silencing FOXA1 in PC cells leads to 
increased AR binding to the chromatin and substantial variation of the AR binding 
sites (Wang et al., 2011b; Sahu et al., 2011). This evidence supports the idea that 
44 
FOXA1 translates epigenetics marks into lineage-specific transcription programs 
(Lupien et al., 2008; Hurtado et al., 2011). This hypothesis has recently been 
confirmed by the finding that activation of FOXA1 and FOXA1 binding are 
dependent and associated with DNA hypomethylation, H3K4 dimethylation, and the 
presence of histone variant H2AZ at the enhancers. These modifications are cell 
lineage-specific markers (Sérandour et al., 2011). Thus, it is not surprising to find 
FOXA1 binding sites adjacent to AR binding sites, which was first demonstrated 
using a ChIP-seq approach (Wang et al., 2009b). Using the same approach, Yu et al. 
(2010) have discovered another cooperative transcription factor of AR in PC. They 
proposed that the TMPRSS2:ERG fusion, which leads to ERG upregulation, 
facilitates AR and ERG cooperation. They suggest that ERG is able to negatively 
regulate AR activity and to activate the polycomb protein EZH2, facilitating a stem-
cell-like dedifferentiation program (Yu et al., 2010). 
1.2.5 Androgen receptor target genes and prostate cancer 
In prostate cells, the AR transcriptional program regulates the development of the 
prostate and drives genes related to the prostate function, such as PSA and prostate 
acid phosphatase (ACPP alias PAP). Both PSA and PAP are known serum markers 
for PC (Gutman and Gutman, 1938; Hugging and Hodge, 1941; Heidenreich et al., 
2011). The gene encoding PSA is kallikrein 3 (KLK3), which is a member of the 
human kallikrein gene family. All of the 15 members of the kallikrein family encode 
serine proteases, and many of them are highly expressed in the prostate. Most of 
these family members are also regulated by androgens (Lilja, 2003; Yousef & 
Diamandis, 2001). 
Riegman et al. (1988) described first the androgen regulation of PSA. Several 
AREs upstream of the PSA TSS have been identified. ARE I is located at -170 to -
156 from the TSS (Riegman et al., 1991), and a low affinity AR binding site is 
located also -400 bp from the TSS (Cleutjens et al., 1996). In addition to these, there 
is also a highly androgen responsive enhancer at -4 kb from the TSS. This enhancer 
consists of ARE III (-4148 to -4134 bp), which contains several AREs and other 
non-canonical motifs that are able to bind AR (Schuur et al., 1996; Huang et al., 
1999). In addition to its role as a diagnostic marker for PC, PSA has also been 
hypothesized to be implicated in the development and progression of the disease 
(Williams et al., 2007), although the data are still poor.  
TMPRSS2 is also a well-known AR target gene (Wang et al., 2007). TMPRSS2 is 
known as epitheliasin and belongs to the family of type II transmembrane serine 
proteases (TTSP). TTSP genes are found in all vertebrates, and the human TTSP 
family consists of 17 members (Bugge et al., 2009). However, the function of 
TMPRSS2 is not yet known because a knockout mouse model failed to show a clear 
phenotype (Kim et al., 2005), suggesting redundancy in the TTSP family. In the 
prostate, TMPRSS2 expression is localized to basal and luminal cells (Lin et al., 
1999). A downstream promoter element that is needed for recognition of RNA Pol 
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II has been identified upstream of the TSS. At position -535 bp from the TSS, there 
is also an ARE (Jacquinet et al., 2001), and 13.5 kb upstream of the TSS are AREs 
that are thought to form an enhancer element. The enhancer region is the primary 
site of AR binding in the TMPRSS2 regulatory region (Wang et al., 2007). 
Several microarray studies screening for new PC-associated genes have profiled 
PC specimens at various stages of the disease. These studies have yielded an 
enormous amount of information on the different cellular processes controlled by 
AR in PC (Dhanasekaran et al., 2001; Varambally et al., 2002; Lapointe et al., 2004; 
Holzbeierlein et al., 2004; Glinsky et al., 2004; Yu et al., 2004; Nanni et al., 2006; 
True et al., 2006; Tomlins et al., 2007; Chandran et al., 2007; Tamura et al., 2007; 
Kim et al., 2007; Nakagawa et al., 2008). Furthermore, it is currently reasonable to 
speculate that 2-4 % of the entire transcriptome is androgen regulated (Dehm and 
Tindall, 2006). 
To date, the best known and characterized AR target gene in PC is the 
TMPRSS2:ERG fusion gene (Tomlins et al., 2005) (see chapter 1.1.4.4). Recent 
studies have also demonstrated that the AR transcriptional program can be cell 
lineage-specific. For example, different genes can be activated in androgen-sensitive 
cells compared to cells that have been grown for a long time in hormone-deprived 
conditions. In the last cells, AR selectively upregulates M-phase cell-cycle genes. 
Among these genes, ubiquitin-conjugating enzyme E2 C (UBE2C) is a gene that 
inactivates the M-phase checkpoint and is overexpressed in CRPC tissues (Wang et 
al., 2009b). The overexpression of AR is also able to increase gene expression of 
cell cycle and metabolism related genes (Waltering et al., 2009). 
Furthermore, a recent study by Massie et al. (2011) has found that the AR 
transcriptional program is directed to regulate aerobic glycolysis and anabolism in 
PC cells. This work identified Calcium/calmodulin-dependent protein kinase kinase 
2 (CAMKK2) as an androgen-regulated gene. CAMKK2 is a metabolic master that 
has been implicated in the stimulation of glycolysis, biosynthesis and proliferation 
in PC cells (Massie et al., 2011). 
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2. AIMS OF THE STUDY 
 
 
 
CRPC continues to be a deadly disease for which there is no effective cure and 
for which there is a strong need for more sensitive and more specific prognostic 
biomarkers. This study aimed to investigate the molecular consequences of AR 
overexpression in CRPC. 
 
More specifically, we aimed: 
1) To investigate the effect of AR overexpression on the genome-wide 
recruitment of AR to the chromatin; 
2) To investigate the effect of AR overexpression on the initiation of AR-
mediated transcription and the dynamics of the recruitment of AR and RNA 
Pol II to AR-target gene loci; 
3) To identify AR coregulators and AR target genes affected by AR 
overexpression and involved in PC progression. 
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3. MATERIALS AND METHODS 
The materials and methods used in this study are listed below. However, a more 
detailed description can be found in the original communications I-III. 
3.1 Cell lines and cell culture procedure (Studies I-III) 
The LNCaP cells overexpressing AR have been described in the original 
communication I and in Waltering et al. (2009). Briefly, the parental LNCaP 
(ATCC, Rockville, MO, USA) were transfected with pcDNA3.1(+) empty 
expression vector (Invitrogen Inc., Carlsbad, CA, USA) and pcDNA3.1(+)with the 
AR coding region inserted. The cells were stably transfected with Lipofectamine-
Plus transfection reagent (Invitrogen Inc., Carlsbad, CA, USA). Transfected clones 
were selected with 400 µg/ml Geneticin (G418) for 2 weeks. The mRNA and 
protein levels of AR were measured from purified clones, leading to the 
establishment of the following 3 stable cell lines: 
-LNCaP-pcDNA3.1 (transfected with empty pcDNA3.1-vector as a control); 
-LNCaP-ARmo (transfected with AR cloned into pcDNA3.1+ vector); 
-LNCaP-ARhi (transfected with AR cloned into pcDNA3.1+ vector).  
LNCaP-ARmo overexpresses AR 2-3 fold more than LNCaP-pcDNA3.1, while 
LNCaP-ARhi overexpresses AR 4-5 fold more. 
These cell lines were cultured according to the ATCC protocol with the addition 
of 200 µg/ml Geneticin (Invitrogen Inc., Carlsbad, CA, USA) and divided in 1:4 
ratio plates when in the exponential growing phase. When DHT treatment was 
performed, the media was changed to RPMI1640 phenol-free medium with 5 % 
charcoal/dextran-treated (CCS) FBS (Hyclone Inc., South Logan, UT, USA) and 1 
% Glutamine (Invitrogen Inc.) for 4 days. The medium was then changed to phenol-
free RPMI1640 including 10 % CCS-FBS (Hyclone Inc.), 1 % Glutamine 
(Invitrogen Inc.), and 0, 0.1, 1, 10 or 100 nM DHT. The cells were maintained in 
such treatment media according to the time and use specified in the different studies.  
In study III, only LNCaP-pcDNA3.1 and LNCaP-ARhi were used, while in 
studies I and II, LNCaP-ARmo cells were also used. 
In study I, LNCaP, VCaP and LAPC4 cells were also used. The cells were 
purchased from ATCC and maintained according to the manufacturer’s instructions. 
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3.2 Xenografts material (Study I) 
Two PC xenografts, LuCaP69 and LuCaP73, were grown in intact male 
immunocompromised mice. These xenografts were provided by Prof. R. Vessella 
(University of Washington Medical Center, Seattle, WA, USA). 
3.3 Clinical samples (Study I) 
Eight BPH and 27 untreated primary PC samples from prostatectomies and 7 
BPH and 15 CRPC specimens from transurethral resection of the prostate (TURP) -
treated patients were snap-frozen in liquid nitrogen, and total RNA was isolated 
with Trizol™-Reagent (Invitrogen Inc., Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Tumor samples contained at least 70 % cancer cells.  
Tissue microarrays (TMAs) contained 185 formalin-fixed paraffin-embedded 
prostatectomy and 92 CRPC (TURP) specimens obtained from Tampere University 
Hospital. For the prostatectomy-treated patients, detectable PSA values (≥0.5 ng/ml) 
in two consecutive measurements or the emergence of metastases were considered 
to be signs of progression. The use of the clinical material and the TMAs was 
approved by the ethical committee of the Tampere University Hospital and the 
National Authority for Medicolegal Affairs. 
3.4 Chromatin immunoprecipitation (Studies I and II) 
The ChIP protocol is described in detail in study I. The antibody used to 
immunoprecipitate AR-DNA complexes is a well-characterized anti-AR polyclonal 
antibody (AR3) (Karvonen et al., 1997, Thompson et al., 2006, Sahu et al., 2011) 
and was provided by Prof. Olli A. Jänne (University of Helsinki, Helsinki, Finland).  
3.5 ChIP-seq assays (Study I) 
The libraries of ChIPped DNA were prepared and sequenced with Genome 
Analyzer II (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s 
protocol. Briefly, the immunoprecipitated DNA was blunt-ended, and the 
sequencing adapters were ligated. The DNA was run on agarose gels. Fragments 
ranging from 150-350 bp were excised and purified with a Qiagen Gel Extraction kit 
(Qiagen Inc., Valencia, CA, USA) according to the manufacturer’s instructions. 
Eluted DNA from the Qiagen columns was PCR-amplified (15 cycles). Amplified 
DNA was run on an agarose gel and purified with a QIAquick Gel Extraction kit 
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(Qiagen Inc., Valencia, CA, USA). Eluted DNA was quantified using a Nanodrop 
(Thermo Fisher Scientific Inc. Wilmington, DE USA) and stored at -20°C before 
sequencing. 
3.6 ChIP-seq data analysis, Motif overrepresentation 
analysis, Gene Ontology analysis and mRNA 
expression profiling (Study I) 
These methods are well-described in the supplementary information provided in 
study I. The raw reads alignment was performed with Bowtie (Langmead et al., 
2009), and the reads were mapped on the human genome version 19 (hg19). The 
peak detection was performed with the tool MACS (Zhang et al., 2008). 
To assess the presence of motifs of other transcription factors (TFs) in the 
ARBSs, overrepresented transcription factor motifs in AR-bound sequences were 
searched. The prediction of transcription factor binding was performed using a 
probabilistic method (Lähdesmäki et al., 2008). The binding probability for each 
human-associated TF with a motif in the TRANSFAC (Matys et al., 2006) database 
(version 2009.3) was calculated for both strands on each ARBS sequence. 
Genes bound by AR at most 25 kb upstream of the transcription start site (TSS) 
or downstream of the 3’UTR were collected into separate gene lists. The gene lists 
were then used in an overrepresentation analysis performed by GeneTrail (Keller et 
al., 2008). 
Raw data from the study by Waltering et al. (2009) were retrieved and reanalyzed 
to obtain the mRNA expression profile of the cell lines treated at various 
concentrations of DHT for 4 and 24 hours. 
3.7 qRT-PCR (Studies I-III) 
The cells were harvested into TRIZOL reagent (Life Technologies Inc., 
Gaithersburg, MD, USA) after the indicated time in each study, followed by total 
RNA isolation according to the manufacturer’s protocol. The cDNA was 
synthesized from RNA with AMV Reverse Transcriptase and oligo(dT)12-18 
primers (Study III) or random examer (Study I and II) according to the 
manufacturer’s protocol (Finnzymes, Espoo Finland). The standards were prepared 
by mixing total RNA from untreated LNCaP cells and universal RNA (Clontech 
Laboratories, Inc., Mountain View, CA, USA) in a ratio of 1:5. After first strand 
cDNA synthesis, serial dilutions corresponding to 1000, 200, 40, 8, 1.6, 0.32, and 
0.064 µg of the RNA pool were prepared and stored in aliquots. The PCR reactions 
were performed in a LightCycler apparatus (Roche Inc.) using an LC Fast Start 
DNA SYBR Green I Kit (Roche Diagnostics, Mannheim, Germany) (Study III) or 
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Maxima™ SYBR Green (Fermentas Inc., Burligton, Ontario, Canada) and a CFX96 
real-time PCR detection system (Bio-Rad Laboratories Inc., Hercules, California, 
USA) (Studies I and II). The final volume of each reaction was 20 µl containing 2 µl 
of cDNA sample (or standard). The expression levels were normalized to the 
expression levels of TBP. 
For the clinical samples (Study I), the relative expression of each gene was 
measured against the average value of TBP, G3PDH2 and β-actin reference genes. 
Standards used for gene expression measurements in the clinical samples consisted 
of an RNA mix from the prostate cancer cell lines prepared as above.  
The primers were designed for amplifying regions of the mRNAs derived from 
different exons to avoid amplification of genomic DNA. A list of the primers used 
can be found in the respective studies. 
3.8 ChIPqPCR (Studies I and II) 
This method is described in the study I. The enrichment relative to input 
chromatin was calculated based on the delta Ct method with the percentages 
calculated using the formula 2-ΔCt, where ΔCt is Ct(ChIP-template)-Ct(Input). 
A standard curve from one of the diluted inputs was included in the run to control 
that the efficiency of the reaction was maintained in the range between 95 % and 
105 %. A qPCR on a control region in which AR is not supposed to bind (between 
the PSA enhancer and promoter (middle region)) was performed for each ChIP 
assay. The ChIP assay was considered specific if the enrichment in the control 
region was not above the enrichment of the non-specific immunoprecipitated sample 
generated with normal rabbit IgG. 
3.9 Statistical analysis (Studies I-III) 
In study III, Grubb’s test was used to detect the outlier values in the repetitive 
PCR runs for each gene, and the one-way analysis of variance (ANOVA) test with 
Bonferroni post-test was used to evaluate the statistical significance of the changes 
in expression levels. 
In study I, hypergeometric distribution computing enrichment p-values for 
differentially expressed genes and AR bound genes was used to test whether the 
DHT concentrations used to stimulate the cells directly controlled the differential 
expression by AR at the 4-hour time point and 24-hour time point. Furthermore, to 
test the hypothesis that not only the androgens but also the amount of AR in the 
cells has an effect on gene regulation, a two-way ANOVA analysis was performed. 
The analysis tested the interaction between the effect on the variance of both AR 
amount and concentration of DHT. 
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In study II, one-way ANOVA was used to compare differences in AR binding 
and to test the influence of the AR level on the variance. 
3.10  Western blot (Studies I and III) 
In study III, Western blot was performed from cytoplasmic and nuclear protein 
fractions. The primary antibodies used were anti-AR (Ab-1 AR441 Neomarkers 
Inc., Fremont, CA, USA); anti-β-catenin (BD Transduction Laboratories, Inc. 
Franklin Lakes, NJ, USA); anti-MAK (C-term) (ABGENT, San Diego, CA, USA); 
anti-CBP (R&D Systems, Inc. Minneapolis, MN, USA) and anti-pan-actin (pan AB-
5, clone ACTN05, Neomarkers, Fremont, CA, USA). 
In study I, Western Blot was performed from total cell lysates. The primary 
antibodies used were anti-FEN1 (clone 4E7; LifeSpan Biosciences Inc., Seattle, 
Washington, USA) anti-ZWINT purified polyclonal antibody (clone RB19982; 
Abgent Inc., San Diego, California, USA), anti-SNAI2 (clone 3C12; Sigma-Aldrich 
Inc., Saint Louis, Missouri, USA), and anti-ATP synthase subunit alpha (clone 
15H4C4; MitoSciences Inc., Eugene, Oregon, USA) monoclonal antibodies. A 
detailed description of the Western blot procedure can be found in the original 
communications I and III. 
3.11  Immunohistochemistry (Study I) 
This method is described in study I. The mouse anti-FEN1 antibody (mAb clone 
4E7; LifeSpan Biosciences Inc., Seattle, Washington, USA) was used with the 
Power Vision+ Poly-HRP IHC kit (ImmunoVision Technologies Co., Burlingame, 
California, USA) according to the manufacturer's instructions. 
3.12  siRNA transfections and Growth curves (Study I) 
Ambion (Applied Biosystems/Ambion, Austin, Texas, USA) Silencer® selected 
siRNAs against FEN1, ZWINT and SNAI2 mRNAs were used. Cells were 
transfected with INTERFERin transfection reagent (Polyplus-transfection, Illkirch, 
France) according to the manufacturer’s protocol. The expression levels of the genes 
relative to TBP were measured by qRT-PCR (2.5 days after transfection), and 
protein levels were measured by Western blot analysis (3 days after transfection). 
Growth curve measurements were started 1 day after siRNA transfection and 
marked as day 1. Images of the same growth area in each well were acquired every 
day using a Retiga-2000R FAST Cooled Mono 12-bit camera (QImaging Inc., 
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Surrey, BC Canada) mounted on a Motorized Inverted Research Microscope IXT1 
(Olympus America Inc.) and a 10X objective. The total growth area occupied by the 
cells (area percent) in each well was determined each day of measurement with 
ImageJ software (Abramoff et al., 2004) and normalized against the growth area of 
the respective well at day 1. 
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4. RESULTS AND DISCUSSIONS 
4.1 AR overexpression enhances AR mediated 
signaling (Studies I-III). 
CRPC overexpresses AR (Linja et al., 2001; Visakorpi et al., 1995) and 
maintains dependence upon the AR signaling pathway (Tran et al., 2009; deBono et 
al., 2011a). In an attempt to mimic the conditions in which CRPC arises and 
progresses, a LNCaP-based AR overexpression model was developed (Waltering et 
al., 2009). LNCaP-ARmo expresses a 2-4 times higher level of AR protein than the 
control cells LNCaP-pcDNA3.1 and LNCaP-ARhi expresses a 5-6 times higher 
level. Furthermore, the LNCaP-ARhi cells grow faster in the presence of low levels 
of androgens than the control cells (Waltering et al., 2009). 
To test the model, the expression of PSA was measured in LNCaP-ARhi and 
control cells after 4 and 24 hours of stimulation with increasing concentrations of 
DHT. As expected, PSA was strongly induced by the DHT (see Figure 2 in Study 
III). However, the PSA response was significantly stronger in LNCaP-ARhi cells 
(one-way ANOVA p<0.0001). 
4.1.1 Binding of AR to chromatin in low androgen concentration 
is enhanced in AR-overexpressing cells (Study I) 
To study the effect of AR overexpression on the chromatin binding of the 
receptor, the LNCaP-based model was utilized. ChIP-seq in LNCaP-pcDNA3.1, -
ARmo, and -ARhi, treated for 2 hours with 0, 1, and 100 nM of DHT was used to 
profile AR binding to the chromatin (Table 1). The binding profile revealed that 
after treatment with a relatively low concentration of androgens (1 nM of DHT), the 
number of AR binding sites (ARBSs) was higher in AR-overexpressing cells. In 
contrast, when the cells were treated with higher concentrations of androgens (100 
nM DHT), the binding to chromatin seemed to be lower in AR-overexpressing cells 
(Table 1).  
To confirm the association between the AR level and the ARBSs, an independent 
AR overexpression model was used. LuCaP69 cells harbor AR gene amplification, 
whereas LuCaP73 cells do not (Linja et al., 2001). Consequently, the expression of 
AR is approximately 10-fold higher in LuCaP69 compared to LuCaP73 according to 
qRT-PCR (Linja et al., 2001). ChIP-seq analysis revealed approximately 19000 and 
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7000 ARBSs in LuCaP69 and LuCaP73, respectively, confirming that an 
association exists between the AR level and the number of ARBSs in vivo. 
 
Table 1. AR ChIP-seq analysis of the LNCaP AR overexpression model. The cell 
lines and the DHT concentrations to which each cell line was exposed for 2 hours before 
ChIP assay, the antibody used in the ChIP assay and the number of raw reads produced 
with Solexa GA II run are listed. A pooled sample of LNCaP-ARhi and LNCaP–ARmo 
treated with ethanol for 2 hours and ChIPped with normal rabbit IgG was sequenced as the 
control sample for peak calling and further ARBSs analysis. 
cell line  Treatment  ChIP antibody  Raw reads 
Sample 
abbreviation 
Number 
of 
ARBSsa 
Number of 
ARBSsb 
LNCaP‐pcDNA3.1   ethanol  AR 9997482 pcDNA3.1_0M  925  2 
LNCaP‐ARmo   ethanol  AR 10429984 ARmo_0M  812  ‐‐‐ 
LNCaP‐ARhi   ethanol  AR 8146731 ARhi_0M  467  ‐‐‐ 
LNCaP‐pcDNA3.1   1nM DHT  AR 10044966 pcDNA3.1_1nM  1600  680 
LNCaP‐ARmo   1nM DHT  AR 11159217 ARmo_1nM  2296  1303 
LNCaP‐ARhi   1nM DHT  AR 9926387 ARhi_1nM  2399  1689 
LNCaP‐pcDNA3.1   100nM DHT  AR 10898431 pcDNA3.1_100nM  3326  3269 
LNCaP‐ARmo   100nM DHT  AR 10780058 ARmo_100nM  1359  395 
LNCaP‐ARhi   100nM DHT  AR 8614715 ARhi_100nM  1207  ‐‐‐ 
LNCap‐ARhi/ARmo 1:1  1nM DHT  Rabbit IgG 9725044 ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ‐‐‐  ‐‐‐ 
The number of ARBSs in each sample is given according to peak detection with a p-value 
threshold of 0.00001 (a) and also controlled for a false discovery rate (FDR) (b) at 5 %. 
 
The ChIP-seq data were validated by the presence of ARBSs in the well-
characterized enhancers of PSA (Shuur et al., 1996; Cleutjens et al., 1996) and 
TMPRSS2 (Wang et al., 2007). Traditional ChIPqPCR was used to study the 
strength of the AR binding to the PSA enhancer and promoter in the LNCaP model 
in the same treatment conditions (2 hours DHT treatment with 0, 1, and 100 nM 
DHT). One hundred times less ligand was needed to achieve the same AR 
recruitment to the PSA enhancer in AR-overexpressing cells compared to control 
cells. Thus, AR overexpression sensitized AR binding by 100-fold. ChIPqPCR on 
the PSA enhancer in the xenografts also showed that the AR binding is stronger in 
LuCaP69 compared to LuCaP73, confirming that the strength of the AR binding is 
also associated with the AR level. 
These data indicated that both the ligand concentration and the amount of 
receptor together affect the chromatin binding of AR. A modest overexpression of 
AR enhances the chromatin binding of the receptor by sensitizing the cells to 100-
fold lower ligand concentration. The data are concordant with the results of a recent 
work by Massie and colleagues (2011), in which almost 5-times more ARBSs in the 
strongly AR-overexpressing cell line VCaP compared to LNCaP cells was found. 
Furthermore, a study by Makkonen et al. (2011) has confirmed that the binding at 
regulatory regions at the single gene level is enhanced in AR-overexpressing cells, 
such as VCaP cells compared to LNCaP (Makkonen et al., 2011). 
The AR binding profiles in the different cell lines upon stimulation with different 
DHT concentrations were reproducible because overlap was observed. Therefore, a 
high-confidence ARBSs map representing the most frequently overlapping ARBSs 
was constructed. This high-confidence map included 1833 ARBSs. 
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The map was first used to confirm that AR overexpression sensitizes the binding 
potency of the receptor to lower concentrations of ligand. The number of sequenced 
reads above background level, which can be assumed to be proportional to the 
binding strength, was reanalyzed in each single sample, and the average was 
normalized against the average binding strength in hormone-deprived conditions (0 
M). Indeed, the binding strength at 1 nM DHT was greater in LNCaP-ARmo and 
LNCaP-ARhi compared to control cells. In contrast, in cells treated with 100 nM 
DHT, the data indicated that a slight decrease in the binding strength may occur in 
these cells. The data are similar to those obtained at the PSA enhancer via 
ChIPqPCR and also with the results by Makkonen et al. (2011).  
The ARBSs of the high confidence map localized mostly in intronic (43 %) and 
distal intergenic (49 %) regions, which most probably accounts for distal enhancers. 
Two percent of the ARBSs were located in exons, and the remaining 6 % of ARBSs 
were located within the 1.5 kb region upstream of the TSS or downstream from the 
3’UTR of genes. The data indicated that AR activity is tightly linked to distal 
enhancer regions, confirming this finding in several previous studies (Lupien et al., 
2008; Jia et al.,2008; Yu et al., 2010; Makkonen et al., 2009; Massie et al., 2011). 
The high confidence ARBS map was also used to compare the binding profiles of 
cell lines and the xenograft models. The poor overlap (from 4 to 31 %) of the high-
confidence ARBS map between the cell lines and the xenografts emphasizes that 
AR binding to chromatin varies significantly between samples, suggesting that 
genetic or other intrinsic differences, such as binding of other transcription factors, 
could strongly contribute to the AR binding. This suggestion is supported by the 
finding that AR regulates gene transcription in cooperation with other transcription 
factors, such as FOXA1 (Wang et al., 2009b; Wang et al., 2011b; Sahu et al., 2011) 
and ETS1 (Massie et al., 2007; Yu et al., 2010). To test this hypothesis, motif 
analyses of the high confidence ARBS map was performed. The analysis showed 
that binding motifs of, especially, FOXA1 and ETS family of transcription factors 
are enriched in the vicinity of ARBSs, which is in an agreement with previously 
published data (Massie et al., 2007; Lupien et al., 2008; Wang et al., 2009b; Yu et 
al., 2010; Wei et al., 2010). 
The re-analysis of the publicly available data from the work by Yu et al. (2010) 
showed that Yu and colleagues obtained 58 % overlap of ARBSs between LNCaP, 
and only 28.7 % overlap between VCaP and a tumor sample. The same tumor tissue 
sample showed 44.1 % overlap with the LNCaP-model high confidence ARBSs, 
while the overlap with the LuCaP69 ARBSs was only 17.9 %. Although the two 
xenografts overlapped poorly within each other and also with the high confidence 
ARBSs map of LNCaP, the ARBSs in the xenografts often localized close to the 
genes that showed ARBSs and androgen regulation in the LNCaP-model. These 
data suggest that androgen-regulated genes may have alternative ARBSs. The poor 
overlap between the cell lines and xenografts could also be due to the 
microenvironmental (cell culture versus mouse) differences. 
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4.1.2 AR binding occurs earlier and more powerfully in AR-
overexpressing cells grown in low concentrations of 
androgens (Study II) 
The majority of the previously reported ChIP-seq and ChIP-chip experiments (Jia 
et al., 2008; Wang et al., 2009b; Yu et al., 2010; Takayama et al., 2010; Sahu et al., 
2011) have compared the binding of AR at the saturating concentration of 
androgens, and thus, missed the dynamics of AR binding. The short term 
recruitment of AR to the PSA enhancer and promoter is cyclical (Kang et al., 2002; 
Welsbie et al., 2009), and this cyclicity has also been observed at the promoter of 
another AR target gene: kallikrein 2 (KLK2). Therefore, the effect of AR 
overexpression on the chromatin binding dynamics of the receptor was studied in 
androgen-regulated PSA and TMPRSS2 genes, for which ARBSs at the promoter 
and enhancer regions are known. 
ChIPqPCR was used to profile the AR binding to the PSA and TMPRSS2 
enhancer and promoter upon stimulation with a low (1 nM) and high (100 nM) 
concentration of androgens (DHT) over a time period of 4 hours (0 M 0 min, 30, 60, 
80, 120, and 240 min). At the PSA locus, recruitment to the PSA TSS, a portion of 
exon 3 and a downstream region less than 1 kb away from the 3’ UTR was also 
tested.  
As expected, AR is recruited more abundantly to the enhancers than to other 
regions. The dynamic recruitment pattern of AR to the PSA enhancer was also 
confirmed for the enhancer of the TMPRSS2 gene. However, the binding profile at 
the TMPRSS2 enhancer was different than for the PSA enhancer (Figure 8). Thus, 
different target genes may exhibit different binding profile dynamics. This 
possibility should be taken into account when planning or analyzing ChIP-seq data 
and suggests that several time points should be ChIP-sequenced for a more 
comprehensive understanding of the dynamic AR binding. 
When the cells were treated with 1 nM DHT, the peak of AR binding was 
achieved 30 minutes (at the PSA enhancer) or 1 hour (at the TMPRSS2 enhancer) 
earlier in AR-overexpressing cells than in control cells. The AR recruitment was 
also significantly stronger in LNCaP-ARhi cells after 30 min and after 1 hour (t-test 
p<0.05 and p<0.001 for PSA and TMPRSS2 enhancers, respectively). Furthermore, 
the potency of AR recruitment in the time period of 4 hours was significantly higher 
in AR-overexpressing cells, at least at the PSA enhancer and promoter (p<0.05).  
Interestingly, when the cells were treated with 100 nM DHT, the overall AR 
binding to the PSA and TMPRSS2 enhancers was greater and peaked differently than 
in cells stimulated with 1 nM DHT. However, the dynamics of AR recruitment was 
not significantly different between the cell lines (see Supplementary Figure 4 in 
Study II). 
Altogether, these data indicate that the binding dynamic is affected by the 
concentrations of androgens to which the cells are exposed and by the AR level. 
This relationship should be taken into account while planning in vitro experiments. 
The dynamicity of the AR binding to the chromatin may be able to partially explain 
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the low degree of overlap between the AR binding profiles in the cell lines in vitro 
compared to the LuCaP xenografts in vivo because ChIP-seq analyses are relative to 
binding to a single time point (see chapter 4.1.1). 
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Figure 8. Dynamics of AR binding to AR target gene enhancers in AR-overexpressing 
cells. AR binding to the enhancer of PSA (A) and TMPRSS2 (B) in the LNCaP-model. 
LNCaP-pcDNA3.1, -ARmo and –ARhi cells were hormone-starved for 4 days and treated 
for the indicated time with 1 nM DHT or ethanol (0 h 0 M). ChIPqPCR was performed to 
assess AR recruitment. The mean and S.E.M. of three biological replicates are shown. 
Several groups have investigated the dynamics of the recruitment of RNA 
polymerase II (Pol II) to the PSA (Shang et al., 2002, Kang et al., 2004, Jia et al., 
2006) and TMPRSS2 regulatory regions (Shang et al., 2002, Jia et al., 2006). In fact, 
binding of AR is known to recruit coregulators, including GRIP1, CBP, and 
ultimately RNA Pol II (Wang et al., 2007; Heemers and Tindall, 2007). Therefore, 
because AR overexpression affects its own dynamic recruitment, it is likely to also 
affect the recruitment of components of the basic transcription machinery. Thus, the 
effect of AR overexpression on the recruitment of RNA Pol II to the PSA and 
TMPRSS2 loci was investigated. 
The RNA Pol II recruitment profile across the three cell lines was similar to the 
AR recruitment, which is concordant with the results by Wang et al. (2005). 
Furthermore, RNA Pol II is also recruited to the TSS, exon 3 and to a locus 
downstream of the PSA gene, although with a certain delay in respect to the 
promoter and the enhancer.  
In AR-overexpressing cells, the RNA Pol II recruitment over the 4 hour time 
period was enhanced at the PSA enhancer, promoter and exon 3 regions (one-way 
ANOVA p<0.05). Furthermore, in all PSA loci tested (except for exon 3 and the 
downstream genomic area immediately at the 3’ end of the PSA gene), more RNA 
Pol II was present in LNCaP-ARhi cells at the 4 hour time point (t-test p<0.05) (see 
Figure 4 in Study II). 
TMPRSS2 displayed a different RNA Pol II recruitment dynamic. However, 
consistent with the AR recruitment, RNA Pol II is recruited earlier in AR-
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overexpressing cells. Thus, the binding pattern of RNA Pol II, which differs from 
gene to gene, is also affected by AR overexpression. 
4.1.3 Chromatin is more open in AR-overexpressing cells (Study 
II) 
The lineage-specific binding to chromatin by transcription factors, such as AR, is 
known to be modulated also by other transcription factors, such as FOXA1, which 
translates epigenetics marks (Wang et al., 2008a; Sahu et al., 2011). For example, 
the status of histone acetylation is critical for androgen receptor-mediated 
transcriptional activation of genes (Nakayama et al., 2000). In addition, in PC, 
several therapeutic approaches have shown efficacy targeting HDACs (Welsbie et 
al., 2009; Antonarakis and Armstrong, 2011). 
Global histone modification patterns have been shown to be able to predict the 
risk of PC recurrence. In low grade PC patients, a certain pattern of histone 
acetylation and methylation can be used to predict whether the patient has a low or 
high risk of PC recurrence (Seligson et al., 2005). Chen and colleagues (2004) have 
found that modest overexpression of AR can alter the abundance of AR coregulators 
recruited to the promoters of AR target genes, many of which have histone 
acetylation activity (Rahman et al., 2004; Chmelar et al., 2006). The activation of 
gene expression is marked by histone 3 (H3) acetylation. Acetylated H3K9 and 
H3K9K14 are necessary marks to render accessibility of the regulatory regions to 
the basic transcription factors (Strahl and Allis, 2000; Verdone et al., 2006; Ito, 
2007). 
To test whether AR overexpression causes epigenetic changes to the chromatin, 
the status of the acetylation of the H3 (AcH3) tail was also profiled. The data 
indicated that the AcH3 increases upon time of stimulation with DHT, with a certain 
variability but it does not seem to vary in a cyclic manner as AR and RNA Pol II. In 
agreement with a recent report (Voss et al., 2011), these results suggest a 
progressive rather an intermittent model of gene activation. Voss and colleagues 
(2011) have recently found that the dynamic, cyclic binding of the GR causes 
continuous increased accessibility to chromatin, which favors the transient binding 
of other factors (Voss et al., 2011). Indeed, this principle could also be applied to the 
AR. 
The data indicated that the AR-overexpressing cells display some sites in which 
the level of acetylation increases more than in the control cells. For instance, the 
AcH3K9 at the PSA enhancer was significantly higher in LNCaP-ARhi compared to 
control cells, although it still peaked at the 2 hour time point in both cell lines (see 
Supplementary Figure 5 in Study II). At the TMPRSS2 enhancer, the AcH3K9 
increased only in the ARhi cells (see Supplementary Figure 6 in Study II). Overall, 
the AcH3 increases upon the time of stimulation with DHT, and the increases are 
more pronounced in LNCaP-ARhi cells. The data suggest that the changes in AcH3 
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and, potentially, the general changes in chromatin marks are sensitive to androgen 
levels and are locus-specific.  
Interestingly, while the recruitment of AR and RNA Pol II did not vary 
significantly under hormone-deprived conditions across the cell lines, AcH3 
differed in the different cell lines upon hormone depletion. Initially, the amount of 
AcH3 in the regulatory regions seemed lower in LNCaP-ARhi cells compared to 
ARmo and control cells. However, quantifying the amount of total H3 at the same 
loci, which is an indirect measure of the amount of nucleosomes, showed that the 
ratio between AcH3 and pan-H3 increases in AR-overexpressing cells. According to 
our hypothesis, fewer nucleosomes are present at such sites. However, the 
remaining histones are more acetylated. These results are in accord with a previous 
report by Jia et al. (2006) that showed that increased histone acetylation is 
associated with the development of androgen independence in vivo. More 
importantly, He et al. (2010) have found that in PC cells, androgen treatment 
dismisses a central nucleosome present at the ARBSs flanked by a pair of marked 
nucleosomes.  
The mechanism for how the histone loss occurs in AR-overexpressing cells and 
how AR affects this process requires further investigation. However, AR 
overexpression may enhance such nucleosome dismissing process. Furthermore, 
given the fact that the progressive loss of nucleosomes may maintain a status of 
gene activation, this could provide evidence that AR overexpression may favor 
phenomena of genomic imprinting (Ferguson-Smith, 2011). In PC, epigenetic 
alterations are important. For instance, silencing of the GSTP1 gene by 
hypermethylation of the promoter is found in 90 % of cases (Lee et al., 1994). Yet 
the molecular features which cause such silencing are not well understood. These 
results suggest that mechanisms leading to epigenetic memories of nucleosome 
positioning may be involved in PC progression and deserve more attention. 
Moreover, a recent study by John and colleagues (2011) pinpointed that chromatin 
accessibility pre-determines GR binding patterns. Another study by the same group 
has linked the DNA methylation status to cell type-specific enhancer activity 
(Wiench et al., 2011). 
Given the effect that the AR overexpression has on the dynamic of recruitment of 
the receptor, and RNA Pol II and given that the chromatin structure is also affected, 
the dynamic of production of mRNA of the target genes PSA and TMPRSS2 over 16 
hours of stimulation with 1 nM DHT was profiled. The mRNA dynamics was 
measured in the 16 hour period assuming that the effect on chromatin binding within 
4 hours is associated with a certain delay to the production of mRNA. 
Indeed, after only 4 hours, PSA mRNA was significantly more produced in 
LNCaP-ARhi cells (t-test p<0.05) compared to control cells, while the TMPRSS2 
mRNA transcription was significantly higher in LNCaP-ARhi cells by 1 hour after 
treatment (t-test p<0.05). The effect of AR overexpression was stronger in 
enhancing TMPRSS2 expression compared to PSA during the 16 hours of hormone 
stimulation, suggesting that the expression of different genes is affected differently 
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by the AR overexpression. Thus, intrinsic properties may define the degree of 
enhancement of mRNA transcription in the context of AR overexpression. 
4.1.4 AR overexpression enhances androgen regulation of AR 
coactivators (Studies I and III) 
Given the profound relationship between AR activity and AR coregulators 
(Heemers and Tindall, 2007), the hypothesis that AR coregulators would be 
regulated by AR was investigated. The aim was to identify AR coregulators whose 
expression is regulated by androgens and/or affected by the AR receptor level. 
The expression of 25 AR coregulators was measured in LNCaP-pcDNA3.1 and –
ARhi cells after 4 and 24 hours of hormone stimulation with increasing 
concentrations of DHT (0, 0.1, 1, 10, 100 nM). The AR coregulators included 17 
coactivators, 6 corepressors and 2 coregulators with reported dual functions on AR 
transcriptional activity (Table 2). The androgens significantly regulated 13 
coregulators (52 %) in control cells, seven of which were upregulated more than 2-
fold over the vehicle-treated cells (0 M DHT) (see Figure 3 and 4 in Study III). Most 
of the upregulated genes were coactivators (AIB1, CBP, MAK, BRCA1, β-catenin, 
and gelsolin), with the exception of the corepressor cyclin D1 (Table 2). In the 
LNCaP-ARhi cells, the majority of the androgen-induced coregulators remained 
under androgen regulation. However, the induction of cyclin D1, gelsolin and β-
catenin expression by DHT was reduced compared to control cells. In contrast, the 
DHT-induced expression of the coactivators AIB1, CBP, MAK and BRCA1 was 
further enhanced in AR-overexpressing cells. Moreover, AR overexpression seemed 
to sensitize the coactivators AIB3, ARA24, and JMJD1A expression because they 
were upregulated greater than 2-fold by DHT in LNCaP-ARhi cells (Table 2). 
The Western blot analysis of CBP, MAK and β-catenin was in concordance with 
the qRT-PCR results. 
Coactivators, such as AIB1, CBP, MAK and BRCA1, showed particularly 
enhanced upregulation in LNCaP-ARhi cells compared to control cells. Certainly, 
all of these coactivators displayed ARBSs in a putative enhancer region (Table 2; 
unpublished data). Furthermore, AIB1 also had an ARBS in the promoter. However, 
attributing this effect to the presence of ARBSs in the proximity of the loci of these 
genes is difficult because non-androgen-regulated AR coregulators also displayed 
ARBSs.  
AIB1 is known to have HAT activity and also recruits CBP, with HAT activity, 
to the transcription multisubunit coactivation complex that favors chromatin 
accessibility to other transcription factors (Heemers and Tindall, 2007). Thus, these 
results are concordant with the data on the enhanced chromatin opening in LNCaP-
ARhi cells. MAK is a kinase that has been found to associate with AR and enhance 
its transcriptional activity (Ma et al., 2006), while BRCA1 enhances AR activity 
through its E3 ubiquitin ligase activity (Park et al., 2000). More recently, Heemers 
et al. (2009) have profiled the expression and activity of 186 AR coregulators.  
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Table 2. AR coregulator expression in PC. List, official names and function of the 25 AR 
coregulators studied in LNCaP-pcDNA3.1 and –ARhi cells upon stimulation with increasing 
concentrations of DHT for 4 and 24 hours according to study III. The table also contains 
information retrieved from study I on whether the gene locus of a particular AR coregulator 
displays ARBSs in the 250 kb bit.  
Gene name 
as in the 
original 
publication 
Official symbol and 
name 
Androgen‐regulated 
(p value) at 
AR overexpression 
effect (p value) at 
ARBSs in 
the 250 
kb bit 
(Study I) 
coactivator 
or 
corepressor 
function 4 h 24 h 4 h 24 h
AIB1  NCOA3 (nuclear receptor coactivator 3)  <0.001*  <0.0001*  <0.001*  <0.0001* 
Intronic + 
promoter  Coactivator 
CBP  CREBBP (CREB binding protein)  <0.05*  <0.05*  <0.01*  <0.05*  Enhancer  Coactivator 
MAK  MAK (male germ cell‐associated kinase)    <0.01*  <0.01*    Enhancer  Coactivator 
BRCA1  BRCA1 (breast cancer 1, early onset)  <0.001*  <0.0001*  <0.01*  <0.0001*  Enhancer  Coactivator 
β‐Catenin 
CTNNB1 (catenin 
(cadherin‐associated 
protein), beta 1, 88kDa)) 
<0.05  <0.0001*  <0.0001  <0.0001    Coactivator 
gelsolin  GSN (gelsolin)  <0.05  <0.0001*  <0.05    Enhancer  Coactivator 
cyclin D1  CCND1 (cyclin D1)  <0.01*  <0.01*        Corepressor 
prohibitin  PHB (prohibitin)  <0.05  <0.01  <0.05  <0.01  Enhancer  Corepressor 
AIB3  NCOA6 (nuclear receptor coactivator 6)  <0.0001  <0.05  <0.0001*      Coactivator 
ARA24  RAN (RAN, member RAS oncogene family)  <0.001  <0.05  <0.001*  <0.01*    Coactivator 
JMJD1A  KDM3A (lysine (K)‐specific demethylase 3A)  <0.05  <0.001  <0.0001*    Enhancer  Coactivator 
JMJD2C  KDM4C (lysine (K)‐specific demethylase 4C)    <0.01  <0.05      Coactivator 
BAG‐1L 
BAG1 (BCL2‐associated 
athanogene (transcript 
variant 1)) 
  <0.01  <0.05  <0.05  Enhancer  Coactivator 
SRC1  NCOA1 (nuclear receptor coactivator 1)         
Intronic + 
promoter  Coactivator 
LSD1  KDM1A (lysine (K)‐specific demethylase 1A)            Coactivator 
ARIP4  RAD54L2 (RAD54‐like 2 (S. cerevisiae))          Intronic  Coactivator 
p300  EP300 (E1A binding protein p300)          Enhancer  Coactivator 
TIF2  NCOA2 (nuclear receptor coactivator 2)          Intronic  Coactivator 
MAGE11 
MAGEA11 (melanoma 
antigen family A, 11 
(transcript variant 1)) 
          Coactivator 
STAT1 
STAT1 (signal transducer 
and activator of 
transcription 1, 91kDa) 
        Enhancer  coA/coR 
PIASx 
PIAS2 (protein inhibitor 
of activated STAT, 2(α 
and β isoforms)) 
          coA/coR 
NCoR1  NCOR1 (nuclear receptor corepressor 1)          Intronic  Corepressor 
PAK6 
PAK6 (p21 protein 
(Cdc42/Rac)‐activated 
kinase 6) 
          Corepressor 
PIAS1  PIAS1 (protein inhibitor of activated STAT, 1)          Promoter  Corepressor 
AES  AES (amino‐terminal enhancer of split)            Corepressor 
* Over 2‐fold upregulated by androgens 
 
62 
Similar to the results presented above, 30 % of the coregulators were androgen-
regulated (Heemers et al., 2009). CBP was one of the AR coactivators upregulated 
in the LNCaP cell line derivative LNCaP-Rf, which was established by long-term 
androgen ablation of LNCaP cells, mimicking the transition toward CRPC 
(Comuzzi et al., 2004; Heemers et al., 2009). 
These data suggest the existence of a positive feedback loop directed to enhance 
AR activity. The presence of a positive feedback loop, which enhances a particular 
signal upon misregulation or loss of degrading proteins, is not new in PC.  
For instance, ETS transcription factor may be stabilized or overexpressed upon loss 
of COP1 (McCarthy, 2011). Additionally, ERG rearrangement positively regulates 
its own expression, increasing the oncogenic stimulus (Mani et al., 2011). The AR 
gene locus shows ARBSs that may explain further positive regulation (Sahu et al., 
2011). 
The levels of coregulators in advanced PC did not give conclusive evidence for 
their implication in CRPC development. However, the coregulators may contribute 
to such processes (Chmelar et al., 2006; Heemers and Tindall, 2007). 
Altogether, the data support the idea that AR overexpression tends to enhance 
AR-mediated signaling in low concentrations of androgens, maintaining AR to be 
able to activate gene transcription. The activation of the gene transcription is very 
likely to be supported by an increased amount of linker DNA, which facilitates AR 
access to genes regulatory regions, even in hormone-deprived conditions. A positive 
feedback loop, such as increased transcription of AR coactivators and decreased 
transcription of AR corepressors, may also concur to maintain and possibly 
potentiate the signaling pathway. 
4.2 Identification of AR target genes in PC (Study I) 
In the attempt to identify AR target genes implicated in the progression of PC to 
CRPC, previously published microarray gene expression profiling data from the 
LNCaP-based model from the Waltering et al. (2009) study and the ARBSs maps 
produced in study I were combined. 
4.2.1 Gene ontology 
First, a gene ontology (GO) analysis of genes located within a 25 kb window of 
the ARBS maps (see chapter 4.1.1) was performed. Only the ARBS maps of 
LNCaP-pcDNA3.1 treated with 1 nM, -ARmo treated with 1 nM, -ARhi treated 
with 1 nM and -pcDNA3.1 treated with 100 nM DHT were used. The analysis 
revealed that more GO categories were overrepresented in LNCaP-ARhi cells (31) 
compared to -ARmo (22) and/or control cells (5), suggesting that the AR level is 
associated with the number of activated biological processes. Cell-cell adhesion 
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(GO:0016337) and regulation of locomotion (GO:0040012) were the biological 
processes exclusively enriched in -ARhi cells. Compared with the GO of genes 
located in proximity of the ARBS map generated in LNCaP-pcDNA3.1 treated with 
100 nM, the same processes were enriched in AR-overexpressing cells (see 
Supplementary Table 3 in Study I). This finding suggests that due to modest AR 
overexpression, low concentrations of androgens are able to activate processes that 
are normally activated by higher concentrations. 
The GO analysis was consistent with previous findings based on the expression 
profiling of the LNCaP model (Waltering et al., 2009). 
4.2.2 AR target genes identified solely using ARBSs data 
(unpublished data) 
Next, the ARBS maps were analyzed in further detail. The two xenografts, 
LuCaP69 and LuCaP73, had only 157 ARBSs in common. By sorting them 
according to the peak height in LuCaP69, the ARBSs showing highest peaks were 
located on chromosome 8q24. The genes in close proximity to these sites include 
the non-coding protein oncogene PVT1 (Guan et al., 2007) and MYC.  
 
Table 3. Genes located in a region less than 25 kb to high-confidence ARBSs in the 
cell lines as well as in the common ARBSs in the two xenografts. Of the 157 ARBSs in 
common between the two xenografts ARBSs, only 47 were also in common with the high-
confidence ARBSs map in the cell lines. Most of the genes close to these ARBSs have 
already been suggested to be involved in PC or other cancers. 
Gene 
symbol   Official gene name  From the literature 
ZBTB16  zinc finger and BTB domain 
containing 16 
Also  known  as  Promyelocytic  leukemia  zinc  finger  protein  (PLZF) 
(Chen  et  al.,  1993),  it  is  an  androgen‐regulated  (Waltering  et  al., 
2009;  Jiang  and  Wang,  2004)  transcription  factor  known  to  be 
involved in cell growth and apoptosis regulation (Wasim et al., 2010; 
Hobbs et al., 2010). 
STK39  serine threonine kinase 39  It  is known to be androgen‐regulated (Qi et al., 2001) and  involved 
in PC progression (Hendriksen et al., 2006). 
FAM134B  family with sequence similarity 134, 
member B 
It was  recently  found  to  encode  for  a Golgi  protein  (Kurth  et  al., 
2009) with oncogenic properties (Tang et al., 2007). 
RASSF3  the RAS association domain 
(RalGDS/AF‐6) family 3 
It is a member of RAS effectors and a tumor suppressor (Jacquemart 
et al., 2009). 
ATAD2  ATPase family, AAA domain 
containing 2 
It  is  known  to  be  androgen‐regulated  (Zou  et  al.,  2009).  It  is  a 
cofactor  of MYC  oncogene  (Cirò  et  al.,  2009)  and  AR  (Zou  et  al., 
2009). It was recently found to predict poor prognosis in breast and 
lung cancers (Caron et al., 2010). 
KCNMA1  potassium large conductance 
calcium‐activated channel, subfamily 
M, alpha member 1 
It is associated with breast cancer invasion (Khaitan et al., 2009).
EMP2  epithelial membrane protein 2 It  is  involved  in  endometrial  and  ovarian  cancer  development 
(Wadehra  et  al.,  2006;  Shimazaki  et  al.,  2008;  Fu  et  al.,  2010; 
Habeeb et al., 2010). 
SFRS1  serine/arginine‐rich splicing factor 1 It was found to be a protooncogene (Karni et al., 2007). 
PLCB1  phospholipase C, beta 1 
(phosphoinositide‐specific) 
It was  found  to be  implicated  in edelfosine  resistance  in Small cell 
lung carcinoma (Strassheim et al., 2000). 
 
Interestingly, this region also contains single nucleotide polymorphisms that have 
been associated with the risk of several malignancies, including prostate cancer 
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(Ghoussaini et al., 2008). Of these 157 ARBSs, only 47 overlapped with our high 
confidence ARBSs derived from the LNCaP model. Among the ARBSs, there were 
several close to cancer associated genes (Table 3). For example, the ARBSs in the 
intron of ZBTB16 and immediately upstream of the RASSF3 gene showed high 
peaks in both xenografts and in the LNCaP-ARhi cells. 
4.2.3 AR target genes identified using ARBSs and microarray 
expression data (Study I) 
To combine ChIP-seq data and expression profiling data, the raw hybridization 
data from the work by Waltering et al. (2009) were reanalyzed. 
The data included expression profiles of LNCaP-pcDNA3.1, -ARmo and –ARhi 
cells stimulated for 4 and 24 hours with increasing concentrations of DHT (0, 1, and 
100 nM). The direct effect of androgens on gene expression was assessed by 
integrating AR binding data, which was obtained after 2 hours of DHT stimulation 
in cells treated in the same DHT concentrations. Using hypergeometric distribution 
to compute enrichment p-values (AR binding information) for differentially 
expressed genes revealed that the direct androgen regulation at the 4 hour time point 
also continues at 24 hours (p < 0.05). These data indicate that AR target genes are 
still under tight control of the AR network. 
Furthermore, because LNCaP-ARhi cells are known to have a growth advantage 
over -ARmo and control cells when grown in 1 nM DHT, the binding profiles of the 
cells treated for 2 hours and the expression profiling at 4 and 24 hours in 1 nM DHT 
were combined to identify AR downstream genes exclusively upregulated more than 
1.5-fold in LNCaP-ARmo or -ARhi cell but not in control cells. The number of 
genes upregulated was positively associated with the overexpression AR. A total 
number of 346 genes had ARBSs in the 250 kb window and was upregulated in 
LNCaP-ARmo and -ARhi cells but not in control cells at 4 or 24 hour time points 
after stimulation with 1 nM DHT (Figure 9 A&B). 
To shorten the list and narrow the search, 14 previously published independent 
studies that had performed microarray analysis on clinical PC specimens (see Table 
4 for references) were interrogated. Among the 346 genes, 38 had shown 
overexpression in PC compared to BPH or normal adjacent material in at least one 
of the studies (Table 4). 
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Figure 9. Identification of androgen-regulated AR target genes that are 
overexpressed in CRPC. The Venn diagrams showing the number of genes that are 
located in a window of 250 kb around the high confidence ARBSs in LNCaP-pcDNA3.1, -
ARmo and -ARhi cells and that showed at least 1.5-fold differential expression upon 1 nM 
DHT stimulation for 4 hours (A) and 24 hours (B) according to the microarray data. 
Androgen regulation of FEN1 (C), SKP2 (D), ZWINT (E), SNAI2 (F), AZGP1 (G), DTL (H), 
TPX2 (I), ATAD2 (J) and RASFF3 (K) AR target genes and the effect of AR overexpression 
on their expression. LNCaP-pcDNA3.1, -ARmo and -ARhi cells were hormone-starved for 4 
days and subsequently treated with the indicated concentration of DHT or with vehicle (0 
M). The expression of the genes was measured by qRT-PCR. The mean and S.E.M. of 
each gene against TBP values normalized against the 0 M time point are shown. 
Expression of FEN1 (L), SKP2 (M), ZWINT (N), SNAI2 (O), AZGP1 (P), DTL (Q), TPX2 (R), 
ATAD2 (S), RASFF3 (T) and ZBTB16 (U) AR target genes relative to the average of 3 
housekeeping genes (TBP, β-actin, G3PDH2) in BPH (n=15), PC (n=27) and CRPC (n=13) 
according to qRT-PCR. Kruskall-Wallis with Dunn post-test results are shown (*** < 0.001; * 
0.01 to 0.05; ns. not significant). 
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Table 4. Androgen-regulated genes overexpressed in PC. Genes that showed 
expression change exclusively in LNCaP-ARhi and –ARmo cells but not in –pcDNA3.1 cells 
and were also upregulated in CRPC compared to PC or BPH in at least one of the 14 
independent studies that performed gene expression array analysis on clinical samples. 
Study   Gene 
Symbol  Gene name 
Dhanasekaran et al. (2001)  MYC  v‐myc myelocytomatosis viral oncogene homolog (avian) 
  FKBP5  FK506 binding protein 5
Varambally et al. (2002)  PPIL5  peptidylprolyl isomerase (cyclophilin)‐like 5
  LAMC1 laminin, gamma 1 (formerly LAMB2)
Lapointe et al. (2004)  AZGP1  alpha‐2‐glycoprotein 1, zinc‐binding
  GUCY1A3 guanylate cyclase 1, soluble, alpha 3
Holzbeierlein et al. (2004)  N/A  N/A
Glinsky et al. (2004)  N/A  N/A
Yu et al. (2004)  ST7  suppression of tumorigenicity 7
  SNAI2  snail homolog 2 (Drosophila)
  STMN4 stathmin‐like 4
  PSMA6 proteasome (prosome, macropain) subunit, alpha type, 6 
Nanni et al. (2006)  CDK2  cyclin‐dependent kinase 2
  RAD21  RAD21 homolog (S. pombe)
  CDC25A cell division cycle 25 homolog A (S. pombe)
  ZWINT  ZW10 interactor
  FEN1  flap structure‐specific endonuclease 1
True et al. (2006) AZGP1  alpha‐2‐glycoprotein 1, zinc‐binding
  MAOA  monoamine oxidase A
Iljin et al. (2006) PEX10  peroxisome biogenesis factor 10
  DSC2  desmocollin 2
Tomlins et al. (2006)  SLC25A3  solute  carrier  family 25  (mitochondrial  carrier; phosphate carrier), member 3 
  MYC  v‐myc myelocytomatosis viral oncogene homolog (avian) 
  MRPL47 mitochondrial ribosomal protein L47
  AZGP1  alpha‐2‐glycoprotein 1, zinc‐binding
  SLC22A3  solute  carrier  family  22  (extraneuronal  monoamine transporter), member 3 
  MCM4  minichromosome maintenance complex component 4 
  MRPL18 mitochondrial ribosomal protein L18
  ABCC4  ATP‐binding cassette, sub‐family C (CFTR/MRP), member 4 
Chandran et al. (2007)  KCTD3  potassium channel tetramerisation domain containing 3 
  TM9SF3 transmembrane 9 superfamily member 3
Tamura et al. (2007)  RAD21  RAD21 homolog (S. pombe)
  ANLN  anillin, actin binding protein
  DTL  denticleless homolog (Drosophila)
Kim et al. (2007) MYC  v‐myc myelocytomatosis viral oncogene homolog (avian) 
  LCP1  lymphocyte cytosolic protein 1 (L‐plastin)
  DDEF2  development and differentiation enhancing factor 2 
  MRPL47 mitochondrial ribosomal protein L47
  SKP2  S‐phase kinase‐associated protein 2 (p45)
  LIFR  leukemia inhibitory factor receptor alpha
  HIPK2  homeodomain interacting protein kinase 2
  GRHL2  grainyhead‐like 2 (Drosophila)
Nakagawa et al. (2008)  CCNA1  cyclin A1
  RAD21  RAD21 homolog (S. pombe)
  RICS  Rho GTPase‐activating protein
  TPX2  TPX2, microtubule‐associated, homolog (Xenopus laevis) 
  GLRX2  glutaredoxin 2
  AZGP1  alpha‐2‐glycoprotein 1, zinc‐binding
  EDG7  endothelial  differentiation,  lysophosphatidic  acid  G‐protein‐coupled receptor, 7 
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4.3 Validation and characterization of AR target genes 
and significance in PC (Study I) 
4.3.1 Androgen regulation and expression in clinical material 
Among the 38 genes in Table 4, five were selected based on information 
retrieved from the literature. To confirm their androgen regulation, their expression 
was measured in LNCaP-ARhi, -ARmo and control cells after 4 and 24 hours of 
stimulation with increasing concentrations of DHT. The androgen regulation of 
FEN1, ZWINT, SKP2, SNAI2, and AZGP1 was first confirmed (Figure 9 C-G). 
Subsequently, DTL and TPX2 genes were also selected for follow-up analyses, and 
their androgen regulation was confirmed (Figure 9 H&I; unpublished data). 
Based on the literature search, 3 genes were also selected from Table 3: ZBTB16, 
RASSF3 and ATAD2. ZBTB16 has previously been shown to be an AR target gene 
(Waltering et al., 2009). To confirm the androgen regulation of ATAD2 and 
RASSF3, their expression was also measured. These genes were strongly induced by 
DHT (Figure 9 J&K; unpublished data). 
A two-way ANOVA analysis was used to test the interaction between the effect 
of the androgens and AR overexpression. The analysis indicated that both androgens 
and AR level affect the gene expression significantly (p<0.0001), except for 
RASFF3, in which there was not significant interaction between the two effects. 
However, for all of the genes, the response to DHT was significantly stronger 
(p<0.0001) in LNCaP-ARhi and –ARmo compared to control cells. 
The expression of these genes was also measured in BPH, PC and CRPC 
specimens.  
SKP2, ZWINT and FEN1 transcripts were significantly overexpressed in CRPC 
compared to PC and/or BPH (Figure 9 L-N), whereas the expression of SNAI2 was 
reduced in CRPC and PC (Figure 9 O). AZGP1 was not significantly overexpressed 
in primary PC (Figure 9 P). In the follow-up analysis, DTL and TPX2 were also 
significantly overexpressed in CRPC compared to primary PC or BPH (Figure 9 
Q&R; unpublished data). 
The finding that 5 out of 7 genes showed overexpression in CRPC compared to 
PC or BPH supports the concept that the AR-overexpressing cell line model mimics 
CRPC-associated AR overexpression.  
SKP2 (S-phase kinase-associated protein 2 (p45)) is known to have oncogenic 
properties and to be overexpressed in many cancers (Nakayama and Nakayama, 
2006). SKP2 has previously been shown to be androgen-regulated (Waltregny et al., 
2001; Wang et al., 2008b) and to be essential for AR-mediated cell proliferation 
(Wang et al., 2008b). The expression of SKP2 has also been associated with a short 
biochemical recurrence following prostatectomy (Nguyen et al., 2011). A recent 
study by Lin and colleagues (2010) has suggested SKP2 as a potential target in 
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cancer treatment and prevention because the inhibition of SKP2 triggered cellular 
senescence in p53/PTEN-deficient PC-3 cells and tumor regression in mice.  
ZWINT (ZW10 interactor) is a kinetochore protein (Starr et al., 2000) that has 
been suggested to have a role in the development of some malignancies (Obuse et 
al., 2004; Kops et al., 2005; Lin et al., 2006).  
SNAI2 (snail homolog 2 (Drosophila)) is a zinc-finger transcriptional repressor 
involved in the epithelium to mesenchyme transition (EMT) (Thiery, 2002). EMT is 
an important concept in cancer, including PC, because increasing Gleason grade is 
associated with a progressive loss of epithelial glandular architecture, which may be 
observed as EMT. The involvement of SNAI2 in such process was proposed but the 
data are still lacking (Nauseef and Henry, 2011). However, PC-3, an AR-negative 
PC cell line that expresses very high levels of SNAI2, is also dependent on SNAI2 
for cell proliferation and invasion (Emadi Baygi et al., 2010). This finding may 
partially explain why in CRPC, the level of this gene is low and indicates that 
expression of AR and SNAI2 may be mutually exclusive. 
TPX (TPX2, microtubule-associated, homolog (Xenopus laevis)) has been found 
to be a coactivator of AURKA (aurora kinase A). AURKA is necessary for spindle 
microtubules assembly in G2 and M phases (Gautschi et al., 2008). Recently, TPX2 
was shown to stabilize AURKA and protect it from degradation (Giubettini et al., 
2011), and TPX2 is potentially implicated in resistance to DNA damage (Bhatia et 
al., 2010). Thus, TPX2 plays a critical role in mitotic cells. Although the role of 
TPX2 in PC is yet to be investigated, both TPX2 and AURKA are overexpressed in 
many malignancies (Asteriti et al., 2010; Gautschi et al., 2008), including PC 
(Waltering et al., 2009).  
DTL (denticleless homolog (Drosophila)) is also essential for the correct cell 
cycle regulation at the early G2/M checkpoint that promotes genome stability 
(Sansam et al., 2006; Abbas and Dutta, 2011). DTL has not been previously studied 
in PC. However, DTL has been found to be overexpressed in different histological 
subtypes of breast cancers (Ueki et al., 2008) and, more recently, overexpression of 
DTL in colon cancer was shown to be a consequence of the deregulation of miR-
215, which is under-expressed in tumor cells (Karaayvaz et al., 2011). Thus, DTL 
may be another potential AR target gene that deserves further investigation. 
FEN1 (flap structure-specific endonuclease 1) is a structure-specific 
metallonuclease that interacts with several other proteins involved in DNA 
replication, apoptosis, DNA repair and telomere stability (Zheng et al., 2011). 
Although mutations of FEN1 in PC are yet to be investigated, somatic mutations of 
FEN1 have been reported in several common cancers (Zheng et al., 2007). These 
mutations abolish the exonuclease activity but retain the flap endonuclease activity 
(Zheng et al., 2007), which is consistent with the finding that mice carrying 
mutations show higher chemically induced cancer incidence (Xu et al., 2011). 
The expression of ATAD2, RASSF3 and ZBTB16 has also been measured in 
clinical specimens. Increased expression of all of these genes was observed in 
primary PC compared to BPH (Figure 9 S-U; unpublished data), although ZBTB16 
was not significantly increased. Concomitantly, all of these genes showed lower 
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expression in CRPC than in PC, although the difference was not significant for 
ATAD2. These findings suggest that the use of both expression profiles and binding 
analysis is a better approach for the identification of AR target genes compared to 
the binding information alone. 
ATAD2 is essential for entry into the S-phase of the cell cycle and has previously 
been shown to be androgen-regulated (Zou et al., 2009). ATAD2 has been reported 
to be a coactivator of both the MYC oncogene (Ciró et al., 2009) and AR (Zou et al., 
2009). Furthermore, ATAD2 was recently found to be overexpressed in several 
malignancies (Ciró et al., 2009) and to predict poor prognosis in breast and lung 
cancers (Ciró et al., 2009; Caron et al., 2010). The data show that ATAD2 levels are 
consistently high in PC in all stages. Thus, further investigation into its role in PC 
initiation is warranted. RASSF3 is a tumor suppressor (Jacquemart et al., 2009) and 
accordingly to its function, it is under-expressed in CRPC specimens. ZBTB16 can 
also oppose cellular transformation through multiple targets, such as inhibition of 
MYC. Furthermore, ZBTB16 is a transcription factor with yet undetermined targets 
that can recruit transcriptional corepressors and HDACs (Hobbs et al., 2010). 
Accordingly with these findings, ZBTB16 levels also decrease in CRPC. The data on 
RASSF3 and ZBTB16 suggest that although a selective pressure may boost their 
levels in PC to contrast the oncogenic activity, an opposing selective pressure tends 
to suppress their expression in CRPCs. Although strongly androgen-regulated, 
ATAD2, RASSF3 and ZBTB16 genes are probably not involved in the emergence of 
the CRPC phenotype.  
4.3.2 ARBSs validation (Study I) 
The ARBSs in the proximity of the genes overexpressed in CRPCs (SKP2, 
ZWINT, TPX2, DTL and FEN1) were confirmed by regular ChIPqPCR in LNCaP-
pcDNA3.1 and –ARhi cells stimulated for 2 hours with 1 nM DHT. Interestingly, 
the AR binding in –ARhi cells was enhanced compared to control cells, suggesting 
that the overexpression of these genes in CRPC may be mediated by the increased 
AR binding. Figure 10 shows examples of the validation of the ARBSs in the 
proximity of the DTL (A&B) and TPX2 (C&D) genes (unpublished data). 
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Figure 10. AR binding on putative enhancers of AR target genes. ChIPqPCR on 
LNCaP-pcDNA3.1 and –ARhi cells, which were hormone-starved for 4 days and treated for 
2 hours with 1 nM DHT or ethanol (0 M), was performed to assess the AR recruitment on 
the putative enhancers of DTL at -31 kb (A) and + 100 kb (B) from the TSS and the AR 
recruitment in the putative enhancers of TPX2 at -70 kb (C) and +200 kb (D), according to 
the ChIP-seq data. The data are presented as fold over percentage of input of the ethanol 
(vehicle)-treated sample. The mean ± S.E.M. are shown. 
4.3.3 Functional significance of FEN1, ZWINT and SNAI2 for PC 
cells growth (Study I) 
To study the functional significance of FEN1, ZWINT and SNAI2 in PC cells, a 
siRNA approach was used. Inhibition of FEN1 expression in LNCaP-pcDNA3.1 
and –ARhi cells resulted in reduced growth of both cell lines, suggesting that FEN1 
is important in PC cell growth. In contrast, both ZWINT- and SNAI2-depleted 
LNCaP-pcDNA3.1 showed a growth advantage compared to control-transfected 
cells. For SNAI2, this result is in agreement with the clinical data showing decreased 
SNAI2 expression in CRPCs compared to PCs. However, inhibition of either of 
these two genes in -ARhi cells did not lead to any effect on growth. 
4.3.4 FEN1 expression predicts clinical outcome 
Finally, Western blotting in the cell line model demonstrated increased protein 
expression in LNCaP-ARhi and -ARmo compared to control cells. FEN1 
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immunohistochemistry of 185 primary PCs and 92 CRPC specimens on tumor 
microarray slides demonstrated increased FEN1 nuclear staining in CRPC samples 
(p < 0.0001). The small proportion of PC patients (n=5) treated with prostatectomy 
with high FEN1 immunostaining also had shorter time to progression. 
Overexpression of FEN1 in PC has previously been reported, where it was shown 
to correlate with high Gleason score (Lam et al., 2006). However, FEN1 expression 
has not previously been studied in CRPC specimens. The data suggest that FEN1 is 
associated with an aggressive form of the disease. Thus FEN1 could be a potential 
biomarker, at least in a subset of PC patients.  
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5. CONCLUDING REMARKS 
AR overexpression sensitizes cells to low androgen concentrations. A 
mechanistic explanation for such sensitization is that genome-wide chromatin 
binding of AR is enhanced in AR-overexpressing cells, and the binding to the 
regulatory regions of AR target genes is faster and more powerful. Chromatin 
binding by AR seems to be dependent on both the level of the receptor and the 
androgen concentrations to which the cells are exposed. Different DHT 
concentrations are able to alter the dynamics of the AR recruitment to the regulatory 
region of AR target genes depending on the level of the receptor. 
 
 
Figure 11. Summary of results. AR overexpression in CRPC cells allows the maintenance 
and enhancement of AR signaling at lower androgen concentrations through different 
mechanisms that involve epigenetic, transcriptional and stoichiometric changes. 
The binding of AR induces basic transcription machinery to be recruited faster, 
as demonstrated by the recruitment of RNA Pol II. H3 acetylation during androgen 
stimulation seems to not be affected by AR levels per se. However, AR 
overexpression seems to predispose AR binding by opening the chromatin via 
displacement of nucleosomes and increased acetylation of flanking H3. Although 
increased chromatin accessibility in AR-overexpressing cells was observed, how the 
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histone loss occurs is unclear. These changes translate into an enhanced gene 
transcription of the AR target genes, which may be different from gene to gene and 
result from intrinsic biological properties of such genes. 
AR overexpression also enhances the expression of coactivators, such as AIB1, 
CBP, MAK and BRCA1, but attenuates the expression of corepressors, such as cyclin 
D1. This selective process may potentially result in a positive feedback loop, which 
sustains the AR activation in low androgen concentrations. 
Altogether, these results indicate that the overexpression of AR in CRPC cells 
allows these cells to maintain and potentiate the AR signaling at lower androgen 
concentrations through several different mechanisms that involve epigenetic, 
transcriptional and stoichiometric changes (Figure 11). 
By combining ChIP-seq and expression data, genes whose expression are directly 
regulated by AR and are transcriptionally upregulated in PC and CRPC were 
identified. Several AR target genes were characterized, and TPX2, DTL, ZWINT, 
SKP2 and FEN1 were found to be androgen-regulated genes that are overexpressed 
in CRPCs. In concordance with the higher expression in CRPC, the ARBSs in the 
proximity of their loci were more occupied in AR-overexpressing cells. Functional 
studies revealed FEN1 to be implicated in PC cell proliferation, and the protein 
expression was also associated with advanced stage and poor prognosis. As an 
androgen-regulated gene that is overexpressed and associated with an aggressive 
phenotype of the disease, FEN1 could be an important AR downstream gene and, 
therefore, a putative drug target in PC. Furthermore, FEN1 could potentially be used 
as a biomarker in a subset PCs. 
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Overexpression of androgen receptor enhances the binding of the
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Androgen receptor (AR) is overexpressed in the majority of
castration-resistant prostate cancers (CRPCs). Our goal
was to study the effect of AR overexpression on the
chromatin binding of the receptor and to identify AR target
genes that may be important in the emergence of CRPC.
We have established two sublines of LNCaP prostate
cancer (PC) cell line, one overexpressing AR 2–3-fold and
the other 4–5-fold compared with the control cells. We used
chromatin immunoprecipitation (ChIP) and deep-sequen-
cing (seq) to identify AR-binding sites (ARBSs). We found
that the number of ARBSs and the AR-binding strength
were positively associated with the level of AR when cells
were stimulated with low concentrations of androgens. In
cells overexpressing AR, the chromatin binding of the
receptor took place in 100-fold lower concentration of the
ligand than in control cells. We conﬁrmed the association of
AR level and chromatin binding in two PC xenografts, one
containing AR gene ampliﬁcation with high AR expression,
and the other with low expression. By combining the ChIP-
seq and expression proﬁling, we identiﬁed AR target genes
that are upregulated in PC. Of them, the expression of
ZWINT, SKP2 (S-phase kinase-associated protein 2
(p45)) and FEN1 (ﬂap structure-speciﬁc endonuclease 1)
was demonstrated to be increased in CRPC, while the
expression of SNAI2 was decreased in both PC and
CRPC. FEN1 protein expression was also associated with
poor prognosis in prostatectomy-treated patients. Finally,
the knock-down of FEN1 with small interfering RNA
inhibited the growth of LNCaP cells. Our data demon-
strate that the overexpression of AR sensitizes the receptor
binding to chromatin, thus, explaining how AR signaling
pathway is reactivated in CRPC cells.
Oncogene advance online publication, 12 September
2011; doi:10.1038/onc.2011.401
Keywords: prostatic neoplasia; AR; ChIP-seq; FEN1;
SKP2; ZWINT
Introduction
The development of prostate cancer (PC) is strongly
dependent on androgens as evidenced by the ﬁnding that
men castrated early in their life will not develop PC
(Isaacs, 1994), and by trials indicating that lowering
tissue levels of 5a-dihydrotestosterone (DHT) with 5a-
reductase inhibitors, reduces the risk of PC (Thompson
et al., 2003; Andriole et al., 2010). The efﬁcacy of
androgen deprivation in the treatment of PC was
demonstrated >50 years ago (Huggins and Hodges,
2002) and castration still remains the main form of
treatment for advanced PC. Despite the initial positive
response, the castration-resistant PC (CRPC) phenotype
will eventually emerge during the therapy. Earlier it was
believed that PCs progressing during castration are
androgen-independent (Thompson et al., 2003). Subse-
quently, the emergence of CRPC has been associated
with increased expression of androgen receptor (AR),
partly due to the ampliﬁcation of the AR gene (Linja
et al., 2001; Chen et al., 2004). Recently, it has been
suggested that also a loss of RB gene could lead to AR
overexpression (Sharma et al., 2010). In addition,
mutations in AR altering transactivation properties of
the receptor, expression of constitutively active AR
splice variants and re-expression of androgen-regulated
genes have been demonstrated in CRPC (Seruga et al.,
2011). It has also been suggested that CRPC cells
could themselves synthesize low levels of androgens
from cholesterol (Seruga et al., 2011). Finally, recent
phase II trials of CRPC with novel superantiandrogen,
MDV3100, and CYP17 inhibitor, abiraterone, have
directly demonstrated that CRPC cells are actually still
androgen sensitive (Tran et al., 2009; Reid et al., 2010).
We showed more than a decade ago that one-third of
CRPCs contain ampliﬁcation of AR (Visakorpi et al.,
1995). In addition, we have demonstrated by quantita-
tive reverse transcriptase (qRT)–PCR that almost all
CRPCs overexpress AR compared with hormone-naı¨ve
PC (Linja et al., 2001). However, expression of AR
protein by immunohistochemistry seems to be variable
in CRPC (Roudier et al., 2004). Later, Chen and co-
workers (2004) showed that in a xenograft model system
overexpression of AR is necessary and sufﬁcient toReceived 3 April 2011; revised 30 July 2011; accepted 2 August 2011
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transform the androgen-dependent growth to an in-
dependent
one. To study the consequences of AR overexpression in
PC cells, we have a stable transfected androgen-sensitive
LNCaP PC cell line with wild-type AR and established
two sublines. LNCaP-ARmo expresses 2–4 and LNCaP-
ARhi 5–6 times higher level of AR protein than the
control cells, LNCaP-pcDNA3.1 (Waltering et al.,
2009). The LNCaP-ARhi cells grow faster in
the presence of low levels of androgens than the control
cells and the androgen-regulated genes are induced,
on average, at 10-fold lower concentrations of DHT in
the AR overexpressing compared with control cells.
As the sublines share the same genomic background, the
model is especially suitable for studying how AR
promotes, maintains and drives the PC progression.
AR is a transcription factor that regulates the
expression of hundreds of genes. Nevertheless, only
one AR target gene that is commonly involved in the
development of the disease, TMPRSS2:ERG fusion
gene, has so far been identiﬁed (Tomlins et al., 2005).
However, the fusion seems not to explain the phenoty-
pical heterogeneity, including hormone responsiveness,
of PC (Leinonen et al., 2010). The identiﬁcation of such
downstream genes could potentially provide new bio-
markers and means to develop novel therapies.
Here, we utilized the LNCaP-based model as well as
LuCaP xenografts to study the effect of the AR
overexpression on the chromatin binding of AR by using
chromatin immunoprecipitation and deep sequencing
(ChIP-seq). In addition, we combined the ChIP-seq data
with expression proﬁling to identify AR downstream
genes that could be important in the progression of PC,
and demonstrated overexpression of ZWINT, SKP2 (S-
phase kinase-associated protein 2 (p45)) and FEN1 (ﬂap
structure-speciﬁc endonuclease 1) and reduced expression
of SNAI2 in clinical samples of CRPC.
Results
In order to map AR-binding sites (ARBSs) across the
genome, we ﬁrst performed ChIP-seq for a total of
nine samples: LNCaP-pcDNA3.1, -ARmo and -ARhi,
treated for 2 h with 0, 1 and 100 nM of DHT (Supple-
mentary Table S1). We found higher number of ARBSs
in LNCaP-ARhi and -ARmo compared with control
cells on stimulation with low concentration (1 nM) of
DHT (Figure 1a). To conﬁrm the association between
AR level and the number of ARBSs in another model
system, we utilized two PC xenografts, LuCaP69
and LuCaP73. They derive from castration-resistant
tumors and have been grown in intact mice. We have
previously demonstrated that LuCaP69 contains AR
ampliﬁcation, whereas LuCaP73 cells do not (Linja
et al., 2001). The expression of AR is about 10-fold
higher in LuCaP69 compared with LuCaP73 according
to qRT–PCR. We found approximately 19 000 and 7000
ARBSs in LuCaP69 and LuCaP73, respectively, verify-
ing that the level of AR is associated with the number of
ARBSs.
To conﬁrm the ChIP-seq data, we used traditional
ChIP–qPCR. We studied the well-characterized enhan-
cer and promoter regions of a known AR target gene,
PSA (Shuur et al., 1996; Cleutjens et al., 1997), in the
cell lines (Figure 1b) and xenografts (Supplementary
Figure S1). The ChIP–qPCR data reproduced the
ChIP-seq data. Furthermore, we were able to conﬁrm
previously identiﬁed ARBSs in AR target genes, such
as TMPRSS2 (Wang et al., 2007) (Supplementary
Figure S1).
In the further analysis of the LNCaP-model, LNCaP-
ARmo and -ARhi displayed high overlap of ARBSs in
cells exposed to 1 nM DHT. On the contrary, in cells
exposed to 100 nM DHT the LNCaP-ARmo and -ARhi
cells showed less ARBSs overlap than -ARmo and
control cells (Figure 1c and Supplementary Table S2).
We then investigated the average peak heights that we
assumed to represent the strength of the AR binding
(Supplementary Table S2). The peak height was deﬁned
as the number of tags present in the speciﬁed loci of the
ARBSs. The average peak height was higher in -ARhi
and -ARmo cells compared with control cells at 1 nM
DHT and lower at 100 nM DHT (Figure 1d and
Supplementary Table S2).
As we used cells with various levels of AR and ligand
concentrations, we were able to make comparison of the
effect of AR and ligand on the binding proﬁles and on
the chromatin loading of AR at the ARBSs (Supple-
mentary Table S2). LNCaP-ARmo and -ARhi grown
in 1 nM DHT had 985 common ARBSs, whereas
pcDNA3.1 at 100 nM and ARmo at 1 nM had 1209,
and pcDNA3.1 at 100 nM and ARhi at 1 nM 1323
ARBSs (Supplementary Table S2). By combining these
ARBS maps, we constructed a high-conﬁdence ARBS
map of 1833 binding sites. The high-conﬁdence ARBSs
map includes all the binding sites with high reproduci-
bility in the three samples mentioned above. We then
re-analyzed the chromatin binding at these high-
conﬁdence ARBSs by computing the binding strength
at each of the 1833 ARBSs. In this way, we were able
to obtain normalized (against vehicle-treated cells)
data on the AR-binding strength (that is, peak height)
(Figure 1e). In cells stimulated with 1 nM DHT, the
average peak height was greater in LNCaP-ARmo and
-ARhi than in control cells. Whereas in cells stimulated
with 100 nM DHT there seems to be a slight decrease in
the peak height in LNCaP-ARhi cells.
Next, we analyzed the genomic localizations of
ARBSs. About 40% of the high-conﬁdence ARBSs
were located in intronic regions and about 50% in distal
intergenic regions. Thus, those regions probably include
most of the enhancer elements (Figure 1f). Similar
results were obtained if the ARBSs maps in every
individual samples were taken into account.
We then performed a motif analysis by searching for
the motifs deposited in TRANSFAC database (Matys
et al., 2006). We found AR (canonical and 6-bp half
site), and HNF3A (alias FOXA1) motifs to be the most
signiﬁcantly overrepresented (Po106). Furthermore,
by categorizing the ARBSs according to their genomic
locations, also ETS family of transcription factor motifs
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were found to be enriched in promoters (P¼ 3.3 103),
and within 1500-bp downstream of transcription start
site (P¼ 4 104) as well as in exons (P¼ 1.1 102).
Next, we performed Gene Ontology (GO) enrichment
analysis of genes located within a 25 kb window in the
ARBS maps generated by pcDNA3.1 grown at 100 and
1 nM, -ARmo at 1 nM, as well as -ARhi at 1 nM DHT, by
using GeneTrail (Keller et al., 2008). In 1 nM DHT-
treated cells, the number of overrepresented GO
(biological processes) categories increased from 5 in
pcDNA3.1 to 22 in -ARmo, and 31 in ARhi. The
processes that showed enrichment exclusively in -ARhi
included, for example, cell–cell adhesion (GO:0016337),
and regulation of locomotion (GO:0040012). Generally,
in cells overexpressing AR, the same category of genes
was enriched than in control cells, except in lower
androgen concentration (Supplementary Table S3).
We then investigated the overlap of the high-
conﬁdence ARBSs map between the cell lines and the
ARBSs maps of the xenografts. The overlap was
surprisingly low. LuCaP69 showed 31% overlap with
the high-conﬁdence ARBS map in the cell lines, whereas
Figure 1 ChIP-seq data analyses. (a) Comparison of number of ARBSs between cell lines treated with 1 nM DHT according to peak
detection with a P-value threshold of 0.00001 (black bar) and controlling also for false discovery rate (FDR) (white bar) at 5%. (b) AR
binding to PSA promoter and enhancer in LNCaP-model. LNCaP-pcDNA3.1, -ARmo and -ARhi cells were hormone-starved for
4 days and treated for 2 h with DHT or ethanol (0M). ChIP–qPCR was performed to assess the AR recruitment. Mean and s.e.m. are
shown. (c) Number of ARBSs in common between the ChIP-seq samples. (d) Average background subtracted height of ARBSs
in common between samples treated with 1 nM DHT (526 ARBSs in total) and between samples treated with 100 nM DHT (274 ARBSs
in total) corrected according to the corresponding amount of raw reads (in millions) obtained in the sequencing (see Supplementary
Table S1). (e) Normalized (against no DHT) average peak height of all high-conﬁdence ARBSs in cell lines treated with different
concentrations of DHT. (f) The genomic location of the 1833 high-conﬁdence ARBSs. The high-conﬁdence ARBSs were divided
according to their location in distal intergenic regions (i), in exons (ii), within 1.5 kb upstream of transcription start site (TSS) (iii),
within 1.5 kb downstream of 30UTR (iv) and in introns (v).
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LuCaP73 only about 4%. When comparing individual
samples, LNCaP-ARhi at 1 nM, -ARmo at 100 nM and -
pcDNA3.1 at 100 nM showed the highest percentage of
overlap with the LuCaP69 ARBS map. In order to
conﬁrm our ﬁnding, we compared LuCaP69 and
LuCaP73 ARBS maps with the publicly available
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LNCaP ARBS map from the work by Yu et al. (2010).
We found even less overlap. The overlap with LuCaP69
was 6.5% and with LuCaP73 0.4%, whereas we found
86.8% overlap between our high-conﬁdence ARBSs in
LNCaP-model and the ARBSs of LNCaP cell line
published by (Yu et al., 2010).
Finally, we integrated the high-conﬁdence ARBS
maps and expression proﬁles of mRNAs (Waltering
et al., 2009) obtained from the LNCaP-model.
We used ﬁrst hypergeometric distribution to compute
enrichment P-values for differentially expressed genes
and AR bound genes. When DHT concentrations were
used to stimulate the cells, we observed that the
differential expression, which was controlled directly
by AR at the 4-h time point, still continued at the 24-h
time point (Po0.05). Thus, we used both time points to
identify direct targets of AR. Since we have previously
shown that LNCaP-ARhi cells grow signiﬁcantly faster
in 1 nM DHT than control cells (Waltering et al., 2009),
we focused on genes that showed AR binding and
differential expression in that DHT concentration.
The Venn diagrams in Figures 2a and b show that there
are more such genes in LNCaP-ARhi and -ARmo than
in control cells. The lists of 346 genes that were AR
bound and androgen-regulated only in LNCaP-ARhi
and -ARmo at 4- and/or 24-h time points are given in
Supplementary Tables S4 and S5, respectively. Next, we
interrogated the expression of these genes in clinical PC
specimens by retrieving data from 14 independent
array-based studies (see Supplementary Table S6 for
references). We found that 38 out of these 346 genes
(Supplementary Table S6) were overexpressed in PC
according to, at least, one of the studies. Subsequently,
of these we selected ﬁve putative target genes (FEN1,
ZWINT, SKP2, SNAI2 and AZGP1) based on informa-
tion retrieved from the literature, and conﬁrmed their
androgen regulation (Figure 2c). Furthermore, in order
to test the hypothesis that not only the androgens but
also the amount of AR in the cells has an effect on such
regulation, we performed a two-way analysis of variance
in which the interaction between the effect on the
variance of both AR amount and concentration of DHT
was tested. The analysis indicated highly signiﬁcant
(Po0.0001) interaction and that both AR amount and
the DHT concentration affect the gene expression
signiﬁcantly (Po0.0001).
Next, we used qRT–PCR to measure the expression
of the genes in benign prostate hyperplasia (BPH),
untreated PC and CRPC (Figure 2d). SKP2, ZWINT
and FEN1 transcripts were signiﬁcantly overexpressed in
CRPC when compared with PC and/or BPH, whereas
the expression of SNAI2 was reduced in CRPC and PC
compared with BPH. The expression of AZGP1 was
signiﬁcantly lower in CRPC than in PC. For SKP2,
ZWINT and FEN1, we also conﬁrmed the closest high-
conﬁdence ARBSs using ChIP–qPCR (Figure 3), and
showed that AR binding is stronger in AR overexpres-
sing than in control cells. To investigate the function of
FEN1, ZWINT and SNAI2 in PC, we suppressed them
using small interfering RNAs (siRNAs) in both LNCaP-
pcDNA3.1 and LNCaP-ARhi cells. FEN1 depletion
reduced signiﬁcantly cell growth of both cell lines
(Figure 4), while SNAI2 and ZWINT depletions
seem to give a growth advantage in control cells, but
not in LNCaP-ARhi cells (Supplementary Figure S2).
To study protein expression of FEN1, we ﬁrst used
western blotting in the cell line model and demon-
strated increased protein expression in LNCaP-ARhi
Figure 2 Identiﬁcation of androgen-regulated AR target genes that are overexpressed in CRPC. The Venn diagrams showing the
number of genes that are located in a window of 250 kb around the high-conﬁdence ARBSs in LNCaP-pcDNA3.1, -ARmo and -ARhi
cells and that showed at least 1.5-fold differential expression on 1 nM DHT stimulation for 4 h (a) and 24 h (b) (see Supplementary
Tables S4 and S5). (c) Androgen regulation of AR target genes and effect of AR overexpression on their expression. LNCaP-
pcDNA3.1, -ARmo and -ARhi cells were hormone starved for 4 days and subsequently treated with the indicated concentration of
DHT or with vehicle (0 M). The expression of the genes was measured with qRT–PCR. Mean and s.e.m. of each gene against TBP
values, normalized against the 0M of each time point are shown. (d) Expression of the indicated AR target genes relative to average of
three housekeeping genes (TBP, b-actin and G3PDH2) in BPH (n¼ 15), PC (n¼ 27) and CRPC (n¼ 13) according to qRT–PCR.
Kruskall–Wallis with Dunn post-test results are shown (***o0.001; *0.01 to 0.05; NS, not signiﬁcant).
Figure 3 AR binding on putative enhancers of AR target genes. ChIP–qPCR on LNCaP-pcDNA3.1 and -ARhi cells, hormone
starved for 4 days and treated for 2 h with 1 nM DHT or ethanol (0 M), was performed to assess the AR recruitment on the putative
enhancers of FEN1 (a), ZWINT (b) and SKP2 (c) genes located 100kb upstream (in the ﬁrst intron of the gene DAGLA), 23 kb
upstream and 120 kb upstream the above mentioned genes, respectively, according to our ChIPseq data. The data are presented as fold
over percentage of input of the ethanol-treated sample. Mean±s.e.m. are shown.
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and -ARmo compared with control cells (Figure 5a).
Next, we immunostained 185 untreated prostatectomy
specimens as well as 92 CRPC samples (Figures 5b–d).
Although cytoplasmic FEN1 staining was equal in PC
and CRPC, the strong nuclear staining was observed
signiﬁcantly (Po0.0001) more often in CRPC than PC
samples (Figure 5e). Only 5/185 (3%) prostatectomy
samples showed nuclear staining in410% of malignant
cells. Interestingly, these cases had short time for
biochemical recurrence (Figure 5f).
Discussion
Overexpression of AR is a common feature in CRPC
(Linja et al., 2001), and it has been shown to sensitize
cells to low levels of androgens (Kokontis et al., 1998;
Chen et al., 2004; Waltering et al., 2009). Here, we
utilized our previously established LNCaP-based model
(Waltering et al., 2009), expressing different levels of AR
to interrogate the effect of both ligand and the receptor
on chromatin binding of AR. The data here indicated
that both the ligand concentration and the amount of
receptor affect together the chromatin binding of AR.
A modest overexpression of AR enhances the chromatin
binding of the receptor by sensitizing the cells to 100-
fold lower ligand concentration. The majority of the
previously reported ChIP-seq and ChIP-chip experi-
ments (Jia et al., 2008; Wang et al., 2009; Takayama
et al., 2010; Yu et al., 2010) have compared the binding
of AR at the saturating concentration of androgens, and
thus, missed the dynamics of AR binding. However, our
data are in line with a recent work by Massie et al.
(2011), in which they found almost ﬁve times more
ARBSs in the strongly AR-overexpressing cell line
VCaP compared with LNCaP cells. The data here are
also consistent with our previous ﬁnding (Waltering
et al., 2009) that androgen-regulated genes are induced
in lower ligand concentrations in cells overexpressing
AR. Thus, the increased chromatin-binding capacity of
the receptor because of the overexpression of the
receptor provides also a mechanistic explanation to the
progression of PC in the presence of only low levels of
androgens.
We conﬁrmed the effect of AR levels on chromatin
binding of the receptor also in another independent
model system. There were almost three times more
ARBSs in LuCaP69 than in LuCaP73 PC xenografts
verifying that the level of AR is associated with the
number of ARBSs. LuCaP69 contains AR gene ampli-
ﬁcation and 10-fold higher expression of AR than
LuCaP73 (Linja et al., 2001). The reliability of the
ChIP-seq data was, on the other hand, conﬁrmed by
traditional ChIP–qPCR of PSA, and our ARBS maps
were able to conﬁrm previously reported ARBS like for
TMPRSS2 enhancer. Furthermore, we obtained a high
degree of ARBSs overlap with previously published data
set on the same cell line.
Although the ChIP–qPCR data conﬁrmed increased
binding in the PSA enhancer in AR-overexpressing
compared with control cell, no such loading difference
was seen in the promoter region (Figure 1b). Previous
studies (Kang et al., 2004; Wang et al., 2005) have
pinpointed the importance of the dynamics of the AR
recruitment in the PSA regulatory regions. Here, we
studied the AR recruitment only 2 h after DHT
stimulation. Thus, we cannot exclude the possibility
that there are differences in the AR recruitment at the
promoter of PSA between the cell lines at later time
points.
Unlike most of the previous AR ChIP-chip and ChIP-
seq studies (Massie et al., 2007; Wang et al., 2007, 2009;
Jia et al., 2008; Takayama et al., 2010; Yu et al., 2010),
we used several ligand concentrations and several
LNCaP derivative cell lines. Thus, we were able to
produce highly reproducible ARBSs data, which we
called high-conﬁdence ARBSs map. We utilized that
map in comparison of the cell line model and the
xenograft as well as in ARBS localizations, motif and
ontology analyses, and also in identiﬁcation of the
critical AR target genes. The poor overlap (from 4 to
31%) of the high-conﬁdence ARBSs map between the
cell lines and the xenografts emphasizes that AR binding
to chromatin varies signiﬁcantly between tissue samples
suggesting that genetic or other intrinsic differences,
Figure 4 Functional signiﬁcance of FEN1. Growth curve of siFEN1-transfected LNCaP-pcDNA3.1 (a) and LNCaP-ARhi (b) cells.
Mean and ±s.d. are shown on different days. Statistical signiﬁcance against control siRNA-transfected cells growth was assessed at
day 4 by t-test. qRT–PCR at day 2.5 and western blot analysis at day 3 after transfection are also shown in each experiment conﬁrming
the FEN1 knockdown.
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such as binding of other transcription factors, in the
cells could contribute strongly to the AR binding
(Zinzen et al., 2009; Kasowski et al., 2010). This notion
is also supported by our re-analysis of the publicly
available data from the work by Yu and co-authors
(2010). According to the re-analysis, Yu et al. obtained
58.1% overlap of ARBSs between LNCaP and only
28.7% overlap between VCaP and a tumor sample. The
same tumor tissue sample showed 44.1% overlap with
our high-conﬁdence ARBSs, while the overlap with the
LuCaP69 ARBSs was only 17.9%. Although the two
xenografts overlapped poorly within each other and also
with the high-conﬁdence ARBSs map of LNCaP, the
ARBSs in the xenografts, localized often close to the
genes that showed ARBSs and androgen regulation in
the LNCaP-model. This suggest that androgen-regu-
lated genes may have alternative ARBSs. The poor
overlap between the cell lines and xenografts may
obviously also be due to the microenvironmental (cell
culture versus mouse) differences.
The genomic localization of the ARBSs indicated that
most of the androgen regulation is mediated by binding
of AR to the distal intergenic elements and intronic
regions as previously suggested (Jia et al., 2008; Lupien
et al., 2008; Yu et al., 2010), instead of, for example, to
promoter regions. Also, the motif analyses were in
concordance with previously published ﬁndings (Massie
et al., 2007; Lupien et al., 2008; Wang et al., 2009; Wei
et al., 2010; Yu et al., 2010) showing that binding sites
of, especially, FOXA1 and ETS family of transcription
factors are enriched in the vicinity of ARBSs. FOXA1
has previously been suggested to be a pioneering factor
for binding of other transcription factors to chromatin
(Lupien et al., 2008, Wang et al., 2011), which is in line
Figure 5 AR overexpression increases FEN1 protein. (a) AR overexpression increases FEN1 protein production. Western blot
analysis of LNCaP-pcDNA3.1, -ARmo and -ARhi cells grown in normal medium showing FEN1 protein being overexpressed in
AR-overexpressing cells compared with control cells. Anti-ATP synthase subunit alpha (ASS1) antibody was used as loading control.
Immunohistochemical staining of (b) untreated PC with no cytoplasmic or nuclear staining, (c) untreated PC, and (d) CRPC specimen
with strong nuclear staining in almost all malignant cells with monoclonal anti-FEN1 antibody. (e) The percentage of tumors
according to percentage of positive nuclei in PC (n¼ 185) and CRPC (n¼ 92) specimens (Po0.0001 according to w2 test). (f) Kaplan–
Meier analysis of biochemical progression-free survival in prostatectomy-treated patients according to the percentage of FEN1 positive
nuclei. Five patients with high frequency of FEN1-positive nuclei had very short progression-free time. The P-value was calculated
with Mantel–Cox test.
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with our data. Also, the ontology analysis of genes
located within a 25 kb window of the ARBS maps was
consistent with our previous ﬁndings based on the
expression proﬁling of the LNCaP model (Waltering
et al., 2009). Cell–cell adhesion and regulation of
locomotion were among the most enriched ontologies.
Finally, to identify AR target genes that could be
important in the progression of PC, we combined the
high-conﬁdence ARBS map with expression proﬁling of
the LNCaP model. The analyses indicated that there are
more genes, which show ARBSs in LNCaP-ARhi and -
ARmo than in control cells. The data are consistent with
our previously published ﬁndings on the expression of
AR target genes in this model (Waltering et al., 2009).
Thus, in cells overexpressing AR, less ligand is needed
for induction of target gene expression. We then further
studied the expression of FEN1, ZWINT, SKP2, SNAI2
and AZGP1 in clinical PC ﬁrst by data mining publicly
available microarray data, and subsequently by using
qRT–PCR to measure the expression in BPH, PC and
CRPC. Of those, the expression of SKP2, ZWINT and
FEN1 transcripts were signiﬁcantly overexpressed in
CRPC when compared with PC and/or BPH while the
expression of SNAI2 was reduced in cancer compared
with BPH. Also, recently published data in advanced PC
conﬁrm the overexpression of these genes (Taylor et al.,
2010). In addition, we conﬁrmed the androgen regula-
tion and the ARBSs of these genes by qRT–PCR, and
ChIP–qPCR, respectively.
SKP2 is known to have oncogenic properties and to
be overexpressed in many cancers (Nakayama and
Nakayama, 2006). It has previously been shown to be
androgen regulated (Waltregny et al., 2001) and the
expression being associated with a short biochemical
recurrence following prostatectomy (Nguyen et al.,
2011). However, to our knowledge, this is the ﬁrst
report showing elevated levels of SKP2 transcripts in
CRPCs. A recent study by Lin and co-authors (2010)
suggested SKP2 as a potential target in cancer treatment
and prevention, because inhibition of SKP2 triggered
cellular senescence in p53/PTEN-deﬁcient PC-3 cells
and tumor regression in mice. ZWINT (ZW10 inter-
actor), on the other hand, encodes a kinetokore protein
(Starr et al., 2000) that has been suggested to have a role
in the development of some malignancies (Obuse et al.,
2004; Kops et al., 2005; Lin et al., 2006). We have
previously shown ZWINT to be an androgen-regulated
gene (Waltering et al., 2009). Depletion of ZWINT in
LNCaP-pcDNA3.1 cells resulted in faster growth,
whereas there was no signiﬁcant effect on LNCaP-ARhi
cells. Thus, the functional data are discordant with the
ﬁnding of overexpression of the gene in cancer. SNAI2
(snail homolog 2 (Drosophila)) is a zinc-ﬁnger transcrip-
tional repressor involved in epithelium to mesenchyme
transition (Thiery, 2002). Depletion of also SNAI2 in
LNCaP-pcDNA3.1, but not in LNCaP-ARhi, cells
resulted in faster growth, which is concordant with the
reduced expression in cancer.
FEN1 encodes a structure-speciﬁc metallonuclease
that interacts with several other proteins involved in
DNA replication, apoptosis, DNA repair and telomere
stability (Zheng et al., 2010). Somatic mutations of
FEN1 have been reported in several common cancers
(Zheng et al., 2007). These mutations abolish the
exonuclease activity but retain the ﬂap endonuclease
activity (Zheng et al., 2007), which is consistent with the
ﬁnding that mice carrying mutations show higher
chemically induced cancer incidence (Xu et al., 2011).
The mutations of FEN1 in PC are yet to be investigated,
however, FEN1 has been reported to be overexpressed
in PC, especially in high Gleason score tumors (Lam
et al., 2006). Here, we showed that the high frequency of
nuclear staining was found signiﬁcantly (Po0.0001)
more often in CRPC than in PC, and that the
staining was associated with poor prognosis in
prostatectomy-treated patients. Thus, FEN1, as an
androgen-regulated, overexpressed and associated
with aggressive phenotype of the disease, could be
an important AR downstream gene and, therefore, a
putative drug target. Also, our preliminary functional
data further suggest that FEN1 could promote the
growth of PC cells, since the knockdown of FEN1
signiﬁcantly reduced the growth of both control and
AR-overexpressing cells.
In conclusion, we demonstrated that chromatin
binding of AR is dependent not just on the ligand
concentration, but also on the level of the receptor.
Thus, the overexpression of AR in CRPC cells allows
these cells to activate the AR signaling even in low
androgen concentrations. By combining ChIP-seq and
expression data, we were able to identify genes whose
expression is directly regulated by AR, and are
transcriptionally upregulated in PC and CRPC. These
genes could be important in the progression of PC.
Materials and methods
Cell line and cell culture procedure
The establishment of LNCaP cells overexpressing AR has been
described previously (Waltering et al., 2009). The cells were
maintained under geneticin 250 mg/ml (Invitrogen Inc., Carls-
bad, CA, USA). The hormone treatments and RNA extrac-
tions were performed as previously described (Waltering et al.,
2011). LNCaP, VCaP and LAPC4 cells were purchased from
ATCC (LGC/ATCC, Rockville, MD, USA) and maintained
according to the manufacturer’s instructions.
Xenografts material
Two PC xenografts, LuCaP69 and LuCaP73, grown in intact
male mice, were provided by one of the investigators (RLV).
Clinical samples
Freshly frozen 8 BPH and 27 untreated primary PC samples
from prostatectomies, as well as 7 BPH and 15 CRPC
specimens from transurethral resection of the prostate-treated
patients were used in the study. The samples were snap frozen
in liquid nitrogen and total RNA was isolated with Trizol-
Reagent (Invitrogen Inc.) according to the manufacturer’s
instructions. Tumor samples contained, at least, 70% of cancer
cells. The use of the clinical material has been approved by the
ethical committee of the Tampere University Hospital.
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Tissue microarrays contained 185 formalin-ﬁxed para-
fﬁn-embedded prostatectomy and 92 CRPC (transurethral
resection of the prostate) specimens obtained from Tampere
University Hospital. For the prostatectomy-treated patients,
detectable PSA values (X0.5 ng/ml) in two consecutive
measurements or the emergence of metastases were considered
as signs of progression. The use of tissue microarrays has been
approved by the ethical committee of Tampere University
Hospital and the National Authority for Medicolegal Affairs.
ChIP, ChIP-seq assays and data analysis
Four million cells were plated and hormone-deprived for
4 days and treated with DHT at different concentrations for
2 h. Cells were ﬁxed by adding formaldehyde (Merck KGaA,
Darmstadt, Germany) in 1% ﬁnal concentration for 10min at
room temperature and lysed in 1% sodium dodecyl sulfate,
10mM EDTA, 50mM Tris–HCl containing 2X protease
inhibitor (Roche Inc., Mannheim, Germany). To perform
tissue ChIP, 3ml of phosphate-buffered saline containing 2X
protease inhibitor (Roche Inc.) were added to 40 20 mm
sections of freshly frozen xenograft specimens. They were ﬁrst
vigorously mixed three times with syringe and 14G needle,
then four times with 25G needle. The cells were ﬁxed for
10min in room temperature by adding 1/10 volume of ﬁxation
solution (11% formaldehyde, 0.1 M NaCl, 1mM EDTA, 0.5mM
EGTA, 50mM HEPES). Fixation was stopped by adding 1/20
volume of 2.5M glycine for 5min at room temperature.
The cells were pelleted, washed twice in phosphate-buffered
saline containing 2X protease inhibitor (Roche Inc.) and lysed
as above. The chromatin was immunoprecipitated with 10 mg
of normal rabbit immunoglobulin G (Santa Cruz Inc., Santa
Cruz, CA, USA) or 10 ml of anti-AR polyclonal antibody
(AR3) (provided by one of the investigators: OAJ) (Karvonen
et al., 1997, Thompson et al., 2006). Supplementary Figure S3
shows a validation of the AR3 antibody in western blot and
ChIP assay. The libraries of ChIP DNA were prepared and
sequenced with Genome Analyzer II (Illumina Inc., San Diego,
CA, USA) according to the manufacturer’s protocol. Detailed
descriptions of the ChIP procedure, sequencing and detailed
data analysis are included in Supplementary Information.
mRNA expression proﬁling
mRNA expression data with Illumina platform (including
RefSeq genes) (Illumina Inc.) were retrieved from the studies
by Waltering et al. (2009). A detailed description of the raw
data analysis is provided in the Supplementary Information.
Quantitative PCR assays
For mRNA expression analyses, ﬁrst-strand complementary
DNA synthesis was performed from total RNA using AMV
reverse transcriptase (Finnzymes Inc., Espoo, Finland) accord-
ing to the manufacturer’s instructions. The relative expression
of each gene against the average value of TBP, G3PDH2
and b-actin reference genes was measured with Maxima
SYBR Green (Fermentas Inc., Burlington, Ontario, Canada)
and CFX96 real-time PCR detection system (Bio-Rad
Laboratories Inc., Hercules, CA, USA) essentially as pre-
viously described (Urbanucci et al., 2008). For the ChIP–
qPCR analysis, the enrichment relative to input chromatin
was calculated according to the delta Ct method with the
percentages been calculated using the formula 2DCt, where DCt
is Ct(ChIP-template)-Ct(Input). A standard curve from one of
the diluted input was included in the run to control that the
efﬁciency of the reaction would be maintained in the range
between 95 and 105%. A qPCR on a control region in which
AR is not supposed to bind, between PSA enhancer and
promoter (middle region) was performed for each ChIP assay.
The ChIP assay was considered speciﬁc if in the control region
the enrichment was not above the enrichment of the non-
speciﬁc immunoprecipitated sample made with normal rabbit
immunoglobulin G. The primers used are listed in Supple-
mentary Table S7.
Western blot
Western Blot was performed from total cell lysates. The primary
antibodies used were anti-FEN1 (clone 4E7; LifeSpan Bio-
sciences Inc., Seattle, WA, USA) and anti-ATP synthase subunit
alpha (clone 15H4C4; MitoSciences Inc., Eugene, OR, USA)
monoclonal antibodies. A detailed description of the western
blot procedure is provided in the Supplementary Information.
Immunohistochemistry
Mouse anti-FEN1 (mAb clone 4E7; LifeSpan Biosciences Inc.)
was used with Power Visionþ Poly-HRP IHC kit (Immuno-
Vision Technologies Co., Burlingame, CA, USA) according to
the manufacturer’s instructions. The protocol has previously
been described (Leinonen et al., 2010).
siRNA transfections
Silencer selected siRNAs from Ambion (Applied Biosystems/
Ambion, Austin, TX, USA) were used. Cells were transfected
with INTERFERin transfection reagent (Polyplus-trans-
fection, Illkirch, France) according to the manufacturer’s
protocol. Brieﬂy, 20 000 cells/24-well plate were seeded and
transfected with 20 nM of siFEN1 (s5103), 20 nM each of
siZWINT (s21949 and s21951), 20 nM each of siSNAI2 (s13127
and s13128) or equal concentration of Silencer negative
control siRNA #1. Expression levels of FEN1, ZWINT and
SNAI2 relative to TBP were measured by qRT–PCR (2.5 days
after transfection) and protein levels by Western blot analysis
(3 days after transfection).
Growth curves
Growth curve measurements were started 1 day after siRNA
transfection and marked as day 1. Images of the same growth
area in each well were acquired every day using a Retiga-2000R
FAST Cooled Mono 12-bit camera (QImaging Inc., Surrey, BC
Canada) mounted on a Motorized Inverted Research Micro-
scope IXT1 (Olympus America Inc., Center Valley, PA, USA)
and a 10X objective. The total growth area occupied by cells
(area percent) in each well was determined each day of
measurement with ImageJ software (Abramoff et al., 2004)
and normalized against the growth area of the relative well
at day 1. Four replicates were used in each siRNA experiment.
T-test was used to assess signiﬁcance of differences in growth
curves at day 4.
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Abstract 
BACKGROUND. Castration-resistant prostate cancers (CRPCs) overexpress often androgen 
receptor (AR). Here, we investigated the effect of AR overexpression on the dynamics of AR 
loading and RNA polymerase II (RNA Pol II) recruitment to chromatin. Acetylation of 
histone 3 (AcH3) on lysines 9 and 14 (K9 and K14) was also studied.  
METHODS. We used an LNCaP-based AR overexpression cell line model that includes a 
control line and two sublines, LNCaP-ARmo and LNCaP-ARhi, which overexpress AR 2–3- 
and 4–5-fold, respectively. Cells were exposed to 1 nM or 100 nM of dihydrotestosterone 
(DHT). Chromatin immunoprecipitation (ChIP) on the promoters and enhancers of prostate 
specific antigen (PSA) and transmembrane protease, serine 2 (TMPRSS2) genes was 
performed. qRT-PCR was used to measure the levels of PSA and TMPRSS2 transcripts.  
RESULTS. Upon stimulation with 1 nM DHT, AR and RNA Pol II were recruited onto PSA 
and TMPRSS2 enhancer regions to a greater extent (p<0.05) in AR-overexpressing cells 
compared to control cells. The difference in AR loading between the control and AR-
overexpressing cells was abolished by a higher DHT concentration. The ratio of AcH3/H3 
was increased in AR-overexpressing cells. The induction of transcription of PSA and 
TMPRSS2 occurred earlier in the AR-overexpressing cells.  
CONCLUSIONS. Our findings suggest that the levels of AR potentiate the recruitment of 
the AR, as well as components of the basic transcription machinery, to chromatin and affect 
the acetylation of histones in the presence of low levels of androgens. These changes result in 
enhanced gene transcription of AR target genes.  
 
Keywords: prostatic neoplasia, PSA, TMPRSS2, AR, RNA polymerase 2, histone 3 lysine 
acetylation.  
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INTRODUCTION 
The mechanisms of the development of castration-resistant prostate cancer (CRPC) are 
incompletely understood, hampering the treatment of this highly lethal form of the disease.  
Overexpression of androgen receptor (AR) has been found in the majority of CRPCs [1]. 
Overexpression is partially explained by amplification of the AR gene [1,2]. Mutations in the 
AR gene, which allow activation of the receptor by ligands other than androgens, have also 
been demonstrated, particularly in CRPCs treated with antiandrogens [3]. It was recently 
discovered that CRPCs may express splice variants of AR that lack the ligand-binding 
domain (LBD) of the receptor [4]. Given the inhibitory function of the unliganded LBD on 
the activation of the receptor [5], such receptors are constitutively active [4]. Although 
several studies reported an association of AR splice variants with advanced PC [4,6] and their 
role in abiraterone resistance has been recently hypothesized [7], the clinical significance of 
splice variants is not yet clear. In fact, suppression of the wild-type AR is enough to reduce 
AR signaling even in the presence of the constitutively active form of AR [8]. Also, 
alterations in the levels of AR coregulators [9,10] and cross-talk with other signaling 
pathways may be involved in the emergence of CRPC [10,11]. Finally, it has been suggested 
that CRPC cells could produce low levels of androgens themselves [12,13].  In recent clinical 
trials, abiraterone, an inhibitor of androgen biosynthesis [14], and MDV3100, a novel 
antiandrogen [15], have shown efficacy in the treatment of CRPC, directly demonstrating that 
AR signaling is still active in CRPC.  
 
AR is a member of the steroid hormone nuclear receptor (SHR) family and shares several 
features with other members of the family. The SHRs are transcription factors activated by 
steroid hormones and mediate cell-fate events, including cell metabolism, organ 
development, cell growth, and differentiation [16]. Like other members of the SHR family, 
AR binds to chromatin through specific consensus sequences (cis-elements) that, for the AR, 
are called androgen response elements (AREs) [17]. In general, transcription factors act in a 
cyclical fashion in order to favor transcription [18,19], and there is some evidence that SHRs 
cycle onto chromatin [20]. Periodicity and detailed features of the binding have been clearly 
demonstrated for the estrogen receptor [21,22] and other members of the family [23,24,25]. A 
proteasome activity-dependent periodic binding has also been shown for the AR [26,27]. 
Finally, Welsbie et al. [28] have shown that AR cycles onto the enhancer of an AR target 
gene, the prostate specific antigen (PSA).  
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We recently demonstrated that overexpression of AR sensitizes cells to lower concentrations 
of androgens [29]. In cells with high levels of AR, cell growth, induction of target genes, and 
AR binding to chromatin occur at lower dihydrotestosterone (DHT) concentrations than in 
cells expressing lower levels of AR [29,30,31]. Here, we investigated the effect of AR 
overexpression on the binding dynamics of the AR and RNA polymerase II (RNA Pol II) to 
chromatin, as well as the effects on acetylation of histone 3 (AcH3). We utilized two well 
characterized AR target genes, PSA and TMPRSS2. We show that in AR-overexpressing cells 
exposed to low concentrations of androgens, the AR loading and the RNA Pol II recruitment 
dynamics to chromatin are altered compared to cells expressing lower levels of AR. Under 
the same conditions, the level of histone acetylation is also altered.  
 
MATERIAL AND METHODS 
Cell line and cell culture procedure 
The establishment of LNCaP cells overexpressing AR was previously described [29]. The 
cells were stably transfected with pcDNA3.1(+) empty expression vector (Invitrogen Inc., 
Carlsbad, CA, USA) and pcDNA3.1(+) inserted with wild-type AR coding region and 
clonally expanded [29]. The cells were maintained under 250µg/ml geneticin (Invitrogen 
Inc., Carlsbad, California, USA). Exposure to DHT at the indicated concentrations was 
performed as previously described [30,31] after 4 days of hormone starvation.  
 
Chromatin immunoprecipitation (ChIP) 
The ChIP procedure was carried out as described in Urbanucci et al. [31]. Chromatin was 
immunoprecipitated with 10 µg of normal rabbit IgG, 13 µg of anti-RNA Pol II (N-20) (Santa 
Cruz Inc., Santa Cruz, California, USA), 10 µl of anti-AR polyclonal antibody (AR3) 
[31,32,33,34], 2.5 µl of anti-AcH3K9, 3 µg of anti-AcH3K9K14 or 2.5 µl of anti-H3 pan C-
terminal (Millipore Inc., Billerica, Massachusetts, USA). Primer sequences for the PSA and 
TMPRSS2 loci examined in this work are shown in Supplementary Table 1. 
 
RNA extraction and quantitative PCR  
RNA was isolated as previously described [31]. First-strand cDNA was synthesized from 
total RNA using AMV reverse transcriptase (Finnzymes Inc., Espoo, Finland) according to 
the manufacturer’s instructions. ChIP-qPCR and mRNA expression analysis of each gene 
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normalized against the average value of the TBP reference gene were performed with 
Maxima™ SYBR Green (Fermentas Inc., Burlington, Ontario, Canada) and a CFX96 real-
time PCR detection system (Bio-Rad Laboratories Inc., Hercules, California, USA) as 
previously described [31]. The primers used are listed in Supplementary Table 1. 
 
Statistical analyses 
Data were analyzed with one-way analysis of variance (ANOVA) with a Bonferroni post-test. 
 
 
 
RESULTS 
We previously established cell lines that have moderate (2–3-fold) or high (4-5-fold) AR 
overexpression compared to LNCaP-pcDNA3.1 control cells, named LNCaP-ARmo and 
LNCaP-ARhi, respectively [29]. We have demonstrated  86 % overlap between the chromatin 
binding of AR in the parental LNCaP and the LNCaP-pcDNA3.1cells. [31]. In addition, we 
have demonstrated similar AR loading on the PSA enhancer in LNCaP-pcDNA3.1 and 
LNCaP-1F5 cells (Suppl. Fig. 1). LNCaP-1F5 cells are glucocorticoid receptor transfected  
LNCaP cells, which have been shown to retain similar AR activity as well as growth 
properties than parental LNCaP [35]. These data suggest that the empty vector transfected 
LNCaP cells share similar AR binding properties with the parental LNCaP cells. 
 
First, we measured mRNA levels of AR in LNCaP-pcDNA3.1 and in -ARhi cells upon 
stimulation with 1 nM DHT within a 16 h time interval. The results show a mild (non- 
significant) upregulation of AR level at 16 h in control transfected cells and a more 
substained upregulation already after 10 h in LNCaP-ARhi cells (t-test p<0.05) (Suppl. Fig. 
2). However, in earlier time points there was no effect on the AR expression. 
 
Next, we investigated how the AR overexpression affects the loading of AR and recruitment 
of RNA Pol II onto well-known regulatory regions of PSA and TMPRSS2 genes upon 
stimulation with DHT, as well as the acetylation status of the H3. For PSA, in addition to the 
AREs located 131 and 150 bp from the transcription start site (TSS), an enhancer region 4 kb 
upstream of the TSS has been documented [36,37]. For the TMPRSS2 gene, the AREs in the 
regulatory region are located 13.5 kb [27,38] and 700 bp upstream of the TSS [38]. We 
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performed ChIP-qPCR analyses on these selected genomic sites of PSA (Fig. 1A) and 
TMPRSS2 (Fig. 1B) following DHT exposure from 30 min to 4 h. For PSA, we also looked at 
three additional genomic sites: the TSS, exon 3, and a site downstream of the gene locus. 
 
In cells exposed to a low DHT concentration (1 nM), more AR was loaded onto the PSA 
enhancer after 30 min in AR-overexpressing cells than in control cells (p<0.05, t-test). A 
comparable level of AR loading was observed in control and LNCaP-ARmo cells at 1 h. 
However, LNCaP-ARhi cells loaded significantly (p<0.05) more AR than the other cell line 
at 1 h and also after 80 minutes (Fig. 2A). Taking all time points and cell lines into account, 
the higher AR level in the AR-overexpressing cells had a significant effect (p<0.05, one-way 
ANOVA) on receptor loading onto the PSA enhancer (Fig 2A). Also, more AR was loaded 
onto the promoter region (p<0.05, one-way ANOVA) in the LNCaP-ARhi cells than in –
ARmo or control cells, especially after 80 minutes of androgen exposure (Fig. 2B). However, 
the difference in AR loading between AR-overexpressing cells and the control cells was not 
as clear as compared with the difference observed in the enhancer region. For the other 
chromosomal regions (TSS, exon 3, and the downstream site), AR loading was generally 
similar to background levels (Fig. 2C-E & Suppl. Fig. 3). 
 
At the 1 h time point, AR loading onto the TMPRSS2 enhancer (Fig. 3A) was already 
significantly (p<0.001, t-test) higher in LNCaP-ARhi cells than in the control cells. However, 
the TMPRSS2 promoter did not significantly recruit AR, at least in the 4 h time (Fig. 3B).  
 
When all cell lines were exposed to 100 nM DHT (Suppl. Fig. 4A&C), loading of AR onto 
PSA and TMPRSS2 enhancers was more abundant than in cells treated with 1 nM DHT (Fig. 
2A & 3A) especially at the 4 h time point. However, there were no significant differences 
amongst the cell lines when treated with 100 nM DHT. At the promoters of the genes, 
comparable levels of AR were loaded in all cell lines treated with 100 nM DHT (Suppl. Fig. 
4B&D) and 1 nM DHT (Fig. 2B&3B).  
 
Next, we profiled recruitment of RNA Pol II onto the same genomic loci (Fig. 1) in cells 
exposed to 1 nM DHT. The PSA enhancer and promoter regions recruited increasing amounts 
of RNA Pol II over time, and the recruitment was higher in AR-overexpressing cells (Fig. 
4A&B) (p<0.05, one-way ANOVA). More RNA Pol II was also recruited onto exon 3 in AR-
overexpressing cells than in control cells (p<0.05, one-way ANOVA). RNA Pol II 
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recruitment to the TMPRSS2 enhancer (Fig. 5A) was, on average, equal in the three cell lines. 
However, in the LNCaP-ARhi cells, RNA Pol II was recruited onto the enhancer already after 
30 min (p<0.05, t-test), and RNA Pol II recruitment onto the TMPRSS2 promoter was 
significantly higher at the 30 min and 4 h time points (p<0.01 and p<0.001, t-test, 
respectively ) compared to the other cell lines (Fig. 5B).  
 
Next, we profiled the changes in AcH3 on lysine 9 (H3K9) and on both lysines 9 and 14 
(H3K9K14) in the PSA (Suppl. Fig. 5) and in the TMPRSS2 regions (Suppl. Fig 6) upon 
treatment with 1 nM DHT. In the AR-overexpressing cells, acetylation in the PSA enhancer 
region (Suppl. Fig. 5 A&B) peaked at the 2 h time point but remained at the same level until 
4 h, while in the control cells, acetylation of H3K9 was significantly lower (p<0.05, t-test), 
although it still peaked at 2 h time point.  AcH3 in the PSA promoter (Suppl. Fig. 5 C&D) 
increased significantly upon stimulation with DHT only in the LNCaP-ARhi cells and only 
after 4 h (p<0.05, t-test). Upon examination of the other genomic sites, the level of 
acetylation increased significantly on H3K9 only at the TSS (t-test p < 0.01) in the AR-
overexpressing cells at 4 h (Suppl. Fig 5 E-J). Furthermore, the  H3K9 acetylation increased 
significantly also at exon 3 at 4 h time point in LNCaP-ARhi compared to control and –
ARmo cells (t-test p < 0.05). The acetylation of H3K9 at the TMPRSS2 enhancer in the 
LNCaP-ARhi cells increased significantly (p<0.05, t-test) after 2 h compared to control and 
LNCaP-ARmo cells (Suppl. Fig. 6A). Acetylation of H3K9K14 was higher at the 4 h time 
point in LNCaP-ARhi cells compared to the other sublines (t-test p < 0.05) (Suppl. Fig. 6B). 
However, the acetylation of TMPRSS2 promoter did not vary significantly from the basal 
level in all cell lines (Suppl. Fig. 6C&D). 
 
After 4 days of hormone starvation, the basal loading of AR and recruitment of RNA Pol II to 
the genomic loci was similar across the three cell lines. However, the level of basal 
acetylation varied across the cell lines (Suppl. Fig. 7), especially in the TMPRSS2 enhancer 
and promoter.  The level of H3 acetylation was lower in the LNCaP-ARhi cells compared to 
the LNCaP-ARmo or control cells. Thus, we hypothesized that the differences across the cell 
lines may be due to the abundance of nucleosomes in the loci studied. We assumed that the 
total level of H3 could be used as indirect measure of the nucleosome abundance at a given 
genomic locus. This approach was previously described and proved to be consistent with 
nucleosomal DNA mapping [39]. Therefore, we normalized the level of H3K9 at the basal 
level (in cells hormone starved for 4 days) in the enhancer and promoter regions of PSA and 
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TMPRSS2 and in the control region (ARE mid) to the signal from the ChIP assays with an 
anti-histone 3 antibody (H3 pan) (Fig. 6). Except for the PSA enhancer, the ratios 
H3K9/H3pan in these loci were significantly higher in LNCaP-ARhi cells compared to 
LNCaP-ARmo or control cells (p < 0.01, t-test), which is consistent with a more nuclesome 
free region in those cells. 
 
Finally, we measured accumulation of PSA and TMPRSS2 mRNAs within a 16 h time 
interval after exposure to 1 nM DHT in LNCaP-pcDNA3.1 and LNCaP–ARhi cells (Fig. 7). 
PSA mRNA accumulated to comparable levels in the two cell lines until 3.5 h. After 4 h, PSA 
mRNA accumulation was significantly (p<0.05, t-test) higher in LNCaP-ARhi cells (Fig. 
7A), whereas TMPRSS2 mRNA levels were significantly (p<0.05, t-test) higher as early as 1 
h after androgen exposure (Fig. 7B). The fold increase in TMPRSS2 mRNA accumulation 
was also greater than that of PSA mRNA at the end of the time interval investigated (16 h). 
 
DISCUSSION 
AR is a nuclear receptor recognized as a major driver of prostate tumorigenesis [40] and is 
overexpressed in the majority of CRPCs [41]. We developed a cell line model to simulate the 
AR overexpression in CRPCs [29]. With this model, we previously demonstrated that the 
overexpression of AR sensitizes the cells to low levels of androgens [29]. The cell line 
LNCaP-ARhi grows faster compared to the control cell line at low androgen concentrations 
(1 nM DHT). Likewise, the expression of many androgen-regulated genes is upregulated at 
lower androgen concentrations in LNCaP-ARhi cells compared to control cells.  Using ChIP-
sequencing technology and the same cell line model, we recently showed that AR expression 
levels affect the receptor's genome-wide chromatin binding [31]. Increased levels of AR 
results in enhanced AR loading to chromatin compared to control cells upon stimulation with 
low concentration of ligand [31].  
 
Here, we focused on the dynamics of AR loading and recruitment of RNA Pol II onto two 
AR target genes. Ligand-bound AR is loaded onto both the enhancer and promoter regions of 
PSA [41,42]. Loading of AR and recruitment of its coactivators onto the PSA enhancer is 
stronger than loading onto the promoter [42,43]. AR loading and RNA Pol II recruitment 
onto the PSA enhancer and promoter are initially cyclical [26,28,42] and then increase 
gradually [43]. Proteasome activity is needed to maintain the initial cyclical behavior [26]. 
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However, all of the previous studies determined the dynamics of AR loading onto and the 
RNA Pol II occupancy of chromatin following exposure of the cells to high concentrations of 
natural or synthetic ligand [26,27,28,42,43].  
 
Using low DHT (1 nM), we showed that the AR binding profile is different in the promoter 
and enhancer regions of both PSA and TMPRSS2 genes than the profiles following high DHT 
treatment. There was more AR enrichment in the enhancer in AR-overexpressing cells 
compared to control cells. This finding that the enhancer region is the primary AR-loading 
site is in agreement with previous studies [37,42,43]. PSA and TMPRSS2 also showed 
different AR-binding profiles, suggesting that various androgen target genes have locus-
specific binding properties. Overexpression of AR also affected the AR-binding profile. In 
AR-overexpressing cells in the presence of low levels of DHT, the receptor not only loaded 
faster but loaded to higher levels onto the enhancers and promoters. However, high androgen 
concentrations abolished the effects of AR levels. This is to our knowledge, the first study 
profiling the AR loading on target genes’ regulatory regions from a dynamic perspective and 
using low concentration (1nM) of DHT to stimulate the cells. 
 
In order to compare our AR binding profile to previous studies, we chose to determine AR 
loading also at 80 minutes time point. In the work by Welsbie et al. [28] the AR binding 
dynamics upon stimulation of LNCaP with 1 nM R1881 shows that AR is strongly recruited 
to the PSA enhancer after 80 min. In our study, using a less potent ligand, the binding was 
reduced, in the case of PSA enhancer (Fig. 2A) or abolished, in the case of the TMPRSS2 
enhancer (Fig. 3A) in control transfected and LNCaP-ARmo cells but not in -ARhi cells. At 2 
h time point the AR loading onto the enhancer of PSA and TMPRSS2 was comparable across 
the cell lines. However, at 4 h time point, more AR was loaded onto these regions in AR-
overexpressing cells. These findings could be due to kinetic variations in the cyclic loading of 
AR onto the chromatin in the differently AR-expressing cell lines. Taken together, these data 
further support the idea that AR level alters the binding dynamics of AR in presence of low 
concentration of androgens. 
 
By measuring AR mRNA levels accumulation, we demonstrated that the hormone stimulation 
upregulates only mildly the AR transcripts in control transfected cells and the AR-
overexpression enhances such upregulation. However, this seems to take place after 8 hours 
of androgen stimulation. Since, the ChIP measurements were done, at latest, 4 hour time 
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point, the increase of AR levels upon DHT stimulation at later time points should not affect 
to the AR-ChIP data. However, we have previously demonstrated that nuclear AR protein 
levels are slightly increased in LNCaP-ARhi cells compared to empty vector transfected cells 
in hormone deprived conditions [29,44]. Thus, we cannot completely rule out that different 
nuclear AR protein levels could influence to the AR loading to chromatin in these cells. 
Interestingly, LNCaP-ARhi cells seemed to load less AR in hormone-deprived conditions 
especially at the PSA enhancer compared to -ARmo or control cells (see Fig. 2A). This 
difference may certainly be due to technical reasons. However, we cannot rule-out that 
differences in the composition of the AR complex at the different genomic loci may have an 
effect on the loading. 
 
Several groups have investigated the recruitment dynamics of the RNA Pol II onto the PSA 
[27,42,43] and TMPRSS2 regulatory elements under high androgen concentrations [27,42]. 
AR loading initiates recruitment of coregulators, including GRIP1 and CBP, and ultimately 
RNA Pol II [45]. We investigated whether AR overexpression affects recruitment of the key 
component in the basic transcription machinery, RNA Pol II, under low androgen 
concentrations. The recruitment of RNA Pol II onto the promoter and enhancer regions of 
PSA and TMPRSS2 across the three cell lines was, similarly to the AR loading, more enriched 
in AR-overexpressing cells compared to control cells. However, the recruitment of RNA Pol 
II at the promoter was significantly higher than for AR. Thus, the binding pattern of RNA Pol 
II is affected by the level of AR. Furthermore, the RNA Pol II was also recruited to the TSS, 
exon 3, and to a locus downstream of the PSA gene, although with a delay with respect to the 
promoter and the enhancer. These results are in concordance with those of Wang et al. [45], 
whereas Kang et al. [43] have reported a significant difference in the RNA Pol II recruitment 
between enhancer and promoter regions of the PSA gene. This discrepancy could be due to 
the difference in the androgen concentrations used.   
 
Chen and colleagues [41] found that a modest overexpression of AR can alter the abundance 
of AR coregulators, many of which have histone acetylation activity, recruited onto the 
promoters of AR target genes [46,47]. Therefore, we investigated the pattern of acetylation of 
recognized markers of active transcription, H3K9 and H3K9K14. These markers are 
necessary to render regulatory regions accessible to the basic transcription factors [48,49,50]. 
AcH3 increases upon time of stimulation with DHT, and increases are more pronounced in 
LNCaP-ARhi cells, but acetylation does not seem to vary as dynamically as AR and RNA Pol 
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II recruitment. The changes in H3K9 and H3K9K14 were more modest compared to those in 
the study by Kang et al. [43], in which the cells were exposed to higher androgen 
concentrations. Thus, the data suggest that the dynamics of chromatin structure are sensitive 
to androgen levels. 
 
Interestingly, we found that the acetylation of H3 was different between the cell lines under 
hormone deprivation. We initially found that the amount of AcH3 in the regulatory regions 
was lower in LNCaP-ARhi cells compared to LNCaP-ARmo and control cells. However, the 
amount of total H3 was also lower in the LNCaP-ARhi cells. The amount of total H3  has 
been used as a measure of nucleosome density [39]. Our preliminary results showed that the 
ratio between AcH3 and H3 pan was higher in LNCaP-ARhi cells. Thus, we speculate that 
there is a reduced number of histone octamers in the regulatory regions of PSA and TMPRSS2 
in these cells. As consequence, the chromatin is more open in those regions in the AR-
overexpressing cells. Since we studied the ratio of AcH3K9 and H3 pan, the H3 that are still 
in those regions seemed to be  more acetylated in the AR-overexpressing cells. The 
acetylation of H3 is known to relieve transcriptional repression given by nucleosomal 
positioning, without influencing the mobility of histone octamers [51]. Our data are 
consistent with two recent reports showing how modification of histone tails such as H3 or 
H4 influence and are tightly connected to the chromatin remodeling factors [52,53]. In a 
recent study by He and colleagues [54], the androgen treatment in PC cells was found to 
induce the release of a central nucleosome flanked by a pair of marked nucleosomes present 
at the AR-binding sites [54]. In the same study, the locations of the positioned nucleosomes 
were concordant between DHT treatment and vehicle control [54], suggesting that the 
nucleosome positioning is pre-determined and independent of AR binding. The chromatin 
opening seems to be dependent on chromatin remodeling factors, such as FOXA1 [55]. Our 
results are concordant with these reports. However, the mechanism by which the nucleosome 
depletion occurs in AR-overexpressing cells and how AR affects this process needs further 
investigation. Our results are also consistent with a previous report by Jia et al. [27] showing 
that increased histone acetylation is associated with the development of androgen 
independence in vivo.  
 
Given the effect that AR overexpression has on the dynamics of AR recruitment, RNA Pol II 
recruitment, and chromatin structure, we measured accumulation of PSA and TMPRSS2 
transcripts in cells stimulated with 1 nM DHT. We have previously demonstrated that upon 
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stimulation with different concentrations of DHT, at 4 hours time point, LNCaP-ARmo and -
ARhi, show comparable induction of PSA and TMPRSS2 mRNA, and more abundant than in 
LNCaP-pcDNA3.1 [29]. At 24 hours time point -ARmo shows intermediate induction of both 
genes [29]. Therefore, we measured the expression of these genes only in the control- 
transfected and LNCaP-ARhi cells. The expression levels of PSA and TMPRSS2 transcripts 
were higher in AR-overexpressing cells compared to the control cells at the endpoint of our 
measurement [29]. The induction kinetics were faster in AR-overexpressing cells, which is 
consistent with the observed earlier recruitment of AR and RNA Pol II to the enhancer and 
promoter regions of PSA and TMPRSS2. The effect of AR overexpression was stronger on 
TMPRSS2 compared to PSA, suggesting that the AR overexpression differentially affects the 
expression of target genes. 
 
CONCLUSIONS 
Our findings suggest that the level of AR affects the dynamics of receptor binding to 
chromatin, potentiating the loading of AR and recruitment of RNA Pol II, especially when 
low levels of androgens are present. Furthermore, AR overexpression seemed to favor 
chromatin accessibility by modifying the acetylation status of H3 and nucleosome occupancy 
at the AR-binding sites. Altogether, these changes in the dynamics of chromatin 
modifications result in enhanced transcription of AR target genes, providing a mechanistic 
explanation of how AR signaling pathways are reactivated in CRPC.  
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FIGURES 
Fig. 1. 
 
Fig. 1. Location of the primers used on the PSA and TMPRSS2 genes. Structure of PSA 
(A) and TMPRSS2 (B) genes and the locations of the primers used on the UCSC genome 
browser showing also DNase clusters for the LNCaP cell line. 
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Fig. 2. 
 
Fig. 2. Loading of AR onto the PSA gene regions upon treatment with 1 nM DHT. AR 
binding to PSA enhancer (A), promoter (B), TSS (C), exon 3 (D) and a downstream site (E) 
in the LNCaP model. LNCaP-pcDNA3.1, -ARmo and –ARhi cells were hormone-starved for 
4 days and then exposed for the indicated time periods to 1 nM DHT or ethanol (0h 0M). 
ChIP-qPCR was performed to assess the AR loading. Mean and S.E.M. of three biological 
replicates are shown. 
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Fig. 3. 
 
Fig. 3. Loading of AR onto the TMPRSS2 gene regulatory regions upon treatment with 
1 nM DHT. AR binding to the TMPRSS2 enhancer (A) and promoter (B) in the LNCaP 
model. LNCaP-pcDNA3.1, -ARmo and –ARhi cells were hormone-starved for 4 days and 
exposed for the indicated time periods to 1 nM DHT or ethanol (0h 0M). ChIP-qPCR was 
performed to assess the AR loading. Mean and S.E.M. of three biological replicates are 
shown. 
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Fig. 4. 
 
Fig. 4. Recruitment of RNA Pol 2 on the PSA gene regions upon treatment with 1 nM 
DHT. RNA Pol II recruitment onto PSA enhancer (A), promoter (B), TSS (C), exon 3 (D) 
and a downstream site (E) in the LNCaP model. LNCaP-pcDNA3.1, -ARmo and -ARhi cells 
were hormone-starved for 4 days and exposed for the indicated time periods to 1 nM DHT or 
ethanol (0h 0M). ChIP-qPCR was performed to assess the RNA Pol II recruitment. Mean and 
S.E.M. of two biological replicates are shown. 
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Fig. 5. 
 
Fig. 5. Recruitment of RNA Pol II onto the TMPRSS2 gene regions upon treatment with 
1 nM DHT. RNA Pol II recruitment to the TMPRSS2 enhancer (A) and promoter (B) in the 
LNCaP model. LNCaP-pcDNA3.1, -ARmo and -ARhi cells were hormone-starved for 4 days 
and then exposed for the indicated time periods to 1 nM DHT or ethanol (0h 0M). ChIP-
qPCR was performed to assess RNA Pol II recruitment. Mean and S.E.M. of two biological 
replicates are shown. 
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Fig.6. 
 
Fig.6. Ratio of acetylated histone 3 in lysine 9 versus the histone 3 in hormone-depleted 
condition. The acetylation status of H3 in lysine 9 in the given loci is presented as ratio of % 
of input values. 
 
 
  24
Fig.7. 
 
Fig.7. Accumulation of PSA and TMPRSS2 mRNAs in response to androgen exposure. 
Normalized (against 0 M 0 h) accumulation of PSA (A) and TMPRSS2 (B) mRNAs in 
LNCaP-pcDNA3.1 and –ARhi cells as measured by RT-PCR. The cells were hormone 
starved for 4 days and the exposed to 1 nM DHT for the indicated time periods. The data are 
presented as PSA or TMPRSS2 versus TBP values normalized against the 0h 0M. Mean and 
S.E.M. of three biological replicates are shown. 
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Supplementary Figure 1. 
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Supplementary Figure 1. Loading of AR on PSA enhancer in LNCaP derivative cell 
lines. Re-analysis of ChIP-qPCR data from Urbanucci et al. [1] showing loading of AR on 
PSA enhancer (See Figure 1A) upon 2 hours stimulation of LNCaP-1F5 and LNCaP-
pcDNA3.1 cells with 100 nM DHT. ChIP-qPCR with the unspecific control antibody (normal 
rabbit IgG) in the same genomic regions shows the background binding level. The data are 
presented as fold over vehicle (0M) of % of input. Mean and S.E.M. are shown. 
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Supplementary Figure 2. Accumulation of AR mRNAs in response to androgen 
exposure. Normalized (against 0 M 0 h) accumulation of AR mRNAs in LNCaP-pcDNA3.1 
and –ARhi cells as measured by qRT-PCR. The cells were hormone starved for 4 days and 
exposed to 1 nM DHT for the indicated time periods. The data are presented as AR versus 
TBP values normalized against the 0h 0M. Mean and S.E.M. of three biological replicates are 
shown. 
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Supplementary Figure 3. Background levels of the ChIP assays. ChIP-qPCR showing the 
loading of AR to ARE mid (See Figure 1A) upon stimulation of LNCaP model cells with 1 
nM DHT (A) or 100 nM DHT (B) for the indicated time periods. ChIP-qPCR with the 
unspecific control antibody (normal rabbit IgG) in cells are treated with 100 nM DHT to 
ARE mid (C), TMPRSS2 enhancer (D) and TMPRSS2 promoter (E) for the indicated time 
periods. Mean and S.E.M. of three biological replicates are shown. 
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Supplementary Figure 4. Loading of AR on the PSA and TMPRSS2 gene regions upon 
treatment with 100 nM DHT. AR binding onto the PSA enhancer (A) and promoter (B) and 
to the TMPRSS2 enhancer (C) and promoter (D) in the LNCaP model cells. LNCaP-
pcDNA3.1, -ARmo and -ARhi cells were hormone-starved for 4 days and then exposed for 
the indicated time periods to 100 nM DHT or ethanol (0h 0M). ChIP-qPCR was performed to 
assess AR loading. Mean and S.E.M. of three biological replicates are shown. 
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Supplementary Figure 5. 
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Supplementary Figure 5. Acetylation of H3 in the PSA locus. ChIP-qPCR results showing 
acetylation of H3 on lysine 9 (A, C, E, G, I) and on both lysine 9 and lysine 14 (B, D, F, H, J) 
upon stimulation with 1 nM DHT for the indicated time periods in the loci shown in Figure 
1A: enhancer (A&B), promoter (C&D), TSS (E&F), exon 3 (G&H) and downstream site 
(I&J). The % of input of each time point is normalized against the 0M 0h. Mean and S.E.M. 
of two biological replicates are shown. 
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Supplementary Figure 6. 
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Supplementary Figure 6. Acetylation of H3 in the TMPRSS2 locus. ChIP-qPCR results 
showing acetylation of H3 on lysine 9 (A&C) and on both lysine 9 and lysine 14 (B&D) upon 
stimulation with 1 nM DHT for the indicated time periods in the loci shown in Figure 1B: 
enhancer (A&B) and promoter (C&D). The % of input of each time point is normalized 
against the 0M 0h. Mean and S.E.M. of two biological replicates are shown. 
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Supplementary Figure 7. 
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Supplementary Figure 7. Acetylation status of H3 in the PSA and TMPRSS2 loci under 
hormone deprived condition. ChIP-qPCR at the PSA (A&B) and TMPRSS2 (C&D) loci 
showing the acetylation of H3 lysine 9 (A&C) and H3 lysine 9 and 14 (B&D) after 4 days of 
hormone starvation. Mean and S.E.M. of two biological replicates are shown. 
 
  10
 
Supplementary Table 1. Primers used in ChIPqPCR and qPCR. 
 
AR mRNA 5'-CTCACCAAGCTCCTGGACTC-3'  
 5'-CAGGCAGAAGACATCTGAAAG-3'  
  
PSA  
Enhancer 5'-TGGGACAACTTGCAAACCTG-3' Wang et al. [2]
 5'-CCAGAGTAGGTCTGTTTTCAATCC-3'  
ARE mid 5'-CAGTGGCCATGAGTTTTGTTTG-3' Jia et al. [3]
 5'-AACCAATCCAACTGCATTATACACA-3'  
Promoter 5'-CCTAGATGAAGTCTCCATGAGCTACA-3' Wang et al. [2]
 5'-GGGAGGGAGAGCTAGCACTTG-3'  
TSS 5'-GGGGCGGAGTCCTGGGGAAT-3'  
 5'-GTGCAGCACCAATCCACGTCA-3'  
Exon 3 5'-CACACCCGCTCTACGATATGAG-3' Jia et al. [4]
 5'-GAGCTCGGCAGGCTCTGA-3'  
Downstream 5'-TCATCATGAATCGCACTGTTAGC-3' Jia et al. [4]
 5'-GCCCAAGTGCCTTGGTATACC-3'  
  
PSA mRNA 5'-GCAGCATTGAACCAGAGGAG-3'  
 5'-AGAACTGGGGAGGCTTGAGT-3'  
  
TMPRSS2 
Enhancer 5'-TCCAGGCAGAGGTGTGGC-3' Wang et al. [5]
 5'-CGTATGTCTCCCTGCACCACT-3'  
Promoter 5'-GCTCGAGTTTGGGTTAAGGAA-3' Jia et al. [4]
 5'-TACAGGAGCTCGTGAGGTAGCA-3'  
  
TMPRSS2 mRNA    5'-CCAGGAGTGTACGGGAATGT-3'  
 5'-CAGCCCCATTGTTTTCTTGT-3'  
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Abstract
Background: The critical role of the androgen receptor (AR) in the development of prostate
cancer is well recognized. The transcriptional activity of AR is partly regulated by coregulatory
proteins. It has been suggested that these coregulators could also be important in the progression
of prostate cancer. The aim of this study was to identify coregulators whose expression is regulated
by either the androgens and/or by the expression level of AR.
Methods: We used empty vector and AR cDNA-transfected LNCaP cells (LNCaP-pcDNA3.1, and
LNCaP-ARhi, respectively), and grew them for 4 and 24 hours in the presence of
dihydrotestosterone (DHT) at various concentrations. The expression of 25 AR coregulators
(SRC1, TIF2, PIAS1, PIASx, ARIP4, BRCA1, β-catenin, AIB3, AIB1, CBP, STAT1, NCoR1, AES, cyclin D1,
p300, ARA24, LSD1, BAG1L, gelsolin, prohibitin, JMJD2C, JMJD1A, MAK, PAK6 and MAGE11) was then
measured by using real-time quantitative RT-PCR (Q-RT-PCR).
Results: Five of the coregulators (AIB1, CBP, MAK, BRCA1 and β-catenin) showed more than 2-fold
induction and 5 others (cyclin D1, gelsolin, prohibitin, JMJD1A, and JMJD2C) less than 2-fold induction.
Overexpression of AR did not affect the expression of the coregulators alone. However,
overexpression of AR enhanced the DHT-stimulated expression of MAK, BRCA1, AIB1 and CBP and
reduced the level of expression of β-catenin, cyclinD1 and gelsolin.
Conclusion: In conclusion, we identified 5 coactivators whose expression was induced by
androgens suggesting that they could potentiate AR signaling. Overexpression of AR seems to
sensitize cells for low levels of androgens.
Background
Prostate cancer is the most and second most common
male malignancy in the USA, and Europe, respectively
[1,2]. The androgen-dependence of the growth of prostate
cancer has been known for a long time [3]. The impor-
tance of the androgens was recently, once again, demon-
strated in a large randomized study. In the study the use
of finasteride, an inhibitor of 5α-reductase, which con-
verts testosterone into more potent 5α-dihydrotestoster-
one, was used for prevention of prostate cancer [4].
Almost 25% reduction in the prevalence of prostate can-
cer was observed in the treatment compared to a placebo
arm. Due to the androgen dependence, the golden stand-
ard treatment for advanced prostate cancer has been
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BMC Cancer 2008, 8:219 http://www.biomedcentral.com/1471-2407/8/219androgen withdrawal (i.e. castration) for the last half cen-
tury [5]. The treatment is palliative and although most
patients respond to it, the disease will eventually progress
[6]. Such tumors, emerging during the androgen with-
drawal, are called hormone-refractory ones.
The molecular mechanisms by which prostate cancer cells
become resistant to endocrine therapy remain incom-
pletely known. However, the key role of androgens and
androgen receptor (AR), not just in early development but
also in the progression of prostate cancer has now been
demonstrated [7]. The recent finding on genetic rear-
rangement leading to formation of TMPRSS2:ERG fusion
gene provides a model for molecular mechanisms how
androgens act in promoting the early development of
prostate cancer. Due to the rearrangement, the putative
oncogene ERG becomes androgen regulated [8,9]. It has
now also become apparent that the emergence of hor-
mone-refractory prostate cancer is due to reactivation of
AR-mediated signaling. It has been experimentally shown
that overexpression on AR is required and it is sufficient to
transform the growth of prostate cancer cells from andro-
gen-dependence to -independence [10]. Furthermore, it
has been shown that hormone-refractory tumors overex-
press AR, and one-third of them contains amplification of
the AR gene [11]. Mutations in the coding region of AR
have also been found in antiandrogen treated prostate
cancers [12,13]. And at least some of the mutations alter
the sensitivity of the receptor to other steroid hormones or
anti-androgens, such as 17 β-estradiol (E2) or hydroxy-
flutamide (HF) [14,15].
The transactivation of AR involves several coregulatory
proteins [16,17]. Large number of coregulatory proteins
have already been identified [18-20]. It has been sug-
gested that changes in the expression of the coregulators
may be involved in the development and progression of
prostate cancer [18,21,22]. Since androgens and AR are
known to be important in the prostate cancer tumorigen-
esis, it is possible that they also regulate the expression of
the coregulators.
In order to identify AR coregulators whose expression is
regulated by androgens, we measured the expression of 20
putative coactivators: SRC1 (alias NCOA1 nuclear recep-
tor coactivator 1), TIF2 (alias NCOA2 nuclear receptor
coactivator 2), PIAS1 (protein inhibitor of activated STAT,
1), PIASx (alias PIAS2 protein inhibitor of activated STAT,
2), ARIP4 (alias RAD54L2 RAD54-like 2 (S. cerevisiae)),
BRCA1 (breast cancer 1, early onset), β-catenin (alias
CTNNB1 catenin (cadherin-associated protein), beta 1, 88
kDa), AIB3 (alias NCOA6 nuclear receptor coactivator 6),
AIB1 (alias NCOA3 nuclear receptor coactivator 3), CBP
(alias CREBBP CREB binding protein (Rubinstein-Taybi
syndrome)), STAT1 (signal transducer and activator of
transcription 1, 91 kDa), p300 (alias EP300 E1A binding
protein p300), ARA24 (alias RAN, member RAS oncogene
family), LSD1 (lysine-specific demethylase 1, alias AOF2
amine oxidase (flavin containing) domain 2), BAG1L
(BCL2-associated athanogene, isoform 1L), gelsolin (GSN
(amyloidosis, Finnish type)), JMJD2C (alias JHDM3C/
GASC1 jumonji domain containing 2C), JMJD1A (alias
JHMD2A jumonji domain containing 1A), MAK (male
germ cell-associated kinase), MAGE11 (alias MAGEA11
melanoma antigen family A, 11) and 5 putative corepres-
sors: NCoR1 (nuclear receptor co-repressor 1), AES
(amino-terminal enhancer of split), cyclin D1 (alias
CCND1), prohibitin (PHB) and PAK6 (p21(CDKN1A)-acti-
vated kinase 6) by using quantitative reverse transcrip-
tion-PCR (Q-RT-PCR) in AR positive prostate cancer cell
line LNCaP treated with different concentrations of DHT.
To mimic the common overexpression of AR in hormone-
refractory prostate cancer, we also stable transfected AR to
LNCaP cell line. The LNCaP-ARhi cells express about 10-
folds more AR mRNA and 3 to 4-folds more AR protein
than that of the control (empty vector-transfected cell
line: LNCaP-pcDNA3.1). The cell model was used to study
whether the level of AR has an effect on the mRNA expres-
sion of the coregulators.
Methods
Cell culture protocols and transfections
pcDNA3.1(+) empty expression vector (Invitrogen Inc.,
Carlsbad, CA, USA) and pcDNA3.1(+) inserted with AR
coding region were stable transfected into LNCaP (ATCC,
Manassas, VA, USA) with Lipofectamine-Plus transfection
reagent (Invitrogen Inc.). Transfected clones were selected
with 400 μg/ml geneticin (G418) for 2 weeks. The mRNA
level of AR was examined from purified clones using
Northern blotting and Q-RT-PCR with Light-Cycler
(Roche Inc., Mannheim, Germany). The protein level of
AR was analyzed using Western blotting with anti-AR anti-
body (441, NeoMarkers-Lab Vision Corporation, Fre-
mont, CA, USA). LNCaP-pcDNA3.1 (transfected with
empty pcDNA3.1-vector as a control) and LNCaP-ARhi
(transfected with AR cloned into pcDNA3.1+ vector) cell
lines were cultured according to the ATCC protocol with
the addition of Geneticin 200 μg/ml (Invitrogen Inc.).
LNCaP-ARhi has about 10 times higher mRNA level of AR
and 3 to 4 times higher protein level of AR than that of the
LNCaP-pcDNA3.1 (Figure 1).
LNCaP-pcDNA3.1 and LNCaP-ARhi cells in the end of the
exponential growing phase were divided in 1:4 ratio
plates in RPMI1640 phenol free medium with 5% char-
coal/dextran-treated (CCS) FBS (Hyclone Inc., South
Logan, UT, USA), 1% glutamine (Invitrogen Inc.) and 1%
penicillin-streptomycin (BioWhittaker Inc., Walkersville,
MD, USA) for 4 days. The medium was then changed to
phenol free RPMI1640 including 10% CCS-FBS (HyclonePage 2 of 10
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gen Inc.) and 0, 0.1, 1.0, 10 or 100 nM DHT. The cells
were harvested into TRIZOL reagent (Life Technologies
Inc., Gaithersburg, MD, USA) after 4 h and 24 h, followed
by total RNA isolation according to the manufactures pro-
tocol.
RT-PCR
The cDNA was synthesized with AMV Reverse Tran-
scriptase and oligo(dT)12–18 primer according to the
manufacturer's protocol (Finnzymes, Espoo Finland). The
standards were prepared mixing total RNA from untreated
LNCaP cells and universal RNA (Clontech Laboratories,
Inc., Mountain View, CA, USA) in a ratio of 1:5. After first
strand cDNA synthesis, serial dilutions corresponding to
1000, 200, 40, 8, 1.6, 0.32, 0.064 μg of RNA pool were
prepared and stored in aliquots. The PCR reactions were
performed in LightCycler apparatus (Roche Inc.) using an
LC Fast Start DNA SYBR Green I Kit (Roche Diagnostics,
Mannheim, Germany). The final volume of each reaction
was 20 μl containing 2 μl of cDNA sample (or standard),
4 mM MgCl2 (except for PAK6 (5 mM) and JMJD1A (3
mM)), 0.5 μM each primer, and 1× ready-to-use SYBR
Green I reaction mix including Taq DNA polymerase,
reaction buffer and a deoxynucleotide triphosphate mix.
The cycling conditions were designed according to the
manufacturer's guidelines which are given in additional
file 1: primers' table. The primers were designed for ampli-
fying regions of the mRNAs derived from different exons
to avoid amplification of genomic DNA. The melting
curve analysis with the LightCycler together with 1.5%
agarose gel electrophoresis of the products were used to
ensure that right size product without significant back-
ground was amplified in the reaction. The expression lev-
els of the coregulators were normalized to the expression
levels of TATA-box binding protein (TBP) as previously
described [23].
Western analysis
Cytoplasmatic and nuclear proteins were isolated from
subconfluent cells of LNCaP-ARhi. Proteins were sepa-
rated in 10% SDS-PAGE gel followed by transfer to a
membrane (Immobilon-P, Millipore Corp., Billerica, MA)
using BIORAD transblot® semi-dry transfer cell (Bio-Rad
Laboratories, Inc). After blocking in PBS 0.1% Tween 5%
BSA (or 5% non-fat dry milk), the membranes were incu-
bated with primary antibody (AR: dilution 1: 200 Andro-
gen Receptor Ab-1 (AR441) Neomarkers, Fremont, CA; β-
catenin: dilution 1:2000 BD Transduction Laboratories,
Inc.; MAK: dilution 1:500 MAK antibody (C-term),
ABGENT San Diego, CA; CBP: dilution 1:1000, R&D Sys-
tems, Inc.) over night at +4°C. After washes and incuba-
tion with secondary antibody (DAKO A/S, Denmark) the
bound antibody was visualized on autogradiography film
using Western Blotting Luminol Reagent (Santa Cruz,
Inc.) according to the manufacturer's protocol. Pan-actin
antibody (dilution 1:1000 pan AB-5, clone ACTN05, Neo-
markers, Fremont, CA;) was used as a reference.
Statistical analysis
Grubb's test was used to detect the outlier values in the
repetitive runs for each gene. One-way ANOVA (Paramet-
ric) test with Bonferroni post-test was used to evaluate the
statistical significance of the expression level's changes.
Western blot analysis of AR in empty vector transfected (LNCaP-pcDNA3.1) and AR-cDNA transfected (LNCaP-ARhi) LNCaP cel sFigure 1
Western blot analysis of AR in empty vector transfected (LNCaP-pcDNA3.1) and AR-cDNA transfected (LNCaP-ARhi) 
LNCaP cells. Cells were grown either in the absence or presence of DHT. Nuclear fraction of LNCaP-ARhi shows clearly 
higher AR expression than the control LNCaP-pcDNA3.1. The quantification of the bands by ImageJ is given below the bands.Page 3 of 10
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To identify androgen regulated coregulators, empty vector
transfected LNCaP (LNCaP-pcDNA3.1) was grown in dif-
ferent concentrations of DHT. The total RNA was then col-
lected at two time points (4 h and 24 h). To confirm the
success of the DHT stimulation, the expression of pros-
tate-specific antigen (PSA), known androgen regulated
gene was first measured (Figure 2). PSA was strongly
induced by DHT (p < 0.0001 at 4 h and 24 h).
Next, we screened expression of SRC1, TIF2, PIAS1, PIASx,
ARIP4, BRCA1, β-catenin, AIB3, AIB1, CBP, STAT1,
NCoR1, AES, cyclin D1, p300, ARA24, LSD1 and BAG1L
coregulators in triplicates (three independent Q-RT-PCRs'
runs). Of the coregulators, PIASx (p = 0.0601 at 4 h and p
= 0.6488 at 24 h), BRCA1 (p = 0.4172 at 4 h and p =
0.0377 at 24 h), β-catenin (p = 0.0272 at 4 h and p =
0.4158 at 24 h), AIB3 (p = 0.0690 at 4 h and p = 0.1455
at 24 h), AIB1 (p = 0.0401 at 4 h and p = 0.2541 at 24 h),
CBP (p = 0.0184 at 4 h and p = 0.0588 at 24 h), cyclin D1
(p = 0.2039 at 4 h and p = 0.4432 at 24 h), ARA24 (p =
0.0220 at 4 h and p = 0.2502 at 24 h) and BAG1L (p =
0.0359 at 4 h and p = 0.3981 at 24 h), showed dose
dependent response to androgens, whereas SRC1, TIF2,
PIAS1, ARIP4, STAT1, NCoR1, AES, p300 and LSD1 did
not.
PIASx, BRCA1, β-catenin, AIB3, AIB1, CBP, cyclin D1,
ARA24 and BAG1L were selected for additional Q-RT-PCR
runs in triplicates. In addition, expression of gelsolin, pro-
hibitin, JMJD2C, JMJD1A, MAK, PAK6 and MAGE11 was
measured in triplicates. Figures 3 and 4 show the expres-
sion pattern of these 16 coregulators upon DHT stimula-
tion. The genes that showed significant dose dependent
expression were AIB1, CBP, MAK, BRCA1, β-catenin, cyclin
D1, gelsolin, prohibitin, JMJD1A, and JMJD2C. Table 1 indi-
cates the p-values of the sixteen genes. Gelsolin showed
reduced and increased expression at 4 and 24 hour time
points, respectively. Others exhibited an androgen-
dependent increase in the expression of the mRNAs. How-
ever, only AIB1, CBP, MAK, BRCA1, and β-catenin showed
more than 2-folds induction after stimulation with DHT.
In order to evaluate the effect of the level of AR expression
on the expression of the coregulators, we utilized LNCaP-
based overexpression model (LNCaP-ARhi). The PSA
response in the LNCaP-ARhi cell line at 24 hours was sig-
nificantly (p < 0.0001) stronger than in the empty vector
transfected cell line (LNCaP-pcDNA3.1) (Figure 2). PSA
Expression of PSA in LNCaP-pcDNA3.1 and LNCaP-ARhi according to Q-RT-PCRFigure 2
Expression of PSA in LNCaP-pcDNA3.1 and LNCaP-ARhi according to Q-RT-PCR. The cells were cultured in presence of 
DHT at different concentrations. After 4 and 24 hours, the cells were collected and expression of PSA and TBP mRNA was 
measured in triplicates by Q-RT-PCR. The bars and whiskers represent mean + S.E.M. of PSA/TBP values normalized against the 
0 M of each time point.Page 4 of 10
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in the LNCaP-ARhi, whereas the stimulation was evident
in 10 nM in the LNCaP-pcDNA3.1.
None of the coregulators showed significant alterations in
the expression in 0 M DHT between the LNCaP-
pcDNA3.1 and LNCaP-ARhi. However, induction of
expression in lower concentrations of DHT in LNCaP-
ARhi compared to LNCaP-pcDNA3.1 was found in MAK,
CBP, AIB1, and BRCA1. In contrast, the androgen regula-
tion of β-catenin, cyclin D1 and gelsolin, which was appar-
ent in LNCaP-pcDNA3.1 at 24 h was less strong in LNCaP-
ARhi (Figures 3 and 4).
Western blot analyses of β-catenin, CBP and MAK were in
concordance with the Q-RT-PCR results (see additional
file 2: WB analysis).
Discussion
We systematically studied the androgen regulation of the
expression of twenty-five AR coregulators. 5 (20%) coreg-
ultators showed statistically significant over 2-fold induc-
tion by DHT. These were AIB1, CBP, MAK, BRCA1 and β-
catenin. In addition, expression of five (20%) other coreg-
ulators (cyclin D1, gelsolin, prohibitin, JMJD1A, and
JMJD2C) was significantly, but less than 2-fold, induced
by androgens.
AIB1 (Amplified in Breast Cancer 1) encodes for a well
characterized protein with histone acetyltransferase activ-
ity. It is thought to be a nuclear receptor coactivator that
interacts with various nuclear hormone receptors enhanc-
ing their transcriptional activity in a hormone dependent
fashion. It is a member of the p160/steroid receptor coac-
tivator (SRC) family and recruits p300/CBP-associated
factor, with histone acetylation activity, and CBP (CREB
binding protein) as a part of the transcription multisubu-
nit coactivation complex [19,24]. AIB1 has been found to
be amplified in about 10% of breast cancers [25]. Previous
studies have indicated that estrogens might have a sup-
pressive role in respect to the expression of AIB1 [26,27].
Here we found that at 4 hours time point AIB1 is nearly 2-
fold induced by any concentration of DHT while at 24
hours time point a 4-fold induction was observed. The
highest induction was at 1 nM DHT while at 10 nM the
expression was declined. We used web-based TESS (Tran-
scription Element Search Software) program and TRANS-
FAC database [28] to search for canonical binding sites for
AR in the 2 kb upstream the transcription start site (TSS)
of AIB1. The program identified several glucocorticoid
receptor (GR) responsive elements (GREs) and two puta-
tive androgen responsive elements (AREs) at -527 and at -
1291 bp from the TSS.
Similarly to AIB1, CBP was nearly 2-folds induced at 4
hours time point by any concentration of DHT while at 24
hours time point a 4-folds induction can be observed,
although such induction can be seen also in 10 nM DHT
concentrated media. In contrast with our results, Comuzzi
et al. have suggested that CBP expression is down-regu-
lated after treating LNCaP cells with synthetic androgen
methyltrienolone (R1881) for 48 hours at concentrations
of 0.01 nM and 1 nM [29].
MAK (Male Germ Cell-Associated Kinase) is a recently
identified AR coactivator [30] that initially has been
found to be strongly androgen-regulated in mice kidney
[31]. In addition, it has previously been demonstrated
that MAK is transcriptionally induced by DHT in LNCaP
cells showing 9-fold induction by 10 nM DHT at 24 hours
[32]. This is confirmed by our finding of 6.5-fold induc-
tion at 24 hours time point by 10 nM DHT. MAK has been
found to be associated with AR and being corecruited in
the transcriptional complex enhancing AR activity. Fur-
thermore the modulation of its expression strongly alters
the vitality of the cells affecting AR pathway mediated sig-
naling [30]. Jia et al. have shown that MAK promoter is a
direct target of AR and identified putative ARE sites within
the promoter of MAK (about -3500 bp from the TSS), and
that AR is recruited to the MAK promoter after DHT stim-
ulation according to chromatin immunoprecipitation
(ChIP) analysis [33]. Altogether the data indicates that the
expression of MAK is regulated by androgens and since it
functions as an AR co-activator, it forms a putative feed-
back loop augmenting the effects of androgens.
Table 1: p-values of the One-way ANOVA (Parametric) test
Gene LNCaP-pcDNA3.1 LNCaP-ARhi
4 h 24 h 4 h 24 h
AIB1 0.0019 < 0.0001 0.0023 < 0.0001
CBP 0.0478 0.0103 0.0035 0.0205
MAK 0.1385 0.0014 0.0090 0.1625
BRCA1 0.0007 < 0.0001 0.0022 < 0.0001
B-catenin 0.0336 < 0.0001 < 0.0001 < 0.0001
Cyclin D1 0.0094 0.0094 0.6382 0.4697
Gelsolin 0.0016 < 0.0001 0.0029 0.4211
Prohibitin 0.0291 0.0084 0.0114 0.0053
JMJD1A 0.0276 0.0009 < 0.0001 0.4592
JMJD2C 0.0588 0.0064 0.0259 0.6450
BAG-1L 0.0029 0.1467 0.0244 0.0150
PIASx 0.9371 0.8551 0.8224 0.7616
PAK6 0.1075 0.4876 0.3359 0.6410
MAGE11 0.7256 0.5952 0.6438 0.6014
AIB3 < 0.0001 0.0135 < 0.0001 0.3818
ARA24 0.0016 0.0276 0.0007 0.0013
p-values of the 16 genes were measured in triplicate in the second 
round analysis.Page 5 of 10
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The expression of AIB1, CBP, MAK, BRCA1, β-catenin, cyclin D1, gelsolin and prohibitin in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 and 24 hours according to Q-RT-PCFigure 3
The expression of AIB1, CBP, MAK, BRCA1, β-catenin, cyclin D1, gelsolin and prohibitin in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 
and 24 hours according to Q-RT-PCR. The measurements were done in triplicates. The bars and whiskers represent mean + 
S.E.M. of each gene against the TBP, normalized against the 0 M of each time point. p-values are given in Table 1.
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The expression of JMJD1A, JMJD2C, BAG1L, PIASx, PAK6, MAGE11, AIB3, and ARA24 in LNCaP-pcDNA31 and LNCaP-ARhi at 4 and 24 hours according to Q-RT-PCRFigure 4
The expression of JMJD1A, JMJD2C, BAG1L, PIASx, PAK6, MAGE11, AIB3, and ARA24 in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 
and 24 hours according to Q-RT-PCR. The measurements were done in triplicates. The bars and whiskers represent mean + 
S.E.M. of each gene against the TBP, normalized against the 0 M of each time point. p-values are given in Table 1.
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breast cancer since mutations in this gene are responsible
of at least 40% of inherited breast cancers and more than
80% of inherited ovarian cancers [34,35]. BRCA1 is also
an AR coactivator that has been demonstrated to enhance
AR transactivation in prostate and breast cancer cell lines
with a synergistic effect with other p160 coactivators [36].
Our data shows an androgen-mediated induction of the
expression of BRCA1. It has previously been demon-
strated that BRCA1 is an estrogen induced gene in breast
and ovarian cancer cells [37,38].
β-catenin is an adherens junction protein with altered
expression in various tumor types. Its fundamental role as
a multifunctional oncoprotein has been established [39].
The gene encodes for a protein that interacts with AR in
close proximity with p160 coactivator family and it is
thought to be important for the formation of the AR tran-
scription complex [40,41]. There is some evidence that AR
could also have an important role as a scaffolding protein
in β-catenin translocation from the cytoplasm into the
nucleus [42-44]. β-catenin has been shown to augment
AR transcriptional function in a ligand-dependent fashion
[43,45]. Here we show that β-catenin is induced up to 2.5-
folds at 24 hours time point, already at a concentration of
0.1 nM of DHT. The induction reaches then the 3-folds
and declines at 2-folds at 100 nM showing a significant
androgen regulation.
In addition to the above mentioned coregulators, cyclin
D1, gelsolin, prohibitin, JMJD1A and JMJD2C showed a sig-
nificant dose dependent effect in their expression level
mainly at 24 hours time point. However, the induction
was very mild, less than 2-fold, suggesting either only
weak androgen effect or secondary mechanisms for the
induction.
It has been demonstrated that AR is commonly overex-
pressed in hormone-refractory prostate cancer [11,46,47].
In addition, it has been shown that the overexpression is
capable to transform androgen dependent growth of pros-
tate cancer cell to independence [9]. To study the effect of
AR overexpression, we stable transfected AR to LNCaP cell
line leading to 3 to 4-fold increased expression of AR. The
growth of LNCaP-ARhi was stimulated on lower concen-
trations of androgens than the growth of LNCaP-
pcDNA3.1 (unpublished data). None of the coregulators
were up- or downregulated by the level of AR alone since
there was no significant difference in the expression of the
coregulators at 0 M of DHT. Instead, the overexpression of
AR seems to sensitize cells to androgens. This was evident
e.g. for PSA, which was significantly upregulated more
and in lower concentrations of DHT in LNCaP-ARhi than
in LNCaP-pcDNA3.1 cells. Similarly, the expression of
MAK, CBP, and BRCA1 was increased more in LNCaP-
ARhi than in LNCaP-pcDNA3.1, and, at least, a 10-fold
sensitization was observed. For MAK and CBP this was
apparent in 4 h time point, whereas for BRCA1 at 24 h
time point. Interestingly, the increased expression of AR
did not affect all androgen-regulated coregulators. β-cat-
enin, cyclin D1 and gelsolin, which showed androgen-regu-
lation in LNCaP-pcDNA3.1 at 24 hours were not
regulated by androgens in LNCaP-ARhi. The data suggest
that the AR overexpression has distinct effects on different
target genes. It should be recognized that during the
androgen withdrawal, there are still adrenal androgens
left. For example, the DHT concentration is only partially
depleted [48]. Thus, the genes that are regulated in
reduced DHT concentrations due to AR overexpression
might be important in the progression of prostate cancer
during the hormonal therapy.
The effects of androgens on gene expression were meas-
ured at two time points, 4 h and 24 h. The 4 h time points
represent a time interval where direct effects of androgens
administration should be seen, although the effect can be
mild. On the other hand, also secondary mechanisms can
already be activated at 24 hours time point. All coregula-
tors (AIB1, CBP, MAK, BRCA1, β-catenin) that were
induced more than 2-fold by DHT, showed the induction
already at 4 time point in one or both cells lines (LNCaP-
pcDNA3.1 and LNCaP-ARhi) suggesting direct regulation.
Whereas, coregulators with lower-level of induction
showed the effect variably in 4 and 24 hour points, which
may also suggest secondary mechanisms of androgen reg-
ulation.
Conclusion
In conclusion, by systematic measurement of 25 AR coreg-
ulators, we identified 5 coregulators whose expression
seems to be significantly androgen-regulated indicating
that they could be a part of positive feedback mechanisms
potentiating the AR signaling. Overexpression of AR
seems to sensitize cells in terms of androgen regulation
but the effect is gene-specific since not all androgen-regu-
lated genes were up-regulated in AR overexpressing
model.
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